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Abstract 
HIV infection has been shown to affect all lymphocyte populations, including the B-cell 
compartment. Defects in phenotype and function of B cells have been well 
characterized in HlV-infected adults. However, only a few studies have investigated the 
effect of HlV on the B-cell compartment in children, and such studies have been less 
detailed than in adults. As a result, much remains to be described with regard to B cells 
in HIV-infected children. 
In this study, I assessed the phenotype and function of B cells in HIV -infected children. 
I also assessed the in vitro effect of various 8-cell stimulant-combinations and the effect 
of recombinant HIV-l nefprotein on the resultant B-cell responses. 
The phenotypic defects observed in the HIV-infected children were broadly similar to 
those observed in HIV-infected adults but with minor differences. Furthermore, high 
viraemia and low CD4+ T-cell percentages interfered with the age-related accumulation 
of B-cell memory, suggesting that children of all ages might benefit from immediate 
initiation of HAART upon diagnosis with HIV-infection. HIV infection was also 
associated with poor B-cell responses to vaccine antigens, implying that such children 
may require revaccination upon initiation of HAART. In the in vitro experiments, 
different B-cell stimulants elicited synergistic effects on 8 cells. However, HlV-l Nef 
did not affect various B-cell responses upon exposure to the B-cell stimulants. 
WHO has recently revised the recommendations for management ofpaediatric HIV. All 
children below five years of age are to be started on HAART the moment they are 
diagnosed with HI V, but such recommendations are yet to be adopted into national 
guidelines. The possibilities of revaccinating HIV-infected children once on HAART 
need to be evaluated. Even though some studies have reported on the possible causes of 
B cell defects in HIV, more research needs to be done to elucidate other causes that may 
offer intervention targets. 
XXII 
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Chapter 1 Introduction 
1 
1.1 Classification of HIV 
Human Immunodeficiency Virus (HIV) is the causative agent of acquired 
immunodeficiency syndrome (AIDS). It exists in the form of two related viruses, HIV-l 
and HIV-2 [1-3]. HIV-} can be further subdivided into four groups; M ("Main"), 0 
("Outlier"), Nand P, with group M being the most prevalent worldwide. Group M 
exists in at least 9 genetically distinct clades (subtypes): A, B, C, D, F, G, H, J and K. 
Occasionally, recombination events between different clades give rise to hybrid forms 
e.g. AlB. Similarly, HIV-2 is divided into 8 groups: A, B, C, D, E, F, G and H. Groups 
A and B are the only epidemic forms while the others are though to be dead-end 
infections in humans [4]. 
1.2 Origins of HIV 
HIV-} and HIV-2 are cross-species (zoonosis) diseases that resulted from crossover of 
Simian Immunodeficiency Viruses (SIV) from non-human primates. HIV-l is suspected 
to have originated from common chimpanzee (Pan troglodytes) that naturally host 
SIVcpz while HIV-2 came from the sooty mangabey (Cercocebus atys) that host 
SIVsm. Evidence to suggest this zoonosis origin include: 
1. Phylogenetic relatedness of the SIVcpz and SIVsm with HIV-l and HIV-2 
respectively [5-7]. 
2. Similarities in genomic organization [5,6]. 
3. Geographical overlap between the natural epidemiology of the SIVsm with 
HIV-2 and SIVcpz with the suspected original epidemic of HI V-I [8,9]. 
4. Existence of SIVcpz and SIVsm in their natural hosts i.e Pan troglodytes and 
Cercocebus atys respectively [8, 9]. 
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5. Close contact between the non-human primates and humans as these primates 
are hunted by humans for food or kept as pets [10, II]. 
Some additional evidence suggests that HIV-l group 0 may have originated from 
gorillas [12]. 
The existence of HI V-I and HIV-2 in several groups suggests that there were multiple 
crossover events for each virus i.e. at least 4 events for HIV -1 and 8 events for HIV -2. 
Indeed, cross-species transmission ofSIV has been documented in non-human primates, 
the most notable being the crossing of SIVsm from captive sooty mangabeys to captive 
rhesus macaques that gave rise to SIVmac [13-15]. Using molecular clocks, the 
crossover event has been estimated to have taken place in 1931 (1915-1941) for HIV-I 
group M [16]. This estimate is in line with the detection of HI V-I in samples dating as 
far back as 1959 despite the fact that the epidemic was only recognized in 1980 [17, 
18]. Another study has estimated the introduction of HIV -2 into the human population 
to have taken place in 1940 (+/-16 years) for group A and 1945 (+/- 14 years) for group 
B [19]. 
Due to the limited prevalence ofHIV-2 in Kenya, this thesis is written in the context of 
HIV -1 infections. Therefore, all subsequent discussions are centered on HIV -I. 
1.3 Biology of HIV -1 
HIV-l is a ribonucleic acid (RNA) virus with a genome consisting of two positive-sense 
RNA molecules. It has nine genes that encode for a total of 15 proteins [20]. Three of 
the nine genes i.e. gag, pol and env are the major genes and encode for structural 
proteins and enzymes. They give rise to Gag, Gag-Pol and Env polyproteins 
respectively. Gag is processed further to give the matrix, capsid, nucleocapsid and p6 
protein in addition to two spacer peptides. Gag-Pol gives rise to integrase, reverse 
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transcriptase and protease while the Env gives rise to the surface gp I 20 and trans-
membrane gp4 I. The remaining six genes encode four accessory proteins (Nef, Vpu, 
Vpr and Vif) and two regulatory proteins (Tat and Rev) that influence various aspects of 
immune evasion or facilitate viral replication [20]. Of particular interest in one chapter 
of this thesis is Nef (negative factor), which has been shown to have a wide range of 
interactions with the host's immune cells. It activates CD4+ T celts and monocytes, 
rendering them more permissive to infection and viral replication [21, 22]. It also 
reduces expression of MHC class I on infected cells to protect them from being killed 
[23] in addition to down-regulating CD4 expression on helper T cells to enhance the 
budding off of newly formed virions [24]. It has also been shown to inhibit antibody 
class switching to prevent optimal antibody response against HIV [25]. Vpu (unknown 
virus protein) too has the ability to modulate expression of CD4 on helper T cells by 
inducing CD4 degradation in the endoplasmic reticulum [26]. It also inhibits the effects 
of CD317. a tether in that is a potent HIV restriction factors. CD317 causes retention of 
formed virions on the surface of infected cells [27]. Vpr (viral protein R) reportedly 
induces apoptosis of T cells, thus contributing to the depletion of CD4+ T cells [28]. It 
also causes cell cycle arrest at 02 phase, providing a conducive condition for 
transcript ion of HIV genes since HIV -1 L TR appears to be most active at the 02 phase 
[29]. Vif (virion infectivity factor) induces the degradation of APOBEC30, a potent 
HIV restriction factor [30]. Tat (trans-activator of transcription) controls the initiation of 
transcription and enhances the processivity of the polymerases that are involved in 
transcribing HIV proteins [31]. Rev (regulator of virion expression) controls the export 
of viral mRNA from the nucleus to the cytoplasm where HIV proteins are translated 
[32]. 
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The replication cycle of HIV can be divided into 13 steps. Firstly, contact between 
gpl20 and a CD4 molecule on the target cell leads to conformational change in the 
gp 120, exposing the binding site for HIV -1 co-receptor molecule (CCR5 or 
CXCR4)(attachment). Engagement of the co-receptor molecule leads to insertion of a 
fusion protein and eventual fusion of the virion's envelope with the host cell's 
membrane, releasing the virus core into the target cell's cytoplasm where reverse 
transcription then starts. Successful completion of the reverse transcription at the 
nuclear pore triggers uncoating to allow shuttling of the pre-integration complex into 
the nucleus where the viral DNA is integrated into the host's genome to form a 
provirus. With the aid of Tat, proviral transcription is catalyzed by the host polymerase 
II. The transcription products are then transported from the nucleus to the cytoplasm 
under the regulation of Rev. Viral proteins are then translated in the cytoplasm, with 
Gag and Gag-Pol polyproteins localizing at the plasma membrane. Env polyprotein is 
translated in the endoplasmic reticulum and transported to the cell membrane. The core 
particle is assembled. It contains Gag, Gag-Pol, Vif, Nef, Vpr and genomic RNA. An 
immature virus then starts to bud out and eventually detaches from the host cell. 
Subsequent proteolytic processing of Gag and Gag-Pol polyproteins to give functional 
matrix, capsid, nucleocapsid, reverse transcriptase, integrase and protease proteins 
renders the virion mature and infectious [33, 34]. 
Each step in the replication cycle of HIV presents a therapeutic or preventive target. 
1.4 Epidemiology of HI V-I 
HIV is assumed to have remained unnoticed until 1981 when health professionals 
realized that some groups of people were suffering from an unusual condition of 
immune suppression. Most patients presented with Kaposi's sarcoma and Pneumocystis 
jiroveci Pneumonia (PCP), diseases that were previously associated with advanced age 
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or pre-existing states of immunosllpression. At first, the problem was noticed among 
men who have sex with men (MSM) and intravenous drug lIsers [35, 36]. Later, infants 
born of women in the high-risk groups [37], heterosexual contacts of the high-risk 
groups [38], hemophiliacs treated with blood products and recipients of multiple blood 
transfusion [39] were recognized as additional groups of persons that were highly likely 
to present with the syndrome [40]. The virus causing the syndrome was later discovered 
in 1983 [1, 2]. 
Presently, mv is in the general population. Heterosexual sex is the primary route of 
transmission [41]. However, homosexual sex and intravenous drug use still remain as 
high-risk practices [42-44]. 
At the end of2011, approximately 25 million people had died of AIDS while 34 million 
people, including 3.4 million children below 15 years old, were living with HIV. 69% 
of these people were in Sub-Saharan Africa, where 4.9% of the population was infected 
with HIV. Notably, the burden of the epidemic varied between regions and countries 
[45]. 
Even though the epidemic initially affected mostly men, the number of infections in 
women has increased considerably over time to match that of men. Currently, in Sub-
Saharan Africa, approximately 61% of HIV cases are in women [46]. This high 
prevalence in women could be due to both socio-cultural and biological factors. For 
instance, access to HIV information and health services is lower in women than in men 
within the region, probably due to existing literacy gaps and unfavorable social norms. 
Furthermore, lack of economic empowerment of women in the region makes it difficult 
for them to negotiate for safe sex practices [45]. Structural differences between male 
and female genitalia could also contribute to the observed differences in infectivity. 
Women generally experience more exposure to infectious fluids during and after sexual 
intercourse due to their receptive anatomy that also presents a wider surface area. Their 
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higher likelihood of experienc ing trauma hence breach of mllcosal barrier may also 
contribute to a higher likelihood of infection [47, 48]. This high prevalence of HIV 
among Sub-Saharan African women has important implications tor vertical 
transmission to infants. Consequently, almost 90% of all HIV -infected children 
worldwide live in Sub-Saharan Africa [45]. 
..... 
No da:a < .1% 
Figure 1.3: Est imated prevalence of HIV in various countries as at 2009 (Source: UNAIDS Global report 
2010)[49). 
Implementation of HIV preventive measures and treatment has significantly reduced 
both the rate of HIV-transmission and HIV-related mortality. As a result, many 
countries in Sub-Saharan Africa have recorded a reduction in HIV incidence [45, 50]. 
However, some reports suggest an increase in prevalence in some areas due to better 
survival oftreated HIV patients after ro II out of antiretroviral treatment [51]. Moreover, 
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the epidemic is still growing in some regions that were previollsly less affected e.g. 
North Africa and the Middle East [45]. 
Of significant importance is the success of prevention of mother to child transmission 
(PMTCT). Even though the reduction of HIV transmission in the adult population can 
contribute to the reduction of transmission from mothers to their children, PMTCT 
antiretroviral-based and infant feeding-based strategies are primarily responsible for the 
recent large declines in vertical transmission [52-54]. However, despite the gains in 
PMTCT, large numbers of children continue to be infected. For instance, in 2011 alone, 
approximately 330,000 children acquired HIV infection from their mothers [45]. 
1.5 Staging and progression of untreated HIV 
Though the clinical manifestation of HIV disease progression varies between patients, 
some general patterns have been observed. In the first weeks of the infection, patients 
develop the acute HIV syndrome that is characterized by fever, headache, malaise, 
lethargy, myalgias and lymphadenopathy among other signs and syndromes. Very high 
viral loads and a sharp decline in peripheral CD4+ T-cell counts characterize this period. 
The induction of adaptive immune responses then leads to subsequent decline in plasma 
viral load and partial recovery ofCD4+ T-cell counts [55-57]. This sets the stage for the 
"clinical latency" stage that can last up to a decade in some individuals. However, 
despite absence of clinical signs and symptoms, the "clinical latency" stage is 
characterized by a gradual depletion of CD4+ T cells among other pathologies. In fact, 
viral replication continues but is maintained at a set point [58]. Eventually, due to the 
immune deterioration initiated in primary infection and perpetuated during the clinical 
latency, the patient develops end stage disease that is characterized by the onset of 
AIDS defining illness, appearance of opportunistic infections and a considerable 
increase in plasma viral load [35-40, 57, 59-61]. 
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Due to the variability ill disease progress ion among HIV pat ients, dist inct patient' 
groups have been identified. For instance, a small proportion of HIV patients maintain 
high CD4+ T-cell counts for decades without developing end stage disease. Such 
individuals have been called long-term non-progressors (LTNP). Interestingly, LTNPs 
do not necessarily have suppressed viral loads [62-65]. On the other hand, another 
group of patients who control viraemia to below detectable levels in absence of 
treatment has been identified and termed elite controllers. Their control of viraemia is 
associated with transient recovery of CD4+ T-cell counts and subsequent stabilization. 
However, not all elite controllers turn out to be LTNPs as some of them experience 
CD4+ T-cell depletion despite viral control while others lose viral control and progress 
normally [64-67]. 
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Figure 1.4: HIV disease progression in absence of treatment: Primary infection, clinical latency and end-
stage disease (Adapted ti'om Pantaleo, G. et al; NEJM 1993) [57]. 
Staging of HI V disease is important in determining treatment options. Currently, 
clinical staging and immunological staging are used for routine care. Virological staging 
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has not been rolled out in deve loping countries, primarily because of lack of the 
resources to implement it. 
According to the WHO, HIV/A IDS clinical stag ing, the course of untreated HIV 
infection has been divided into four stages i.e. clinica l stage 1 to clinical stage 4 [68] . 
Clinical 
stage 
Stage I 
Stage 2 
Stage 3 
Stage 4 
Clinical presentation 
Asymptomatic/persistent generalized lymphadenopathy 
Moderate weight loss, persistent hepatosp lenomegaly and parotid 
enlargement in chi ldren, herpes zoster (shingles), sk in les ions and 
recurrent respiratory tract infections 
Severe weight loss (> I 0% of body weight) or moderate malnutrition 
(children), severe bacterial infections, pulmonary tuberculosis, 
recurrent oral fungal infections, persistent diarrhoea and persistent 
unexplained fever. 
Wasting syndrome (adults), severe malnutrition (children), recurrent 
severe bacterial infections, Kaposi 's sarcoma, candida infection of 
trachea, bronchi and lungs, Pneumocystis jiroveci pneumonia, 
chromic herpes simplex infection (oral and genital), cryptococcal 
meningitis, eNS Toxoplasma gondii infection, lymphoma, chronic 
diarrhoea due to cryptosporid ium infection and disseminated funga l 
infections. 
Table 1.1 : WHO clinical staging ofHlv. WHO Case detinitions of HI V for surveillance and revised 
clinical staging and immunological classification of HI V-related disease in adults and children) [68] 
11 
WHO immunological staging of HIV infect ion is also divided into four levels [68]. 
HlV-associa ted Age-related C04+ T-cell values 
imm un odeficiency < 11 >5 yea rs 
months 12-35 months 36-59 months (Absolute CD4 
(%,ofCD4 !- T (% of C D4+T ('y" ofCD4+T numbcrs/mm3 or 
cells) cells) cells) % ofCD4+ T 
cells) 
Non or not 
>35 >30 >25 >500 
sign incant 
Mild 30-35 25-30 20-25 350-499 
Advanced 25-29 20-24 15- 19 200-349 
Severe <25 <20 < 15 <200 or < 15% 
.. Table 1.2 : WHO Immunological stagtng of HIV tnfectlOn (adapted fi'om: WHO Case definItions of HIV 
for survei llance and revi sed clinical staging and immunological classification of HI V-related disease in 
adults and chi ldren). Percentage ofCD4+ T cells is ca lcu lated as a proportion of total lymphocytes [68]. 
1.6 HIV-l treatments 
The replication cycle of HI V-I presents several steps that can be exp loited to curtail the 
process. A range of drugs have been developed and licensed to target some of those 
steps, while additional drugs are in development. The table below summarizes the 
details of the main licensed drugs [69]. 
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Targeted replication step Drug Sub-class 
Entry Maraviroc CCR5 binding inhibitor 
Enfuvittide Fusion inhibitor 
Reverse transcription Delavirdine Non-nucleoside reverse 
Efavirenz 
Etravirine transcriptase inhib itors 
Nevirap ine 
Abacavir Nucleoside reverse 
Didanosine 
Emtricitabine transcriptase inhibitors 
Entecavir 
Lamivudine (NRTI) 
Stavudine 
Tenofovir 
Zalcitabine 
Zidovudine 
Integration Raltegravir Integration inhibitor 
Protease processing (virion Atazanavir Protease inhibitors 
Fosamprenavir 
maturation) Daruavir 
Ritonavir 
Lopinavir 
Nelfinavir 
Squinavir 
Tipranavir 
Indinavir 
Table 1.3 : Licenced antlretrovlral drugs, their classes and HIV-rephcatlon stages to which they target 
[69]. 
These antiretroviral drugs have dramatically changed the clinical course of HIV/AIDS. 
Before their introduction, HIV infection was perceived as a "death sentence", but has 
now become a chronic infection [70]. A recent paper showed that maintaining patients 
at CD4+ T -ce II counts above 500 cells/mm3 improves their survival considerably [71]. 
According to recent reports, the upscale of use of anti ret rovira I drugs may have also had 
a significant impact on the containment of the spread of the epidemic as witnessed in 
many countries since low viraemia correlates with a low chance of transmitting [45, 
72]. 
Initially, antiretroviral drugs were used as monotherapies. Due to the rapid mutation rate 
of the virus, resistant variants quickly arose, lead ing to frequent treatment failures [73]. 
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The introduction of highly active antiretroviral therapy (HAART), which comprises a 
combination of three drugs with different modes of action, can limit the occurrence of 
treatment failure and resistance. However, pre-existing drug resistance and poor 
compliance to the required dosing regimen can limit its usefulness. WHO recommends 
that the first line of treatment should combine 2 nucleoside reverse transcriptase 
inhibitors with 1 non-nucleoside reverse transcriptase inhibitor. Several other regimens 
are recommended for second line therapy [74, 75]. 
According to the current WHO guidelines, whose adoption varies between countries, 
adults are eligible for HAART if their CD4+ T cell counts fall below 500 celis/ilL or if 
they are in WHO clinical stage 3/4, whichever comes first. Children, on the other hand, 
become eligible for HAART if they meet any of the following criteria [76]: 
I. Ifthey are below five years of age i.e. all HIV-infected children below five years 
are put on HAART. 
2. If they are above five years and their CD4+ T-cell counts fall below 500 celis/ilL 
or if they are in WHO clinical stage 3/4 (like adults). 
Until recently, the WHO recommended all children below two years to be put on 
HAART the moment they were diagnosed with HIV. This is because some studies 
showed that untreated children maintained high viral loads and had high mortality with 
more than half dying before the end of two years [77-80]. However, children between 
two and five years were recommended to be put on HAART only if their CD4+ T-cell 
counts fell below 750 celiS/ilL or below 25% or if they were in WHO clinical stage 3/4 , 
mainly because there was little evidence to suggest that immediate initiation ofHAART 
conferred any biological advantages on the children who were above 2 years of age 
[80]. The recent revision of the guidelines to recommend immediate initiation of 
HAART on all children below five years was informed by the possible operational and 
programmatic advantages of having simplified paediatric treatment guidelines, but 
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evidence for any biological benefit is still lacking with regard to the two to five years 
age group [76]. 
Antiretroviral drugs are also used to prevent HIV infection. For instance, they are used 
to prevent transmission of the virus from infected mothers to exposed children 
(PMTCT)[81]. Recently, pre-exposure prophylaxis was recommended by WHO to 
protect people who are at high risk of HIV acquisition [82]. Antiretroviral drugs have 
also been long used for post-exposure prophylaxis especially on exposed health 
professionals and victims of sexual assault [83]. 
Of interest is the emerging consensus that early initiation ofHAART is beneficial to the 
individual as well as the community. People who are started early on HAART appear to 
do better immunologically [84. 85]. They also transmit less, since the probability of 
transmitting correlates directly with viral load [86]. In fact, recent reports suggest that 
administration of antiretroviral drugs very early into the infection can lead to functional 
cure with such patients maintaining undetectable levels ofthe virus long after cessation 
of administration of the antiretroviral drugs [87, 88]. It will therefore be not surprising 
to see a policy change towards universal immediate initiation of HAART upon 
diagnosis with HIV infection. This may reduce subsequent healthcare costs at the 
individual level and at the same time help control the spread of the epidemic. 
1.7 Immune responses and immunopathogenesis in HIV-l 
Based on available evidence, most HIV -1 infections are due to a single 
founder/transmitted virus. Homogeneity in the early virus population also suggests that 
the initial stage of infection is established on a single focus of CD4+ T cells in the 
genital mucosa [89]. Transmission is usually followed by an eclipse phase during which 
viraemia remains below the conventional detection limit. This phase is estimated to last 
about 10 days [90]. The virus eventually reaches the draining lymph nodes. Dendritic 
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cells have been shown to playa major role in this as they can internalize the virus via 
DC-SIGN in the mucosa and then transport it to the activated T cells in the lymph nodes 
[91]. Rapid replication of the virus ensues, with it spreading to other lymphoid organs. 
Of particular importance is the gut-associated lymphoid tissue (GALT), which then 
becomes the primary site of HIV replication. Approximately 20% ofT cells in GALT 
are lost due to direct infection while an additional 60% die due to bystander activation 
and apoptosis during the acute phase of HIV infection. The numbers of CD4+ T cells 
also fall in the peripheral circulation [92-94]. B cells in the GALT are also affected. One 
study showed that B cells in GALT experience apoptosis, polyclonal activation and 
terminal differentiation amidst loss of germinal centres and follicular damage during 
this acute phase. This could explain the suboptimal antibody response that is mounted 
against the virus particularly in the early phase of the infection [95]. This replication of 
the virus continues until peak viraemia is achieved 3-4 weeks after transmission [90]. 
The peak viraemia is associated with emergence of CDS+ T cell responses. However, as 
the viral load decreases under the pressure of the immune responses, viral 
diversification occurs, leading to generation of escape mutants. The selected mutants 
have amino acid changes at CDS+ T-cell epitopes, suggesting that the initial control of 
viraemia is driven by CDS+ T-cell responses [96-99]. In the end, a viral set point is 
achieved and maintained in the chronic phase [100]. Individuals carrying HLA-B*57 
and HLA-B*27 tend to have better HIV viral control, while those carrying HLA-B*35 
tend to have poorer control [101, 102]. This has been suspected to be associated with 
the Gag-specific CDS+ T-cell response among other factors. Some HLA class types 
could be selecting for Gag escape mutants that have reduced replicative fitness [103, 
104]. 
The first antibody responses, in the form of immune complexes, appear approximately 
one week after detection of viraemia. Free antibodies against gp41 are detectable a 
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week later, while free antibodies against gp 120 become detectable a further two weeks 
later. This initial antibody response is non-neutralising and appears to play no role in 
viral control [105]. Autologous neutralising antibodies only appear about three months 
or later after infection. Even though they are capable of neutralising the quasi species 
present at the time, rapid viral escape occurs [106,107]. Eventually, 10-30% of HI V-
infected adults develop moderate to broadly neutralising sera in the chronic phase of the 
infection [108]. Unfortunately, due to viral escape, they do not clear the infection. In 
fact, presence of broadly neutralising antibodies has been positively correlated with 
high viral load, suggesting that continued viral turnover could contribute to their 
generation [109-111]. Other suggested effector functions ofantibodies in the control of 
HIV could include complement-mediated lyses as well as antibody-dependent cell-
mediated cytotoxicity (ADCC) [112, 113]. 
In children, the course of HlV-infection differs considerably from that observed in 
adults. Most notable is the fact that high viral load is maintained throughout the first 
year of life in most HIV-infected children and drops only slowly with age [77, 79]. As a 
result, more than half of infected children die before their second birthday if left 
untreated [78]. The poor control of viraemia suggests that children could be having a 
poorer immune response to HIV infection. Indeed, early life is generally characterized 
by a more tolerogenic immune system. Fetal T cells, generated from a different 
hematopoietic stem cell lineage compared to adult T cells, tend to be more responsive to 
stimulants. They also have a tendency to differentiate to a regulatory T-cell phenotype 
[114]. Children and fetuses have higher frequencies of regulatory T cells when 
compared with adults, suggesting that the tolerogenic environment persists postnatally 
[115]. 
This tolerogenic situation is reinforced by the increased ability of neonatal innate 
immune cells to produce ILl O. When exposed to Toll Like Receptor (TLR) ligands, 
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neonatal innate immune cells also tend to produce cytokines that Sllpport TfJ2 and T~d7 
differentiation that targets mainly extracellular pathogens as opposed to T HI responses 
that would target primarily intracellular pathogens like HIV [116]. However, T HI 
responses have been described in neonates who experience congenital infection with 
cytomegalovirus, though such responses are weaker than those observed in adults [117, 
118]. 
Furthermore, since CDS+ T-cell responses appear to play an important role in 
controlling viraemia, it is likely that children may miss out on the potential advantages 
of carrying particular HLA class 1 types that are associated with slow progression (e.g 
HLA-B*57 and HLA-B*27) if the transmitted virus has already been adapted to those 
HLA alleles in the mother [101, 102, 119]. Also, the sustained high viral load may lead 
to accumulation of compensatory mutations that can negate any loss of fitness that 
would result from CD8+ T-cell-mediated Gag mutations [120]. 
1.8 Systemic immune activation in HIV 
Systemic immune activation is one of the most important phenomena associated with 
HIV infection. It has been described in almost all compartments of the immune system 
in untreated HIV patients. In the T-cell compartment, both CD4+ and CD8+ T cells 
from HIV patients have increased expression of markers of activation, namely CD38 
and HLA-DR [121]. Hypergammaglobulinaemia, the production of large amounts of 
immunoglobulins that are not targeted to any particular antigen, is the classical indicator 
of aberrant polyclonal activation of B cells in HIV [122]. B cells from HIV patients 
have also been shown to express increased levels of markers of activation and terminal 
differentiation [123]. The innate compartment is not spared either, as HIV has been 
shown to directly activate plasmacytoid dendritic cells (pDes), leading to production of 
large amounts ofcytokines that could modulate the adaptive arm [124]. 
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The consequence of immune activation is a constant supply of activated T cells that are 
targets for infection [125]. Secondly, the uncontrolled activation is suspected to be an 
immune escape strategy that the virus employs to blunt the immune response against 
itself by causing exhaustion and apoptotic depletion of various lymphocyte subsets 
[126, 127]. Interestingly, CD4+ T-cell depletion has been observed in elite controllers 
and shown to correlate with their levels of T-cell activation despite their undetectable 
viral loads [128]. Furthermore, HAART treated patients who maintain high levels T-cell 
activation despite control of viraemia have poorer recovery of CD4+ T-cell counts 
[129]. More importantly, the level of T-cell activation is a reliable predictor of 
progression to AIDS [130]. Unlike non-pathogenic SIV, pathogenic SIV models have 
shown similar patterns of immune activation when compared with HIV in humans, 
further underscoring the importance of immune activation in pathogenesis [131]. 
Despite intensive research, the causes of the immune activation in HIV have not been 
fully elucidated. However, it has been shown that viral factors could play, at least in 
part, an important role. The HIV virion has several known activators of immune cells. 
The envelope glycoprotein has been shown to have activatory effects on B cells and 
monocytes via DC-SIGN [132]. The viral genome, ssRNA, has also been shown to 
activate pDCs via toll like receptors 7 [124]. HIV Nef, one of the accessory proteins, 
has been shown to activate monocytes and consequently indirectly activate B cells via 
ferritin from the activated monocytes [133]. All these activatory effects lead to 
production of soluble and contact factors that could cause the activation observed in the 
T and B-cell compartments. 
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The observation of some continued immune activation in elite controllers and HAART 
treated patients without detectable viraemia suggest that the observed activation could 
also be due to non-viral factors [128, 129]. This argument is further supported by the 
fact that non-pathogenic SIV models show low levels of chronic immune activation 
when compared with pathogenic SIV models despite both presenting with comparably 
high viral loads, implying that the activation in pathogenic models could be independent 
from direct viral replication [131]. Alternatively, as has been argued in one study, the 
non-pathogenic SIV models could be missing some pathways that are activated by the 
HIV factors [134]. 
Microbial translocation from the gut has been proposed as the mechanism by which 
HIV mediates systemic immune activation independently from HIV factors. Systemic 
levels of LPS have been shown to correlate with systemic immune activation [135]. 
Even though LPS only activates cells in the innate immune system, the subsequent 
release of inflammatory factors could have activating effects on cells in the adaptive 
arm of the immune system. Furthermore, the presence of LPS in circulation is an 
indication of the possible translocation of other bacterial components that could have a 
direct effect on T and B cells, e.g. bacterial DNA could activate B cells via toll like 
receptor 9. 
Despite the technical challenges in accessing appropriate biological samples from the 
gut, a few studies have successfully revealed valuable information on the effect of HI V 
infection on the gut. HIV has been shown to significantly compromise both the 
structural and the immunological barrier in the gut. For instance, severe depletion and 
dysregulation ofT and B cells in the gut associated lymphoid tissue (GALT) has been 
shown to start in the acute phase of the infection and is maintained in the chronic phase 
[93,95]. In addition, increased intestinal permeability, impaired digestion and impaired 
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absorption characteri se the accompanying enteropathy [1 36- 138]. The increased 
permeability, together with the destruction of the immunological defences in the gut, 
would arguably allow the resultant microbial translocation. 
HIV PAMPs 
e.g. gp120, ssRN 
H IV replication 
Immune activation 
CD4+ T-cell activation 
Apoptosis, exhaustion 
of lymphocytes 
Immune deficiency 
Microbial PAMPS 
e.g LPS, bacterial DNA 
Microbial translocation 
Damage to gut 
immunological and 
structural barrier 
Figure 1.5: Summary of the events that cou ld account for the systemic immune activation that is observed 
in H!V. PAMPs-pathogen associated molecular patterns [1 39]. 
1.9 Broadly neutralising antibodies 
Currently, the generation of neutralising antibodies is of primary research interest. . 
Such antibodies targeting the HIV sp ikes (envelope glycoproteins) have been shown to 
effectively control viraemia as well as provide protection from infection by HIV and 
SIV in animal models [140-144]. Furthermore, administration of broadly neutralising 
antibodies to humans has been shown to delay viral rebound upon interruption of 
antiretrov iral therapy [144]. 
However, HIV has several Immune evasion strategies, the most notable being the 
presence of an error-prone reverse transcriptase that gives rise to a high degree of 
antigenic variation both w ithin the host and at the population level. As a result, there is 
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up to 35% variation between different HIV-I clades and up to 20% variation between 
viruses within the same clade [145]. Consequently, the neutralising antibodies that are 
produced, albeit late (several months after infection), tend to neutralise only the 
autologous virus that in turn rapidly mutates to neutralisation-resistant phenotypes [106, 
107]. 
The antigenic variation on HIV envelope glycoproteins can be countered by generation 
of broadly neutralising antibodies that presumably target conserved regions of the spike 
[146]. The realization of the existence of such antibodies in 10-30% of chronically 
infected individuals provides hope that they can be elicited upon immunization with 
appropriate antigens [108]. A major current objective is the design of immunogens that 
can elicit such antibodies by vaccination to protect against infection. Such antibodies 
might also be used for therapy in established infections [144, 147-149]. 
Initially, attempts to isolate anti-HlV neutralising antibodies resulted in first generation 
broadly neutralising antibodies that were, to some extent, limited in either breadth or 
potency. However, recently, through a renewed international effort, a number of 
second-generation broadly neutralising antibodies have been isolated from HIV-infected 
patients whose sera show broad neutralising activity. The table below summarizes the 
details of some of the broadly neutralising antibodies that have been isolated to date. 
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Antibody S pee ifie ity Breadth Year Reference 
at 
ICso<50 
f!g/ml 
bt2 gpl20CD4bs 34% 199 1 [150, 151] 
2F5 gp41MPER 57% 1994 [152, 153] 
4E I0 gp4lMPER 96% 1994 [151 , 152] 
2G I2 32% 1994 [151 , 152] 
PG9 G Iycans & V IIY2 78% 2009 [153, 154] 
PGI6 Glycans & VI/V2 73% 2009 [153, 154] 
HJI6 gp l20CD4bs 40% 20 10 [ 155] 
VCROI gp120CD4bs 91% 2010 [156] 
VRC02 gp l20CD4bs 9 1% 20 10 [156] 
VRC03 gp120CD4bs 50% 20 10 [156] 
POTI21 Complex type V3 N-glycans 70% 20 11 [151 157J 
POTI22 65% 20 1 I [151] 
PGTI23 67% 20 11 [151 ] 
POT126 60% 20t I [151 J 
POTI28 Olycans and V3 beta strand 72% 201 1 [151 ] 
POTI45 o Iyeans and V 11Y2 78% 20 11. [151] 
CHO I- Olycans and V IIY2 50% 20 11 [ 158] 
3BNC I17 gp120CD4bs 84% 20 tl [153, 159] 
NIH45-46 gp l20CD4bs 85% 20 11 [153, 159] 
VRC-CH30 gp l20CD4bs 83% 20 11 [160] 
VRC-PG04 gpl20CD4bs 76% 201 1 [160] 
IOE8 gp4 1MPER 98% 2012 [153] 
3BC I76 CD4iIY3 60-70% 20 12 [161 ] 
J3 gp 120CD4bs 96% 20 12 [162J 
, .. .. Table 1.4: Details of some In vItro broadly neutrall smg antibodIes Isolated to date. TheIr specIficI tI es, 
breadths and years of publication are shown. The publications reporting their isolation are reterenced. 
These broadly neutral ising antibodies are currently being used to inform structure-based 
vaccine design. For instance, introduction of alanine and glycan residues has been done 
to direct immune responses to bl2 binding sites ofgp120 [163-165]. Also, identification 
of the bt2 binding epitopes on the gpt20 outer domain (00) has enabled the design of 
OD constructs in a bid to generate better responses against the b 12 bind ing epitopes that 
are poorly immunogenic in the context of intact gp 120 [166]. In addition, the mapping 
of the binding site of 20 12 on the glycan shield has informed the development of 
glycoconjugates with the aim of eliciting 20 12-like antibodies [167]. The target 
epitopes for 2F5 and 4E lOon gp4 1 MPER have also been mapped and used to design 
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peptides that are meant to elicit anti-gp41 broadly neutralising ant ibodies [168]. 
However, thus far, all these strategies have yielded disappointing results. Further studies 
on the possible mechanism through which some HIV patients generate broadly 
neutralising antibodies are expected to inform novel and more successful strategies. 
1.10 HIV vaccine development 
HIV vaccine development has proven to be a daunting task. The biggest obstacles are 
the high degree of antigenic variation of the virus that renders vaccines unprotective 
against field isolates [145, 169]; and the absence of an effective immune response 
capable of completely controlling the natural infection, with the exception of few elite 
controllers and long-term non-progressors., has made it difficult to identify definitive 
correlates of protection and viral control [170]. 
Most of the HIV vaccine development effort in the past decade has focused on eliciting 
anti-HIV CDS+ T-cell responses. This is partly because previous antibody based 
vaccines failed to elicit protective neutralising antibodies [171, 172]. In addition, CDS+ 
T-cell responses have been shown to playa crucial role in the partial control of viraemia 
during acute HIV infection and in chronic infection in patients carrying some HLA 1 
alleles [96, 97, 99, 101, 102]. However, the failure ofa purely T-cell based vaccine in 
the STEP trial coupled with the realization that a subset of chronically HI V-infected 
individuals naturally develop broadly neutralising antibodies has rekindled the interest 
in developing antibody based vaccines [lOS, 173]. Moreover, RV144, the only HIV 
vaccine to show some efficacy, did not elicit any CDS+ T cell responses but had 
detectable CD4+ T cell responses and antibody responses [174], suggesting that a 
combination of responses may confer better efficacy. 
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CD8+ T cells respond to antigen-derived peptides that are presented on MHC class I 
molecules. This is best accomplished if the antigen of interest is produced 
endogenously, even though exogenously produced antigens can also be presented via 
MHC class I, but less efficiently, by cross-presentation [175]. To achieve endogenous 
production of HIV antigens in antigen presenting cells, viral vectors and plasmid DNA 
have been used to deliver the genetic codes of antigens into host's cells [173]. 
The administration of plasmid DNA can be manipulated to elicit the desired CD4+ T 
cell responses that may act as appropriate helper cells to either CDS+ T cells or B cells 
in subsequent immunizations [176]. As a result, DNA vaccines have mainly been used 
to prime the immune system in prime-boost regimens. Unfortunately, they have poor 
immunogenicity when compared to other platforms. However, in vivo electroporation 
as well as incorporation of molecular adjuvants (cytokine and chemokines) have been 
shown to enhance their immunogenicity [177, 178]. A considerable advantage of using 
plasmid DNA has been the lack ofvector-directed immune responses in vaccinees. 
The most widely used viral vectors are poxvirus and adenovirus based vectors. The 
most commonly used poxvirus vectors are modified Vaccinia ankara (MVA) and 
AL V AC. Poxvirus vectors tend to express other vector proteins that may focus the 
immune response away from the HlV antigen of interest, whereas adenovirus vectors 
can be easily engineered to express only the HIV antigen of interest [179]. However, 
preexisting immunity against the various serotypes of adenovirus may greatly influence 
their immunogenicity [180). To address this problem, chimpanzee adenoviruses that 
humans rarely encounter naturally are now being used with relatively good success 
[181, 182]. 
Previous protein-based vaccines that failed to generate broadly neutralising antibodies 
consisted of recombinant envelope glycoproteins expressed from particular laboratory 
and field strains [171, 172). Following the recent intensive investigation of B-cell 
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biology and propelties of HIV-I glycoproteins, coupled with the isolation of several 
broadly neutral ising antibodies that inform on the most promising targets for 
neutralisation, the design of HIV protein immunogens has taken a rational form [183]. 
Immunogens have been designed to focus the immune response to neutralisation 
sensitive epitopes as well as to limit the flexibility of the glycoprotein among other 
strategies [184]. 
To date, three phase III efficacy HIV -I vaccine trials have been reported. The first trial, 
named V AX004, evaluated AIDSV AX BIB that contained two recombinant gp 1 20 
antigens, one from the MN laboratory strain and the other from the ONE8 primary 
isolate. The vaccine did not show any protective efficacy, but peak antibody response 
among vaccinees seemed to negatively correlate with mV-I incidence [171, 185]. The 
second phase III efficacy trial, V AX003, was done in Thailand among intravenous drug 
users to evaluate AIDSV AX BIE that contained two recombinant gp 120 antigens, one 
from the CXCR4-dependent MN laboratory clade B strain and the other from a CCR5-
dependent CRFOI_AE primary isolate. It, too, did not show significant efficacy [172]. 
The third phase III efficacy trial, RV144, evaluated a prime-boost regimen whereby 
vaccinees were primed with a series of doses of ALVAC-HIV (vCP1521) followed by 
boosting with AIDSYAX B/E. ALVAC-HIY (vCP1521) is a recombinant Canarypox 
vectored vaccine that encodes for gag, pro and gp 120 linked to the transmembrane 
anchoring portion of gp41. The RVI44 trial showed a protective efficacy of 31.2%, 
proving for the first time that HIV -I infection can be prevented by vaccination in 
humans [174]. Subsequent analysis for immune-correlates revealed that binding of IgO 
to VIIV2 region of gpt20 correlated inversely with rate of infection while binding of 
plasma IgA correlated directly with rate of infection [186]. 
Many more HIY vaccines have been tested in preclinical, phase I and phase II trials 
with varying outcomes. Notable among them is MRKAd5 HIV -I gaglpoVnef vaccine 
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that was evaluated in the Phase lib STEP study on individuals at high risk of /-IIV 
acquisition. It comprised of I: I: 1 mixture of three replication-defective AdS vectors, 
one each encoding for gag, pol and nef. Interim analysis showed that the vaccine neither 
protected from infection nor controlled viral load upon infection, prompting termination 
of the study. Surprisingly, there was an increase in the rate of HIV infection among 
vaccine recipients who were uncircumcised or had pre-existing high titres of anti-vector 
antibodies [173]. A similar phase lIb trial that comprised of AdS vectors encoding for 
Gag, Pol, Nef and Env proteins, HVTN 505, also showed lack of efficacy despite the 
fact that individuals who had high titres of anti-vector antibodies were excluded in the 
recruitment [187]. 
1.11 B-cell biology 
B cells are the lymphocytes that are responsible for the production of antibodies. They 
also produce cytokines that affect other immune cells during immune responses. 
Several receptors that play a role in the activation of human B cells have been 
described. They include B cell receptor (BCR), CD40, Toll like receptors (TLRs) and 
cytokine receptors among others. 
The BCR is a transmembrane receptor that interacts with the cognate antigen for the 
particular B-cell clone and initiates the B-ce\1 response. It consists of two moieties 
namely [188]: 
(a) Surface immunoglobulin that acts as the ligand binding moiety 
(b) Signal transduction moiety consisting oftwo components, Igcx and Igp. 
CD40, on the other hand, is a membrane bound receptor belonging to the TNF-receptor 
superfamily. It is expressed on B cells, dendritic cells and macro phages among other 
cells. Its natural ligand is CD40 ligand (CD40L) that belongs to the TNF-superfamily 
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and is expressed on the surface of activated helper CD4+ T cells [189-191]. The CD40-
CD40L interactions between T cells and B cells are crucial in the generation of optimal 
antibody responses as evidenced in humans that have defective CD40 signalling and 
subsequently have defective antibody responses [\92]. 
Another important signal in activation of B cells is mediated via Toll like receptors 
(TLRs), germ line encoded receptors of the innate immune system that were so named 
due to their similarity with the toll protein in drosophila. They recognise conserved 
structural patterns on pathogens (pathogen associated molecular patterns-PAMPs) and 
like the toll protein, they initiate innate immune responses against the invading 
pathogens. They belong to a class of receptors called pattern recognition receptors 
(PRRs) [193-196]. Ten different toll like receptors have been identified in humans, 
TLRI-TLRI0. They are mainly found in the cells of the innate immune system, though 
some are also expressed in B cells [197, 198]. In addition to initiating innate responses, 
they have been shown to significantly modulate the adaptive immune response [199-
201]. Human B cells express TLR1, TLR2, TLR6, TLR7, TLR9 and TLRIO [197. 198, 
202]. Of particular interest for this thesis are TLR7 and TLR9 that are located in 
endosomal compartments and act as ligands for single stranded RNA and DNA, 
respectively [203-205]. They are located intracellularly in endosomal compartments so 
that they can detect the genetic material of pathogens after degradation of the pathogens 
by intracellular lytic enzymes. Their ligation by pathogen DNA or RNA initiates 
signalling via NFKB that eventually influences the expression of various 
proinflammatory genes, some of which playa role in influencing the antibody response 
[206]. 
Cytokine receptors have been shown to strongly modulate the effect of CD40L, TLR 
ligands and BCR ligands on B cells. For instance, IL21 is the most potent cytokine that 
is produced by activated T cells to influence the proliferation and differentiation of B 
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cells during an immune response (206). It also promotes the antitumor effect of natural 
killer cells and cytotoxic T cells [207,208]. It is a member of IL-2 family of cytokines, 
which also comprises IL-2, IL-4, IL-7, IL-9 and IL-15.lts receptor, IL-2IR, is generally 
expressed on B cells, but with varied expression levels in different B-cell subsets [209, 
210]. 
In an ideal T-dependent antibody response, the activation of B cells starts with the 
interaction of the B cell receptor (BCR) with the cognate antigen on the invading 
pathogen. The binding of the antigen onto the BCR leads to two outcomes. Firstly, the 
BCR delivers signals via various intracellular signalling pathways. Secondly, the BCR 
delivers the antigen to intracellular endosomal compartments by a process of receptor-
mediated endocytosis. In some instances where the antigen is part of a whole 
pathogenic organism, the process may lead to internalization of the whole pathogen 
[206]. The antigen is then degraded into peptides, among other components, leading to 
release of any associated genomic material that can act as ligand to the endosomally 
located toll like receptor (TLR) 7 and TLR 9 that recognise single stranded viral RNA 
and bacterial DNA, respectively. Signalling via toll like receptors therefore leads to a 
second signal in the responding B cell [211]. The peptides that are generated from the 
degradation of the antigen are then loaded onto MHC-II molecules and displayed on the 
surface of the B cell. The peptide:MHC-1I complexes are recognised by the T cell 
receptors (TCR) of cognate helper T cells that have been primed by dendritic cells that 
display the same peptides after encountering the same antigen, a phenomenon called 
linked recognition. This interaction leads to the provision of T-cell help onto the B cell 
via contact and soluble factors. Most notable is the interaction of membrane-bound 
CD40 ligand on the T cells with CD40 on the surface of the B cell. CD40-CD40L 
interaction has been shown to be a crucial additional (third) signal that dictates the fate 
of the responding B cell [206]. Cytokines (e.g. IL2l and IL4) produced by the helper T 
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cells al so provide an additional (fourth) signal that modulates the response of the 8 ce ll s 
[212]. 
AIL .............. LA 
Figure 1.6: Activatory signals that influence S cell s during an immune response. Signal I-SeR cross 
linking; Signal 2-signalling via to ll li ke receptors; Signal 3-contact T-cell help; Signal 4-signalling via 
cytokine from helper T cell s 01' innate cells (Adapted from Lanzavecch ia et al [211)). 
When B cells are activated via the above-described signals, the 'quality and magnitude 
of the response is greatly influenced by the processes that take place in germinal centre 
microenvironments. Germinal centres are anatomical s ites in lymphoid organs where B 
cell-T ce ll interactions occur. Normally, when a B cell encounters its cognate antigen, it 
undergoes clonal expansion. Some of the daughter cells may differentiate extra-
follicularly into short-lived plasma cells that secrete mainly IgM. Others may part icipate 
in a germinal centre reaction where they undergo severa l rounds of somatic hyper-
mutat ion of their immunoglobu lin genes and Darwinian selection, lead ing to antibody 
av id ity maturation. Concurrently, they also undergo class-switch recombination, lead ing 
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to expression of switched immunoglobulin isotypes. Eventually, the ce lls diftereilliate 
into either long-lived plasma ce ll s or memory B ce lls (F igure 4. 1) [213]. 
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Figure 1.7: An ideal B-cell response. B cell s go through clonal expansion, extra to ll icular differentiation 
into short-li ved plasma cell s, germinal centre reaction consisting of somatic hyper mutation (SHM). class 
switch recombination (CSR), and selection with the eventual production of long-lived plasma cell s and 
memory B cells [213]. 
Thus, the germinal centre reaction influences the quality of antibody response by 
enabling avidity maturation and class switching from IgM and IgO expression to IgG, 
IgE and IgA expression. Depending on the cytokine environment, the IgO class 
switching cou ld be to any of the subc lasses IgO 1, Ig02, Ig03 or Ig04 [206]. 
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Role of cytokines in regulating expression of antibody classes 
Cytoklnes IgM IgG3 IgG1 IgG2b IgG2a IgE IgA 
IL-4 I Inhibits I 'Inhibits I I Induces I D 'Inhibits I I Induces I! I 
IL-S D D D D D D I~ Augments.1 production 
IFN4 I Inhibits I !Induces I I Inhibits I D !Induces I I Inhibits I! I 
TGF-~ !Inhlblts I 'Inhibits I D !Induces I D D !Induces I 
Figure 1.8: Effect of various cytokines on the secretion of different immunoglobulin isotypes and sub-
classes by mouse B cel ls. Red-inhibits, violet- induces, blue-augments.The inhibitory etfect on secretion 
of particular isotypes or sub-classes is as a result of the mutually exclusive induction of other isotypes or 
sub-classes (From Janeways lmmunobiology [206]). 
Avidity maturation leads to production of antibodies that bind their target antigen more 
avidly and therefore have better efficacy in controlling the infect ion. On the other hand, 
class switching confers new effector functions that are critical in the efficacy of the 
antibodies to control the target infections as summarised in the table below [206]. 
Functional activity 
Neutralization 
Opsonization 
Sensitization for 
killing by NK cells 
Sensitization 
of mast cells 
Activates complement 
system 
IgM IgO IgG1 Ig62 IgG3 IgG4 IgA IgE 
Figure 1.9: The effector functions of various human immunoglobulin isotypes and subclasses. +++/Red-
major effector function, ++/dark pink-lesser effector function , +/Iight pink-minor effector tunct ion. * 
IgG2 opsonisation effect is dependent on presence of a certain Fc receptor allotype (From Janeways 
lmmunobiology [206]). 
32 
In so me pathological conditions like HIV and malaria, other than naNe ane! class ical 
memory B cells, other B-cell subsets have been detected in significant fi'equencies in 
peripheral circulation. Some of these subsets have been previously described in the 
developmental pathway of B cells e.g. HIV infection in adults has been associated with 
increased frequencies of immature/transitional B cells, plasmablasts and activated 
mature B cells. However, a newly described B-cell subset has also been detected in HIV 
and malaria patients as opposed to healthy controls. These cells have been referred to as 
atypical memory B cells or tissue-like memory B cells or exhausted memory B cells 
[214, 215]. 
BONE MARROW PERIPHERY 
Immaturel ~@) Transilional Naive B cell B cells ImmatlnBcetI C02l·C027· C02l. C027· COlO. 
COlO. C019. COlO. C038+C010+ 
© Classical Memory B cetts C02l. C027+ COlO. 
))) @D @ 
~ Atypical memory B cell C02l · C027· COlO· 
long-lived plasma cells @) cQ]) C0191owC02o.C010· C02 I· C027 ++ 
Activaled mature B cell Short·llved plasma cell 
C021- C027. COlO· C02l · C027++C038+++ 
Fi gure 1.10: Summary ofthe possible difterentiation pathways that B cells may go through both in health 
and disease [214. 215]. 
33 
1.12 Justification for the study 
With the renewed interest in developing antibody-based HIV vaccines, it is important to 
understand the interactions of the virus with the B-cell compartment. Current literature 
suggests that HIV has deleterious effects on B cells, either directly or indirectly, and it 
could benefit from some of these effects which blunt antibody responses against itself 
[215]. 
Detailed descriptions of the B-cell defects in adults infected with HlV have been 
reported [84, 215]. However, descriptions of B cell defects in children have not been 
done to the same depth. Unlike adults who become infected in adulthood when their 
immune systems have already matured, children differ in that they have less experience 
of antigen exposure and have an immature immune system that develops against a 
background of HIV infection. Children do not control viral load and have a much more 
rapid disease progression if untreated [77-79]. Moreover, the tolerogenic nature of the 
early immune system may affect the interaction of the virus with the B-cell 
compartment [115]. 
The general objective of this study was to describe the nature and cause of phenotypic 
and functional defects of B cells in children infected with HIV. The specific objectives 
were to: 
1. Describe the subset distribution ofB cells in children infected with HIV. 
2. Describe the B-cell responses to common childhood vaccines in children 
infected with HIV i.e. 
a. Quantities ofantibodies in circulation. 
b. Avidities ofantibodies in circulation. 
c. Frequencies of memory B cells in peripheral blood. 
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3. Describe the memory B-cell responses to pneumococcal capsular 
polysaccharides in children after natural exposure or vaccination with a 
pneumococcal conjugate vaccine. 
4. Determine the in vitro response of B cells to different B-cell stimulant-
combinations and evaluate the in vitro effects of recombinant HIV -1 Nefprotein 
on B-cell responses to such stimulant-combinations. 
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Chapter 2 Materials and methods 
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2.1 Study site 
HIV-infected children were recruited from the Comprehensive Care and Research 
Clinic (CCRC) in Kilifi District Hospital (KDH). The hospital is located in Kilifi along 
Kenya's Indian Ocean coast, approximately 60KM north of Mombasa. Community 
controls were recruited from the 'Ngerenya cohort', a low endemicity malaria 
epidemiological surveillance cohort located to the north of KDH [216]. Additional 
children were recruited from the Pneumococcal non-typeable Haemophilus Influenza 
protein 0 conjugate vaccine (PHiD-CV) Reactogenicity and Immunogenicity Study in 
nearby Malindi (PRISM) to evaluate the acquisition of B-cell memory after natural 
exposure to pneumococcal antigens and after adminstration of the pneumococcal 
conjugate vaccine [217]. Biological samples from all study participants were analysed 
at the KEMRI-Wellcome Trust Research Programme laboratories. 
In vitro experiments to evaluate the effect of different stimulants on B cells and effects 
of pre-incubation with recombinant HIV -1 Nef on B-cell responses to the stimulants 
were done in Dr Britta Urban's laboratory at Liverpool School of Tropical Medicine. 
Bufry coats obtained from healthy blood donors were purchased from the National 
Health Service Blood and Transplant service. 
2.2 Ethical considerations 
The study was approved by the Kenya Medical Research Institute (KEMRI) Ethical 
Review Committee (ERC) under protocols SSC No: 113 I, SSC No: 1633 and SSC No: 
1635. Written informed consent was obtained from the parent/guardian of every 
participating child. 
Buffy coats were ordered from National Health Service Blood and Transplant service 
under the Liverpool School of Tropical Medicine Research Tissue Bank Approval 
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CREe ref ll /H 1 002/9) and were held uncleI' the Huma n Tissue Authori ty lice nse num ber 
12548 . 
2.3 Study designs 
The CCRC study was a cross-sectional study a imed at recruiting ch ildren of comparable 
ages belonging to the four treatment groups as shown in figure 2.1. 
Untreated HIV 
(first clinic visit) 
Age-matched groups of children 
HIV 
+ 
cotrimoxazole 
HIV 
+ 
cotrimoxazole 
+ 
HAART 
Community 
Controls 
1. Multi-parameter flow cytometry: distribution of B-cell subsets 
2. Cultured B-cell ELiSpot: IgG memory B cells responses: 
(tetanus toxoid, pneumococcal capsular polysaccharides, measles) 
3. ELISA: antibodies in plasma 
4. Modified ELISA: antibody avidity 
Figure 2. 1: Cross-sectional design of the study comparing 1-IIV-infected children at CCRC with 
community control children in Ngerenya 
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The PRISM study was a double blind randomized controlled clinical trial. It evaluated 
imtnunogenicity and reactogenicity to a PHiD-CV vaccine in children aged 12-59 
months. In a memory B cell sub-study, PBMCs from 35 participants in group B (see 
Table 2.1) aged 12 to 24 months were collected on the day of enrollment Gust before 
the first dose), 30 days after enrollment (1 month after first dose) and 210 days after 
enrollment (1 month after second dose) and were used to evaluate the frequencies of 
memory B cells against tetanus toxoid, diphtheria toxoid and some of the pneumococcal 
capsular polysaccharides in the PHiD-CV vaccine. Therefore, the sub-study was a 
longitudinal study whereby participants were followed lip after receiving the PHiD-CV 
vaccine on the day of enrollment, DTaP (Diphtheria and Tetanus toxoids and acellular 
Pertusis) vaccine 60 days after enrollment and a second dose of PHiD-CV 180 days 
after enrollment. Data generated by other scientists in the randomized clinical trial on 
nasopharyngeal pneumococcal carriage and plasma anti-pneumococcal IgO levels were 
used in the analysis and interpretation ofthe ELiSpot data generated in the sub-study. 
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Group A Gro up B Group C 
N=200 N=200 N=200 
Day 0 PHiD-CV PHiD-CV 
Hepatitis A 
vaccine (Havrix) 
Day 60 PHiO-CV DTaP (Infanrix) DTaP (Infanrix) 
Hepatitis A 
Day 180 DTaP (lnfanrix) PHiD-CV vaccine (Havrix) 
and PHiO-CV 
Table 2. 1: The vaccinatIOn schedu le In the PRISM study: DTaP-Dtphthena and Tetanus toxolds and 
acellular Pertusis, PHiD-CV- Pneumococcal non-typeable Haemophilus Inf/uen=a protein D conjugate 
vaccine. 
PHiD-CV 
vaccine 
NP swab 
Blood 
o 
Blood 
30 
DTaP 
vaccine 
60 
PHiD-CV 
vaccine 
NP swab 
180 
Blood 
210 
Figure 2.2: Longitudinal design of the memory B cell sub-study showing time points when participants 
received the PHiD-CV, received a nasopharyngeal swab or donated a blood sample. Cultured B-cell 
ELlSpots were done on the PBMCs that were isolated fi·om the blood samples. 
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In the in vitro assays, PBMCs were isolated t1'om buffy coats to determine the etl'ects of 
various stimulant-combinations on B cells. The effects of recombinant HIV -I proteins 
were assessed by pre-incubating the PBMCs with the recombinant proteins and then 
stimulating them with the various B-cell stimulant-combinations. 
2.4 Criteria for inclusion of study participants 
HIV-infected children 18 months to ten years who were registered in the CCRC were 
recruited if they consented and met any of the following criteria. 
• They had not started cotrimoxazole prophylaxis i.e. on their first visit to the 
CCRC. 
• They had been on cotrimoxazole prophylaxis (without HAART) for at least six 
months. 
• They had been on HAART and cotrimoxazole prophylaxis for at least six 
months. 
Community controls from the malaria surveillance cohort were recruited if they had 
consented to take part in the malaria surveillance and if they were of similar age to the 
HIV-infected children recruited from the CCRC. 
Children participating in the PH iD-CV clinical trial were included in the memory B cell 
sub-study if they were 12-24 months old and if they consented to take part in the 
PRISM study. 
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2.5 Criteria for exclusion of study participants 
Any child whose guardian did not give written informed consent or withdrew consent to 
participate in the study was excluded. In addition, HIV -infected children at CCRC were 
excluded if: 
• They had severe malnutrition i.e. mid upper arm circumference <t tcm. 
• They had any other active infection e.g. tuberculosis. 
Community controls from the malaria surveillance cohort were excluded if: 
• They had an acute illness at the time of sampling or in the previous week. 
• They had a positive malaria slide. 
Children participating in the PHiD-CV clinical trial were excluded if: 
• They had febrile illness (temperature >38.5°C axillary) at the time of vaccine 
dose t. 
• They had previously received any pneumococcal vaccine. 
• They had previously received DTP-containing vaccine after the first year of life. 
• They had severe malnutrition (mid upper arm<I1.5 cm) or other serious 
medical conditions (e.g. AIDS, tuberculosis, malignancy). 
• They had convulsions in the past 6 months. 
• They had known allergies to vaccines or vaccine components. 
• They were resident in Kilifi Demographic Surveillance area. 
• They intended to leave the study area in the following six months. 
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2.6 Sampling procedures 
At the CCRC, study pa11icipants were asked to donate additional 3 ml of blood in 
heparin tubes for the study at the same time when they gave 2 ml in Ethylene Diamine 
Tetraacetic Acid (EDTA) tubes for routine monitoring of their CD4+ T-cell counts. 
This reduced the distress associated with being bled. They were also asked if the left 
over blood from the CD4+ T-cell count could be used for the study. 
Community controls donated 5ml of blood in heparin tubes during the annual cross-
sectional survey that is part of the malaria surveillance studies. 
Participants of the PRISM clinical trial donated 5 ml of blood in heparin tubes during 
each of the scheduled time points as per the protocol ofthe trial. 
Trained phlebotomists, nurses or clinical officers did all collection of blood samples. 
In the collection of nasopharyngeal swabs, a rayon-tipped nasal swab was passed along 
the nasal-cavity floor to the posterior wall of the nasopharynx where it was left for two 
seconds then rotated) 80° before being removed. The swabs were then placed in skim-
milk tryptone glucose glycerol (STGG) transport media and processed within 8 hours. 
Optochin susceptibility testing and Quellung serotyping were used to identify 
Pneumococci from gentamicin-blood agar. 
2.7 Processing of samples in the laboratory 
Once collected, the blood samples were transported to the laboratory in cooler boxes. In 
the laboratory, the EDTA sample was used for complete blood counts and CD4+ T-cell 
counts determination. It was then used for whole blood flow cytometry staining. Plasma 
was separated from the left over EDT A sample and stored at -20°C for later 
determination of plasma viral load. For cultured B-cell ELI Spots, the heparin tube 
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samples were used. First, plasma was separated fi'om the cellular fraction by 
centrifugation and stored at -20°C for later determination of plasma antibodies and 
cytokines. The cellular fraction was then re-suspended in culture media and PBMCs 
isolated by density gradient centrifugation using Lymphoprep®. The freshly isolated 
PBMCs were then cultured for ELlSpots to determine the frequencies of antigen 
specific memory B cells. 
Buffy coats were suspended in RPMI and subjected to density gradient centrifugation 
for isolation of PBMCs. Some of the cells were stored in liquid nitrogen for later in 
vitro experiments. 
2.8 Determination of CD4+ T cell counts and complete blood counts 
Determination of CD4+ T-cell counts and complete blood counts was outsourced from 
the KEMRI-Wellcome Trust Research Programme Clinical Trials Laboratory (CTL). 
CD4+ T-cell counts were done using BD FACSCount™ machine. Complete blood 
counts were done using Beckman Coulter Ac.T 5 diffCP machine. 
2.9 Determination of plasma viral loads 
Determination of plasma viral loads was outsourced from the International Centre for 
Reproductive Health (lCRH) laboratories in Mombasa. They used the Generic HIV 
Viral Load assay, (Biocentric) - a RT-qPCR test developed by the Agence Nationale de 
Recherches sur Ie SlDA (ANRS) targeting a well-conserved LTR region [218, 219). 
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2.10 Cell preparation and staining of surface markers for 
determination of phenotypes of B cells in children infected with 
HIV 
Frequencies of the lymphocyte subsets were determined in whole blood by multi-colour 
flow cytometry. The following antibodies were used: anti-CD19-ECD, anti-CD3-ECD, 
anti-CD27-Pe-Cy5, anti-CD I O-FITC, anti-IgD-PE, anti-CD2I-FITC (Beckman 
Coulter); anti-CD3-FITC, anti-CD4-Pe-Cy7, anti-CD8-APC-H7, anti-CD20-APC-H7, 
anti-CD 1 O-PE (BD Biosciences); anti-CD21-PE and anti-CD38-Pe-Cy7(eBioscience}. 
Whole blood was washed twice with Phosphate Buffered Saline containing 2% Fetal 
Calf Serum (FCS), 5mM EDTA and 1% Sodium Azide. It was then incubated with 
staining antibodies for 30 minutes, RBCs lysed for 10 minutes in OptiLyse C® lysis 
Solution (Beckman Coulter) and washed again before analysis. A no-wash staining 
procedure in Trucount tubes (BD Biosciences) was done to determine absolute counts 
ofT cells and B cells. A nine-colour Cyan ADP flow cytometer (Beckman Coulter) was 
used. The data were analysed using Flowjo version 9.2 (TreeStar). 
2.11 ELISA for determination of quantities of antibodies to vaccines 
and common childhood infections 
Plasma samples were tested for IgO and IgM against vaccine antigens using a 
previously established ELISA protocol with various modifications [220]. Briefly, plates 
were coated overnight at 4°C with 100 J.LUwell antigen solution (lJ.lg/ml for tetanus 
toxoid and diphtheria toxoid, 5J.lglml for measles antigen) in bicarbonate buffer. Tetanus 
toxoid and diphtheria toxoid were obtained from Statens Serum Institut whereas the 
measles virus lysate/antigen was obtained from Meridian Life sciences. For 
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determination of antibodies against pneumococcal capsular polysaccharides, a mixture 
of capsular polysaccharides from ATCC (serotypes 1,5, 6B, 14, 19F and 23F, each at 
10 J.lg/ml) in PBS was used. The plates were then washed three times with the wash 
buffer (0.05% tween in PBS) followed by blocking for at least 1 hour with 200 ~lUwell 
of blocking buffer (10% Foetal Calf Serum in PBS). After discarding the blocking 
buffer, the plates were incubated with 100 J.lUwell of the test plasma samples at a 
dilution of 1 :200 in the sample diluent buffer (0.3% tween in PBS +EDTA) for two 
hours. They were then washed four times and incubated with 100 J.lUwell HRP-
conjugated donkey antihuman IgG/lgM diluted at 1 :5000 in the conjugate diluent buffer 
(0.05% tween in PBS). After one hour, the plates were washed five times and the HRP 
labelled conjugate revealed with 100 J.lUwell OPD substrate (Sigma). The substrate 
reaction was stopped by adding 50 J.lUwell of 2N sulphuric acid. The optical density 
was determined at 490 nm. Antibodies were quantified against hyper-immune plasma 
that was used to generate a standard curve for each plate. Antibody concentrations were 
expressed as arbitrary units that were calculated against the standard curve for the 
respective plates. 
For the PRISM study, the determination oflgG against each of the 10 vaccine serotypes 
was done by other scientists in the WHO Pneumococcal Reference Laboratory at 
Institute of Child Health, University College, London. 
2.12 Modified ELISA for determination of avidity of antibodies to 
vaccines and common childhood infections 
For determination of the avidity of IgG antibodies, the above ELISA method was used 
with some modifications. After incubating with the test plasma samples, the bound 
antibodies were eluted by incubating the plates with 100 J.lLlwell of a chaotropic agent 
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(2M Guanidine Hydrochloride in conjugate buffer) for ten minutes. The control wells 
for each sample (on the same plate) were incubated with the conjugate buffer. The 
plates were then incubated with HRP-conjugated donkey antihuman IgG and developed 
as described above. The avidity index was calculated as the ratio of the quantity of 
antibodies in the eluted wells to the quantity in the control non-eluted wells. 
2.13 Cultured B-cell ELISpot for determination of frequencies of 
antigen specific memory B cells 
Memory B cells against vaccine antigens were quantified using the standard method 
developed by Crotty et al [221]. Briefly, freshly isolated PBMCs were cultured for 6 
days in RPMI complete media (RPMI + 10% newborn bovine serum + L-glutamine + 
penicillin Streptomycin + Hepes + J3-mercaptoethanol) containing 2.5 ~lg/ml CpG OON 
2006 (Hycult Biotech), 1:5000 dilution of Staphylococcus aureus Cowan Strain protein 
A (Sigma) and 0.083 l1g/ml of Poke-Weed Mitogen (Sigma) at 2xl05 cells per 200 l1L 
in V-bottomed 96-well culture plates. 
ELiSpot plates were pre-coated overnight at 4°C with the antigen of interest (at a 
concentration of5~lg/ml for tetanus toxoid or 10~lg/ml for measles antigen) or with Goat 
antihuman Igs (Caltag) at 1 O~lg/ml. Negative control wells were coated with 1 % BSA as 
a non-specific protein control. For determination of memory B cells against 
pneumococcal capsular polysaccharides in CCRC and Ngerenya children, a mixture of 
capsular polysaccharides from ATCC (serotypes 1, 5,68, 14, 19F and 23F, each at 10 
).lg/ml) conjugated with 30 ~lg/ml of methylated human serum albumin (mHSA) 
(National Institute for Biological Standards and Control-UK) was used. For 
determination of serotype-specific memory B-cell responses in children who 
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participated in the PRISM study, pneumococcal capsular polysaccharides for serotypes 
I (20 Ilg!ml), 6B (10 ~Lg!ml), 14 (10 Ilg/ml), 19F (20 ~Lg/ml) and 23F (20 ~lg/ml) 
obtained from GSK biologicals, Rixensart, Belgium were used separately and were 
conjugated to mHSA at a concentration of 10 ~lg!ml for serotypes I & 14 and 20 Ilg/ml 
for serotypes 6B, 19F & 23F. Negative control wells were coated with mHSA at to 
~lglml. 
The ELlSpot plates were washed three times with PBS and blocked for at least one hour 
with 10% New Born Bovine Serum (NBBS) in RPMI. PBMCs harvested from the 6-
day cultures were seeded into the ELlPSpot plates at 200 and 2000 cells lweI! (totallgG 
secreting cells) and at 2 x 205 cells/well (antigen-specific \gG secreting cells) and 
incubated at 37°C in 5% carbon dioxide and 95% humidity overnight. The cells were 
discarded and the plates were washed four times with 0.25% tween in PBS followed by 
a five-minute soak with PBS. They were then incubated with 50 ~lL/well of Alkaline 
phosphatase conjugated donkey antihuman IgG (Jackson ImmunoResearch 
Laboratories) for two hours followed by five washes with 0.25% tween in PBS and 
three washes in distilled water. Spots were developed by adding 50IlL/well of substrate 
(Bio-Rad). The reaction was stopped by washing with distilled water. The plates were 
left to dry, then scanned using CTL Immunospot analyser. The spots were counted 
using pre-established settings in Immunocapture software. 
2.14 Staining PBMCs with carboxyfluorescein diacetate succinimidyl 
ester (CFSE) for determination of proliferation in culture 
Tracking of proliferation of PBMCs was done using the CellTrace™ CFSE Cell 
Proliferation Kit (Invitrogen) in accordance to the manufacturer's instructions. Briefly, 
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the ce lis were suspended in prewarmed PBS/D. I % BSA at a tinal concentration of 
IXI06 cells/ml. CFSE dissolved in anhydrous DMSO was then added to the cells to 
give a final working concentration of I J.lM. The cells' suspension was mixed thoroughly 
and incubated at 37°C for 10 minutes. The staining was quenched by adding 5 volumes 
of ice-cold culture media to the cells followed by incubation in ice for 5 minutes. The 
cells were then pelleted by centrifugation, resuspended and washed twice before being 
placed in culture. 
2.15 Setting up of cultures for determination of in vitro effects of 
various B-cell stimulants and the effects of recombinant HIV-l 
Nef on the B-cell responses to the stimulants. 
PBMCs isolated from buffy coats donated by healthy donors were cultured at 2xl05 
cells per 200 ,...L in U-bottomed 96-well culture plates at 37°C in 5% carbon dioxide and 
95% humidity. In some cases, stored PBMCs were thawed rapidly at 37°C, washed and 
counted then cultured. Some of the cultures were set up using CFSE-stained cells for 
tracking of proliferation in cu lture. 
In experiments where the effect of HIV-l Nef (Jena Bioscience) was being evaluated, 
cells were first pre-incubated with recombinant HIV-l proteins (100 nglml of wild-type 
HIV-l Nef or mutant non-myristoylated HIV-l Net) or media alone for 24 hours. 
The various stimulant-combinations were then added at pre-determined concentrations: 
CpG at IJlglml, R848 at 100 ng/ml, CD40L at 125 nglml (with enhancer for ligand at 
250 nglml), anti-Igs (BCR ligand) at 1.25J.lglml and IL21 at 50 nglm\. Supernatants and 
cells were harvested from some of the wells 48 hour after addition of stimulants. The 
supernatants were used for determination of secretion of IL6 and TNF-alpha while the 
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cells were used for determination of expression of activation markers on B cells. Five 
days after addition of stimulants, cells were harvested from some wells for 
determination of proliferation and differentiation into plasmablasts. Eight days after 
addition of stimulants, culture supernatants were harvested from the remaining wells 
and used for determination of secretion of immunoglobulins. 
PBMCs 
~ ! 
Wild-type Nef 
24hrs ~ 
Mutant non-myristoylated Nef 
~ 
Stimulants Nil Stimulants Nil Stimulants Nil 
\ y J 
1. Day 3: CD86 & TACI expression (markers of activation) 
2. Day 3: ELISA for IL6 & TNF-a 
3. Day 6: Proliferation & differentiation into plasmablasts 
4. Day 8: ELISA for totallgG & IgM 
Figure 2.3: Experimental design for detetmination orin vitro effects of recombinant HIV-J Ner. 
The various assays used to evaluate B-cell responses have been listed. 
2.16 Flow cytometry for determination of proliferation, differentiation 
into plasmablasts and expression of activation markers in 
cultured cells 
Anti-CD19-Brilliant Violet 421TM (Biolegend) was used for identification of B cells 
while Aqua LIVE/DEAD ® Fixable dead Cell Stain kit (Invitrogen) was used to 
50 
identify live cells. For determination of expression of activation markers, anti-CD86-PE 
(Biolegend) and anti-TACI-PE (Biolegend) were used. Differentiation of B cells into 
plasmablasts was assessed using anti-CD38-PeCy7 (Biolegend) and anti-CD27-PeCy5 
(Beckman Coulter). Proliferating cells were identified based on their content of CSFE 
stain. 
Harvested cultured cells were stained for viability in accordance with the Aqua 
LIVE/DEAD stain Aqua LIVE/DEAD ® Fixable dead Cell Stain manufacturer's 
instructions. Briefly, the cells were washed once in PBS and resuspended in PBS at a 
concentration of2xl05 cells per 200J..lL. 0.2J..lL of the viability stain was added and the 
mixture was vortexed thoroughly. The sample was incubated on ice, protected from 
light, for 30 minutes. The cells were then washed in 1 ml PBS and resuspended. 
To stain for expression of surface markers, the cells were incubated with staining 
antibodies for 30 minutes, washed in FACS buffer and acquired in an eleven-colour 
LSR II flow cytometer (BD). The data were analysed using Flowjo version 9.2 
(TreeStar). 
2.17 ELISA for determination of total immunoglobulins secreted into 
culture supernatants 
Culture supernatants were tested for total IgG and IgM using the protocol for 
determination of antigen specific antibodies with various modifications. Briefly, plates 
were coated overnight at room temperature with Goat antihuman Igs (Caltag) at 
10J..lg/ml in PBS (l00 J..lUwell). They were then washed three times with the wash buffer 
(0.05% tween in PBS) followed with blocking for at least 1 hour with 200 J..lUwell of 
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blocking buffer (1 % BSA in PBS). After discard ing the blocking butTer, the plates were 
washed 3 times and incubated with 50 ~LLlwell of the test culture supernatants at a 
dilution of 1:4 in the reagent diluent buffer (1% BSA in PBS) for two hours. They were 
then washed three times and incubated with 50jlLlweil HRP-conjugated donkey 
antihuman IgG/lgM (Jackson Immunoresearch laboratories) diluted at I :5000 in the 
reagent diluent (1 % BSA in PBS). After one hour, the plates were washed three times 
and the HRP labelled conjugate revealed with 100 jlLlwell OPD substrate (Sigma). The 
substrate reaction was stopped by adding 50 jlLlwell of 2N sulphuric acid. The optical 
density was determined at 490 nm. Antibodies were quantified against purified human 
IgG/lgM (Sigma) that was used to generate a standard curve for each plate. 
2.18 ELISA for determination of cytokines secreted into culture 
supernatants 
Determination of TNF-oc in culture supernatants was done using the DuoSet® ELISA 
system (R&D systems) in accordance with the manufacturer's instructions. First, 96-
well microplates were coated/incubated with 50jlL of capture antibody solution, mouse 
anti-human TNF-oc, at 4/lg/ml in PBS overnight at room temperature. They were then 
washed three times with the wash buffer (0.05% tween-20 in PBS). They were 
subsequently blocked by adding 200 J.lL of the reagent diluent (1 % BSA in PBS) for at 
least 1 hour. After discarding the reagent diluent, the plates were washed thrice and 
incubated with 50jlL of the culture supernatants diluted at 1:2 in the reagent diluent. 
They were then incubated for two hours at room temperature. The wash (three times 
with wash buffer) was repeated followed by incubation with 50J.lL of detection 
antibody, biotinylated goat anti-human TNF-oc, at a concentration of SOOng/ml in 
reagent diluent. The plates were incubated for a further two hours at room temperature, 
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washed three times with wash buffer and incubated with 50)..lL of 1:200 streptavidin-
HRP solution in darkness at room temperature for 20 minutes. They were then washed 
with wash buffer three times. 100)..lL of OPO substrate (Sigma) solution was added and 
left for 10 minutes away from light for the colour to develop. The reaction was stopped 
by adding 50 J.lL of 2N sulphuric acid. The optical density was determined at 490 nm. 
TNF-oc levels were quantified against recombinant human TNF-ac that was used to 
generate a standard curve. 
Determination of IL6 in culture supernatants was also done using the OuoSet® ELISA 
system (R&D systems) in accordance with the manufacturer's instructions. The 
procedure was the same as that used for determination ofTNF-oc levels but with some 
modifications. The capture antibody used was mouse anti-human IL6 (at 2)..lglml) while 
the detection antibody used was biotinylated goat anti-human IL6 (at 50ng/ml). The 
standard curve was generated using recombinant human IL6. 
2.19 Data storage 
The data were stored in personal computers and backed up in a central server and 
external hard disks. 
2.20 Statistical analysis 
The data were analysed using STATA version 11.0 (STATA Corporation TX, USA). P 
values below 0.05 were considered to be significant. Since the data were skewed, 
comparisons between groups were done using non-parametric tests. In particular, 
Wilcoxon rank-sum test was used to compare groups of children that were not paired 
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whereas Wilcoxon sign-rank test was used to compare paired samples from the same 
children that were collected at different time points. Regression analyses were done 
using quantile regression models. Stata Predxcon package (using linear regression 
models) was used to test for statistical interactions. Spearman's correlations were done 
to assess correlations between various variables. 
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Chapter 3 Phenotype of B cells in children 
infected with HIV 
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3.1 Literature review 
Although HIV primarily targets CD4+ T cells, it has been shown to affect all other 
lymphocyte populations, including B cells. In fact, defects in the B-cell compartment 
were among the first to be described in the early days of the epidemic [122]. Later 
studies showed that B cells in HIV patients over-express markers of activation and are 
terminally differentiated [123, 222]. 
The effect of ongoing viral replication in viraemic patients reflects a combination of 
both direct interactions of B cells with the virus and indirect interactions that are 
associated with a wide range of systemic alterations. There is little evidence to suggest 
that HIV can productively replicate in B cells. However, B cells in HIV patients' 
peripheral blood and lymphoid tissue have been shown to bind virions through CD21-
complement interactions and transmit infectious virus to activated T cells [223]. They 
therefore act as extracellular reservoirs like follicular dendritic cells, but with the added 
capability of circulating in peripheral blood and migrating through tissues where they 
can potentially interact with and pass the virus to T cells. Other surface receptors that 
interact with HIV virions have been described in B cells. DC-specific ICAM 3-grabbing 
non-integrin (DC-SIGN) has been described as a portal on a subset of B cells for HIV-I 
infection of T cells [224]. It has also been demonstrated that a subset of B cells binds 
gp120 through mannose C-type lectin receptors (MCLRs), leading to polyclonal class 
switch recombination through a CD40-independent mechanism [132]. In another study, 
B cells that express VH3 family Immunoglobulin were shown to polyclonally bind HIV 
gp 120 by means of membrane immunoglobulin. The gp 120 selectively induced 
immunoglobulin secretion by VH3 B cells, indicating that the binding of gpl20 
functionally activated these cells. These results indicate that naturally occurring VH3 
immunoglobulin is a ligand for gp120 and that gpl20 is a candidate superantigen for 
VH3 B cells [225]. Of note, the direct effects of HI V virions on B cells described above 
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have only been demonstrated in vitro. Furthermore, the fraction of B cells carrying HIV 
virions on their surface is relatively low compared to the extent of B-cell dysfunction, 
suggesting that other indirect systemic effects may playa major role. 
Recent introduction of HAART has enabled delineation of the immune defects 
associated with HIV infection that are related to ongoing viral replication as opposed to 
defects that persist despite the suppression of detectable viraemia. Additionally, 
technological advancement with detailed characterization of B-cell subpopulations in 
health and disease has allowed scientists to better understand the mechanisms of 
pathogenesis of HI V by comparing B-cell subset distribution in patients before and after 
control of viraemia. 
In healthy adults, most B cells in the peripheral blood are either mature naive B cells or 
resting memory B cells. These two populations express high levels of C02 I (CR2). 
However, in viraemic HIV -infected adults, there is expansion of a C021 low subset that 
appears to contract to normal levels upon control of viraemia with HAART [123]. This 
C021 low subset has been shown to be heterogeneous, consisting of smaller subsets 
that are themselves independently expanded in the viraemic state. 
The C021 low immature/transitional B cells (COI9+, COlO+, C021 1ow, C03S++) are 
particularly increased in these patients. Their frequencies in adults have been shown to 
negatively correlate with C04+ T-cell counts, implying that C04+ T-cell lymphopenia 
drives this expansion and not viraemia per se. IL7, a T cell homeostatic cytokine, has 
been suggested to playa major role in causing this defect [226]. 
Another C021 low B cell subset (CDI9+, CDIO-, CD21 1ow, CD2T) has been recently 
described and is also expanded in viraemic patients. It comprises of cells that show 
properties of memory B cells i.e. some degree of somatic hypermutation and class 
switching as well as some replication history despite lacking C027 expression, the 
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classical marker of human memory B cells. These cells also express a range of 
inhibitory markers and homing receptors that favour migration to inflammatory sites 
away from lymphoid organs. Their phenotypic profile is similar to that observed in B 
cells isolated from tonsils of patients undergoing tonsillectomy [227]. 
Other CD21 low B-cell subsets that are elevated in HIV viraemic adults are 
plasmablasts (CDI9+, CD2110w, CD20low, CD27++, CD38+++) and activated mature B 
cells (CD 19+, CD21low, CD27+). Their frequencies have been shown to increase several 
fold in viraemic states and resolve after initiation ofHAART [123,215]. 
Notably, HIV infection in adults depletes the resting memory B-cell compartment 
(CDI9+, CD21 high, CD27+) [228]. This depletion has been shown to occur early in 
infection. Initiation of HAART does not restore this compartment. The mechanism of 
the depletion amidst generalized immune activation is poorly understood. It has been 
shown to correlate with the subsequent reduction of serum antibodies to non-HIV 
antigens and may contribute to the observed impairment of the humoral immune 
responses in HIV-infected patients [229]. 
The above B-cell defects have been mainly described in adults with HIV. Children 
infected with mv differ from adults in that their immune system is immature and 
develops against a background of HIV infection while adults get infected much later in 
life when their immune system has already matured. Additionally, children get infected 
when they have already been exposed to some HIV factors in-utero while adults get 
infected when they are totally naive to exposure to such HIV factors. Exposure of 
children to activating cytokines from their mothers in-utero could also modulate the 
interaction of their immune system with the virus. 
Much less is known about the subset distribution of B cells in children infected with 
HIV. One study was conducted in older children receiving HAART and showed that 
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despite effective HAART, these children had reduced fi'equency of [gO"'- memory while 
IgO" memory B-cell numbers were not affected [230], On the other hand, another study 
indicated a reduction in both switched and unswitched memory B cells that correlated 
with viral load [231], An additional study investigated the effect of early initiation of 
HAART. It reported that initiation of HAART in the first year of life preserved the 
memory B-cell compartment while later initiation, regardless of the resultant control of 
viraemia, led to depletion of memory B cells [232]. Notably, the above studies limited 
their investigation on the memory B-cell compartments. A later study investigated the 
effect of active HIV viraemia on immature/transitional B cells in children. Unlike 
healthy and aviraemic children, viraemic children showed a lack of age-related 
contraction of the immature/transitional B-cell compartment [233]. A more detailed and 
recent study showed that HIV-infected children who have very low C04+ T-cell 
percentages have reduced frequencies of naive B cells and resting memory B cells while 
their activated subsets are expanded [234]. 
Noteworthy is the fact that determination of B-ceU subset distribution in children has 
not been done to the same depth as in adults. 
3.2 Objective: 
To determine the subset distribution ofB cells in children infected with HIV. 
3.3 Gating strategy and data analysis 
Samples were prepared and acquired on the flow cytometer as described in chapter 2.10. 
The data were analysed using Flowjo version 9.2 (TreeStar). Lymphocytes were gated 
on the forward versus side scatter plot. Na'ive B cells were defined as CO 19+ C02T 
C02 I +, resting memory B cells were defined as CD 19+ C027+ C02 I +, activated mature 
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B cells were defined as CO 19+ C027+ C02 I", atypical memory B cells were defined as 
C019+ C02T C021", plasmablasts were defined as COI9+ C027++ C038+++, 
immature/transitional B cells were defined as COI9+ CO\o+ C038++, IgO+ 
(unswitched) resting memory B cells were defined as COI9+ C027+ C021+ IgO+ and 
IgO" (switched) resting memory B cells were defined as CO 19+ C027+ C02 I + IgO". For 
the determination of absolute counts of lymphocyte lineage populations, B cells were 
defined as COI9+, C04+ T cells were defined as C03+ C04+ C08" while C08+ T Cells 
were defined as C03+ C04" C08+. 
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Figure 3. 1: Gating strategy to identify the ditleren t B-cell subsets in peripheral blood ti'om a HIV-
infected child with high viraemia. Lymphocytes were identified on forward scatter-side scatter plot. 
Within th e lymphocytes gate, B cells were identified based on the expression of CD 19. Subsequent 
identitication of 8-cell subsets \¥as done within the 8-cell gate. 
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3.4 Results 
3.4.1 General population characteristics and frequencies of various lymphocyte 
lineages 
A total of 78 HIV-infected children were recruited into the study. 36 (46 %) children 
had high viraemia (>=5000 RNA copies per ml) while 42 (54 %) children had low 
viraemia «5000 RNA copies per ml). A further 28 children were recruited from a low-
endemicity malaria surveillance cohort as community controls. The population 
characteristics are as shown in table 3.1. 
As would be expected, the HlV-infected children had lower CD4+ T-cell percentages 
(25.5% [IQR, 17.8%-32.1%]) when compared with the community control children 
(33.8% [IQR, 28.1%-39.3%] P=O.OOOI). In addition, the high viraemia group had CD4+ 
T-cell percentages (22.2% [IQR, 9.2%-26.8%]) that were significantly lower than those 
of both the community controls (33.8% [IQR, 28.1 %-39.3%] P<O.00005) and the low 
viraemia group (29.4% [IQR, 22.5%-34.6%] P=0.0026). Notably, the low viraemia 
group had CD4+ T-cell percentages that were lower than the community controls 
(P=0.OI02). 22 (61%) highly viraemic children had low CD4+ T-cell percentages while 
14 (33%) of children with low viraemia had low CD4+ T-cell percentages. 
Consequently, among the HIV -infected children, there was an inverse correlation 
between viraemia and CD4+ T-cell percentages (rho=-0.4454, P=O.OOOI). 
Further stratification of the low viraemia group showed that those treated with HAART 
for at least 6 months also had lower percentages ofCD4+ T-cells when compared with 
community controls (29.8% [IQR, 25.5%-36.3%] P=0.0446), suggesting that they had 
only experienced partial recovery of CD4+ T-cell percentages despite effective control 
of viraemia upon initiation ofHAART. Similarly, the HAART na'ive children who had 
low viraemia had lower frequencies of CD4+ T cells when compared with community 
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controls (23.0% [IQR, 20.4%-33.4%] P=0.0125), suggesting that they had lost CD4+ T 
cells despite maintaining low viraemia. Their CD4+ T-cell percentages were also similar 
to those ofHAART na'ive children who had high viraemia (18.9% [IQR, 8.8%-27.4%] 
P=0.2048) and HAART-receiving children who had high viraemia (23.1% [IQR, 
13.0%-26.6%] P=0.4009). Notably, the children who had low viraemia and were on 
HAART had higher CD4+ T-cell percentages when compared with those who had high 
viraemia without HAART (P=0.0039), confirming that control of viraemia after 
initiation ofHAART leads to some recovery ofCD4+ T-cell percentages. There were no 
differences in CD4+ T-cell percentages when HAART-treated children were compared 
with HAART-na'ive children within both high viraemia and low viraemia groups. 
B-cell percentages were lower in the HIV -infected children (16.5% [IQR, 11.1%-
20.9%]) when compared with community controls (20.5% [IQR, 15.7%-23.7%] 
P=O.O I 06). This effect was also observed in the low viraemia group (15.3% [IQR, 
11.2%-20.7%] P=0.0091). On the other hand, the high viraemia group only had a trend 
towards having low B-cel1 percentages (17.8% [IQR. 9.8%-22.2%] P=0.0611) when 
compared with community controls. Further stratification of the low viraemia group 
revealed that the children who were on HAART had lower B-cell percentages (15.0% 
[IQR, 11.8%-19.5%]) when compared with community controls (P=O.OlI3). However, 
children who had low viraemia and were HAART na'i've did not differ from community 
controls in their B-cell percentages. HAART-na'ive HIV-infected children were similar 
with regard to their B-cell percentages regardless of their levels of viraemia. Similarly, 
children who were HAART -na'ive and had high viraemia were comparable to children 
who were on HAART and had low viraemia, implying that controlling viraemia after 
initiating HAART had not caused a difference in percentages of total B cells. Further 
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comparison of HAART-receiving versus HAART-na"ive children did not reveal any 
differences in 8-ce\1 percentages within both high viraemia and low viraemia groups. 
When the children were stratified on the basis of their CD4+ T-cell percentages, 
children who had low CD4+ T-cell percentages showed lower frequencies of 8 cells 
(15.2% [IQR, 9.6%-19.8%]) when compared with the community controls (20.5% 
[IQR, 15.7%-23.7%] P=0.0048). Upon further stratification on the bases of HAART 
treatment, both HAART-na"ive and HAART-treated children with low CD4+ T-cell 
percentages had lower frequencies of B cells (15.2% [IQR, 10.3%-20.9%], P=0.0270 
and 16.0% [IQR, 9.4%-19.3%], P=0.0106 respectively) when compared with 
community controls, suggesting that immunological failure correlated with depletion of 
total B cells. Interestingly, children who were HAART na"ive but had high CD4+ T-cell 
percentages were comparable with community controls, implying that maintenance of 
CD4+ T-cell frequencies in absence ofHAART is associated with maintenance of total 
8-cell frequencies. However, children who had high CD4+ T-cell percentages and were 
on HAART had lower frequencies of B cells when compared with community controls 
(15.8% [IQR, 12.1%-19.5%] versus 20.5% [IQR, 15.7%-23.7%], P=0.0180), suggesting 
that initiation of HAART and subsequent restoration of CD4+ T-cell frequencies was 
not associated with restoration ofB-cell frequencies. 
CD8+ T-cell percentages were elevated in the whole HIV-infected cohort when 
compared with the community controls (32.8% [IQR, 25.2%-41.7%] versus 15.8% 
[IQR. 13.7% .. 17.0%] P<0.00005). Both high and low viraemia groups had higher CD8+ 
T-cell percentages (37.1% [IQR, 31.5%-44.9%] and 27.0% [IQR, 22.2%-39.0%] 
respectively) than the community controls (15.8% [IQR. 13.7%-17.0%] P<0.00005 in 
both cases). In addition, the high viraemia group had higher CD8+ T-cell percentages 
than the low viraemia HIV-infected group (P=0.0003). When the children were further 
stratified on the basis of their HAART -treatment status, there were no differences 
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between HAART-treated and HAART na'ive children in both high viraemia group 
(37.2% [IQR, 31.8%-43.9%] versus 35.4% [IQR, 29.4%-50.4%] P=0.8684) and low 
viraemia group (25.5% [IQR, 16.6%-38.4%] versus 29.4% [IQR, 24.5%-40.7%] 
P=0.2589) with regard to CD8+ T-cell percentages. Furthermore, both HAART-treated 
and HAART-na'ive children with high viraemia had higher percentages ofCD8+ T cells 
when compared with HAART naiVe children who had low viraemia (P=0.0040 and 
0.0298 respectively). HAART -na'ive children who had high viraemia also had higher 
frequencies of CD8+ T cells when compared with HAART -receiving children who had 
low viraemia (P=0.0033), suggesting that control ofviraemia after initiation of HAART 
leads to some recovery of the CDS+ T-cell compartment. In addition, children with low 
viraemia, regardless ofHAART treatment status, had higher frequencies ofCD8+ T-cell 
frequencies when compared with community controls (P<0.00005 for HAART -na'ive 
children and P=O.OO 17 for HAART -treated children), suggesting that control of 
viraemia only partially normalizes CD8+ T-cell percentages. 
Similar effects were observed when the children were stratified on the basis of their 
immunological status. Children who had low CD4+ T-cell percentages showed higher 
frequencies ofCD8+ T-cell frequencies (39.4% [IQR, 32.1%-43.9%]) when compared 
with children that had high CD4+ T-cell percentages (29.2% [IQR, 24.6%-36.0%] 
P<0.00005) and community controls (15.7% [IQR, 13.7%-17.0%] P<0.00005). Even 
after further stratification on the bases of HAART treatment, the HAART -na't've and 
HAART-treated children, regardless of their CD4+ T-cell percentage status, had higher 
frequencies of CDS+ T cells (38.4% [IQR, 25.4%-43.9%] and 40.7% [IQR, 34.7%-
47.6%] for children with low CD4+ T-cell percentage and 30.7% [IQR, 26.4%-38.1%] 
and 26.6% [IQR, 23.3%-32.4%] for children with high CD4+ T-cell percentage) when 
compared with community controls (P<0.00005 in all cases), suggesting that 
immunological recovery does not cause full restoration of normal CDS+ T-cell 
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frequencies and maintenance of high CD4+ T-cell frequencies does not preserve the 
state of the CD8+ T-cell compartment. However, immunological recovery upon 
initiation of HAART was associated with partial recovery in the CD8+ T-cell 
compartment as children on HAART and having high CD4+ T-cell percentages had 
lower frequencies of CD8+ T cells when compared with HAART -naiVe children who 
had low CD4+ T-cell percentages (P=0.0164). 
Interestingly, ]3 of the 38 HAART na'ive children had viral loads below 5000 RNA 
copies/ml, implying that some children were able to control viraemia naturally. In 
addition, t 1 of the 40 HAART receiving children had virological failure (viral loads 
above 5000 RNA copies/ml despite HAART), suggesting that a significant proportion 
of children could be unable to control viral replication despite being on HAART for at 
least six months. 
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Value P value 
(versus community 
controls) 
Number (N) 106 
Community controls 28 
HIV-intected 78 
Low viraemia 42 
High viraemia 36 
High CD4+ T-cell percentage 36 
Low CD4+ T-cell percentage 42 
Median age in months 49(3 1-74) 
Community controls 56 (39-86) 
HIV-infected 46 (26-71) 0.0656 • 
Low viraemia 46 (25-80) 0. 186 1" 
High viraemia 43 (31-60) 0.0503 • 
High CD4" T-cell percentage 48(3 1-72) 0.8054" 
Low CD4+ T-cell percentage 38 (27-69) 0.0209" 
% Female (n) 53 (54) 
Community controls 54 ( 15) 
HIV-intected 53 (4 I) 0.937 b 
Low viraemia 47 (17) 0.748 b 
Hi gh viraemia 59 (24) 0.6 10 b 
High CD4+ T-cell percentage 6 1 (25) 0.541 b 
Low CD4; T-cell percentage 42 ( 14) 0.385 b 
% on HAART(n) N/A 
Commun ity controls N/A 
HIV-infected 5 1 (40) 
Low viraemia 69 (29) 
High viraemia 3 1 (11) 
Hi gh CD4+ T-cell percentage 62 (26) 
Low CD4+ T-cell percentage 39 (14) 
Viral load, 10glO RNA copies/mL N/A 
Community controls N/A 
HIV-infected 3.4 (0.18-4.78) 
Low viraemia 1.25 (0.0-3.2) 
High viraemia 4.8 (4.4-5.3) 
High CD4+ T-cell percentage 2.7 (0.0-4.1) 
Low CD4't T-cell percentage 4.6 (3.2-5.0) 
CD4+ T cells (Percentage) 27.6 (21.1-34.5) 
Community controls 33.8 (28. 1-39.3) 
HI V-infected 25.5 (17.8-32.1) 0.0001 • 
Low viraemia 29.4 (22.5-34.6) 0.0102 8 
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High viraemia 
High C04 ' T-cell percentage 
Low C04+ T-cell percentage 
CD8+ T cells (Percentage) 
Community controls 
HIY- inlected 
Low viraemia 
High viraemia 
High C04+ T-cell percentage 
Low C04+ T-cell percentage 
B ce lls (Percentage) 
Community controls 
HIY-intected 
Low viraemia 
High viraemia 
High C04 ' T-cell percentage 
Low C04+ T-cell percentage 
Hemoglobin. g/dL 
Community controls 
HIY-infected 
Low viraemia 
High viraemia 
22.2 (9.2-26.8) 
31.9 (27.9-37 .8) 
17. 1 (8.6-22.5) 
27.2 ( 16.9-39.3) 
15.8 (13 .7- 17.0) 
32.8 (25 .2-41.7) 
27.0 (22.2-39.0) 
37. 1 (31.5-44.9) 
29.2 (24.6-36.0) 
39.4 (32. 1-43.9) 
17.9 ( 12.4-22.5) 
20.5 ( 15.7-23.7) 
16.5 (1 1. 1-20.9) 
15.3 ( 11.2-20.7) 
17.8( 9.8-22.2) 
17.3 ( 12.4-23.3) 
15.2 (9.7- 19.8) 
11.1 (9.9-1 1.9) 
11.9 ( 11.4- 12.3) 
10.6 (9.6- 11 .6) 
11.3 ( 10.2- 12.0) 
10. 1 (9. 1- 11.1 ) 
<0.00005 a 
0.3377 " 
<0.00005 8 
<0.00005 • 
<0.00005 • 
<0.00005 • 
<0.00005 8 
<0.00005 • 
0.0 106" 
0.009 1' 
0.06 11 ' 
0.0777' 
0.0048 ' 
0.0001 8 
0.02 17 ' 
<0.00005 • 
High C04+ T-cell percentage 11.3 (10.1- 12. 1) 0.0340' 
Low C04 ' T-cel l percentage 10.0 (8.8- 11 .0) <0.00005 • 
Table 3.1 : Baseline characteristics of the HIY-infected chi ldren and the community controls whose 
samples were used tbr determination ofB-cell phenotypes. Values shown al'e medians (inter-quarti le 
range) unless otherwise stated. Statistical tests usedl: 'Wilcoxon rank-sum test (Mann Whitney test). bChi-
squared test. 
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Figure 3.2: Frequencies of lymphocyte lineages in the HIV -infected and community control children after 
strati fying the children on the basis oftheir viral loads or C04+ T-cel l percentages. Blue squares 
represent chi ldren who were treated with I-IAART, red circles represent children who were HAART na'ive 
and brown triangles represent the community controls. Horizontal line shows the median frequency for 
each sub-group. High viraemia group: >/=5000 RNA copies/ml, low viraemia group: < SOOO RNA 
copies/ml, low C04 percentage group: <2S% and high C04 percentage group: >/=2S%. Statistical test 
used: Wilcoxon rank-sum test. * represents p<O.OS. 
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3.4.2 Comparison ofdifferent children's groups with regard to fi'eguencies of various 
B-ce II Sli bsets 
When the HIV-infected cohort was compared with community controls, there were no 
statistically significant differences in the frequencies of atypical memory B cells, 
activated mature B cells, plasmablasts and immature/transitional B cells. However, as 
previously reported, HIV -infected children had lower frequencies of resting memory B 
cells when compared with community controls (6.42% [IQR, 3.64%-7.67%] versus 
11.25% [IQR, 8.11 %-14.83%] P<0.0005) [232, 234]. In addition, frequencies of naiVe 
B cells were lower in the HIV-infected children (47.30% [IQR, 35.88%-66.45%]) when 
compared with community controls (57.45% [IQR, 54.20%-63.90%] P=0.0433) [234]. 
3.4.3 Comparisons after stratifying the HIV -infected children on the basis ofviraemia 
and HAART treatment 
The median frequency of naYve B cells was significantly lower in the high viraemia 
group (37.35%[IQR, 23.7%-48.2%]) than in both the low viraemia group (62.75% 
[IQR, 45.4%-70.1%] P<0.00005) and the community controls (57.5% [IQR, 54.2%-
63.9%] P<0.00005). Further stratification of the children on the basis of HAART 
treatment revealed no differences between the HAART -naive and HAART treated sub-
groups within both high viraemia and low viraemia groups. In addition, there were no 
differences when the HAART-naYve children and the HAART-receiving children within 
the low viraemia group were compared with community controls, suggesting that both 
control of viraemia upon initiation of HAART and spontaneous control of viraemia in 
absence of HAART are associated with recover and maintenance of na'ive B-cell 
compartment, respectively. On the other hand, the two sub-groups within the high 
viraemia group had lower frequencies ofnaYve B cells when compared with community 
controls. Notably, the lowly viraemic children who were on HAART had higher 
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frequencies of naTve B cells than the two sub-groups of highly viraemic children, 
reinforcing the impression that successful HAART with control of viraemia is 
associated with recovery ofthe naTve B-cell compartment. 
Both the high viraemia group and the low viraemia group (i.e. regardless of viraemia 
level) had similar median frequencies of resting memory B cells (5.2% [IQR, 3.5%-
7.1 %] and 6.8% [IQR, 3.6%-8.5%] respectively, P::::::0.1809), which were both lower 
when compared with the community controls (11.3% [IQR, 8.1%-14.8%] P<0.00005 in 
both cases). There were no differences between the HAART -naTve and HAART-treated 
children within both the high and low viraemia groups with regard to frequencies of 
resting memory B cells. Furthermore, all the HAART -nai've and HAART -treated sub-
groups, regardless of viraemia, had comparable frequencies of resting memory B cells 
that were all low when compared with community controls, suggesting that, like in 
adults, the memory B-cell compartment is permanently damaged. 
There was viraemia dependency on the frequency of activated mature B cells whereby 
the high viraemia group had significantly higher median frequency (9.0% [IQR, 7.3%-
13.1 %]) than both the low viraemia group (3.0% [IQR, 1.8%-6.3%] P<0.00005) and the 
community controls (4.0% [IQR, 2.8%-4.7%] P<0.00005). The low viraemia group was 
comparable with community controls in frequencies of activated mature B cells 
(P=0.3847), suggesting that active viraemia contributes directly to the aberrant 
activation ofB cells. Interestingly, the high viraemia subgroup that was on HAART had 
lower frequencies of activated mature B cells when compared with the high viraemia 
subgroup that was HAART -na'ive (10.1 % [IQR, 8.3%-14.4%] versus 5.5% [IQR, 2.6%-
8.8%] P::::::0.0067), implying that initiation of HAART alone could lead to restoration of 
normal frequencies of activated mature B cells even before the viral load drops to below 
5000 RNA copies per ml. The HAART -na'ive children who had low viraemia were 
comparable with the HAART -treated children who also had low viraemia with regard to 
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frequencies of activated mature B cells (5.2% [IQR, 1.9%-7.2%] versus 2.4% [IQR, 
1.8%-5.7%] P=0.2705). 
A similar trend was observed in atypical memory B cells whereby the high viraemia 
group had higher median frequency (28.6% [IQR, 20.5%-39.2%]) than the low viraemia 
group (14.9% [IQR, 9.7%-23.0%] P<0.00005) and the community controls (12.6% 
[IQR, 10.4%-16.4%] P<0.00005). There were no differences between the HAART-
na'ive and HAART -treated sub-groups in frequencies of atypical memory B cells within 
the high viraemia group (30.2% [IQR, 20.5%-38.9%] versus 25.9% [IQR, 17.6%-
40.2%] P=0.5477). However, those children who were HAART naive and had low 
viraemia showed higher frequencies of atypical memory B cells when compared with 
those who were on HAART and had low viraemia (18.5% [IQR, 11.4%-36.6%] versus 
13.3% [IQR, 7.9%-19.6%] P=0.0128). Furthermore, while the low viraemia HAART-
treated children were similar to community controls (P=0.9047), the low viraemia 
HAART naive children had higher frequencies of atypical memory B celIs when 
compared with community controls (P=0.0092). 
The high viraemia group also had higher median frequency of plasma blasts (4.0% [IQR, 
2.0%-7.0%]) than the low viraemia group (1.9% [IQR, 0.9%-3.6%] P=0.0021) and the 
community controls (1.9% [IQR, 1.3%-4.7%] P=0.0230). Further stratification on the 
basis of HAART treatment revealed no differences between HAART treated and 
HAART -naYve children within both low viraemia and high viraemia groups. Notably, 
the highly viraemic children who were HAART naive had higher frequencies of 
plasmablasts (4.1% [IQR, 2.5%-7.1%]) than the lowly viraemic HAART treated 
children (1.7% [IQR, 0.9%-3.1%] P=0.0007) and the community controls (1.9% [IQR, 
1.3%-4.7%] P=0.0114), suggesting that initiation of HAART with adequate control of 
viraemia leads to restoration in this compartment. 
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There were no differences in frequencies of immature/transitional B cells between the 
groups. 
The resting memory B-ce\1 compartment was further analysed to give the frequencies of 
its IgO+ (unswitched) and IgO- (switched) subsets. The picture was similar to that 
observed in total resting memory 8 cells above. Similar to previous reports, there were 
reduced frequencies of IgO+ resting memory 8 cells in the HIV -infected cohort (2.24% 
[IQR, 1.32%-3.22%]) when compared with community controls (4.05% [IQR, 3.44%-
5.49%] P<0.00005) [230, 231, 234]. However, similar to a previous report [231], but 
not others [230, 234], there were reduced frequencies ofIgO- resting memory B cells in 
HIV-infected children (3.03% [IQR, 1.62%-4.65%] versus 6.57% [IQR, 4.66%-7.93%] 
P<0.00005). 80th high viraemia and low viraemia groups had lower frequencies of 
IgO+ resting memory B cells (1.7% [IQR, 1.0%-2.9%] and 2.7% [IQR, 1.6%-3.6%] 
respectively) than the community controls (4.1% [IQR, 3.4%-5.5%] P<0.00005 and 
P=O.OOOI, respectively). Similarly, the two HIV-infected groups had lower median 
frequencies of switched resting memory 8 cells (2.4% [IQR, 1.7%-3.9%] and 3.2% 
[IQR, 1.4%-5.6%]) than the community controls (6.6% [IQR, 4.7%-7.9%] P<0.0005 in 
both cases). Notably, the low viraemia group showed partial recovery/preservation of 
the IgO+ resting memory compartment when compared with the high viraemia group 
(P=O.0380). Stratification of the children further based on HAART treatment did not 
reveal any differences between HAART-na"ive and HAART-treated children within both 
high viraemia and low viraemia groups with regard to frequencies of IgO+ and IgO-
resting memory B cells. Notably, all HIV -infected subgroups had lower frequencies of 
IgO+ and IgO- resting memory 8 cells when compared with community controls. 
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Figure 3.3: Frequencies of various B-cell subsets in the three groups of ch i Idren after virological 
classification. Blue squares represent children who were treated with HAART, red circles represent 
children who were HAART na'ive and brown triangles represent the community controls. Horizontal line 
shows the median fi'equency for each subgroup. High viraemia group: >/=5000 RNA copieslml. low 
viraemia group: < 5000 RNA copieslml. Statistical test used: Wilcoxon rank-sum test. * represents 
p<0.05 . 
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3.4.4 Comparisons after stratifying the HIV-infected children on the basis ofCD4 t T-
cell percentages and HAART treatment 
Similar results with few variations were obtained when the children were classified on 
the basis of their immunological profile (Le. based on the 25% CD4+ T-cell percentage 
cut off as recommended by WHO). 
Children with low CD4T T-cell percentages had lower frequencies of naIve B cells 
(41.0% [IQR, 24.3%-54.5%]) when compared with community controls (57.5% [IQR, 
54.2%-63.9%] P=0.0003) and children with high CD4T T-cell percentages (58.0% [IQR, 
39.7%-68.3%] P=O.0046). However, community controls did not differ from children 
having high CD4+ T-cell percentages. Interestingly, there were significant differences 
between HAART-na"ive and HAART-treated children within both high and low CD4+ 
T-cell percentage groups. The HAART-na"ive children in the low CD4T T-cell 
percentage group had lower frequencies of naiVe B cells when compared with HAART-
treated children who had low CD4+ T-cell percentages (34.3% [IQR, 21.8%-48.2%] 
versus 49.6% [IQR, 39.4%-62.6%] P=O.0297). Similarly, the HAART naive children in 
the high CD4T T-cell percentage group had lower frequencies of naiVe B cells when 
compared with their HAART-treated counterparts (43.6% [IQR, 35.4%-62.0%] versus 
66.0% [IQR, 44.8%-73.1%] P=0.0227). Moreover, when compared with community 
controls, the HAART-treated high CD4+ T-cell percentage subgroup had comparable 
frequencies of naive B cells (P=O.1608) while the HAART -naiVe children with high 
CD4+ T-cell percentages had significantly lower frequencies of naive B cells 
(P=0.0218). The same trend was observed when the low CD4+ T-cell percentage 
subgroups were compared with community controls. The HAART naive children with 
low CD4T T-cell percentages also had lower frequencies of na"ive B cells when 
compared to community controls (P=O.OOOI). However, their HAART treated 
counterparts did not differ from community controls (P=O.0927). 
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Similar to previous reports, both groups of children with low and high CD4+ T-cell 
percentages had lower frequencies of resting memory B cells (4.8% [IQR, 3.4%-7.0%] 
and 6.9% [IQR, 4.3%-8.6%] respectively) than community controls (11.3% [IQR, 
8.1%-14.8%] P<0.0005 in both cases). Interestingly, children with high CD4+ T-cell 
percentages had higher frequencies of resting memory B cells when compared with the 
group that had low CD4+ T-cell percentages (P=0.0124), suggesting that they had 
. experienced partial recovery or partial preservation of this compartment. Further 
stratification of the children on the basis of HAART treatment revealed no differences 
between the HAART-nai've and HAART-treated children within both high and low 
CD4+ T-cell percentage groups. Notably, HAART-na'ive children with low CD4+ T-cell 
percentages had significantly lower frequencies of resting memory B cells when 
compared with HAART-treated children who had high CD4+ T-cell percentages, 
reinforcing the possibility of partial recovery of this compartment when CD4+ T-cell 
frequencies recover upon initiation ofHAART. 
In addition, the children with low CD4+ T-cell percentages had higher frequencies of 
activated mature B cells (7.3% [IQR, 2.7%-11.2%]) than the community controls (4.0% 
[IQR, 2.8%-4.7%] P=O.0056). Further stratification into HAART-na'ive and HAART· 
treated children revealed significant differences between the two subgroups within both 
low and high CD4+ T-cell percentage groups. For instance, the HAART-na'ive children 
who had low CD4+ T-cell percentages had significantly higher frequencies of activated 
mature B cells when compared with the HAART-treated children in the same low CD4+ 
T-cell percentage group (9.6% [IQR, 6.1%-13.3%] versus 3.2% [IQR, 1.9%-7.5%] 
P=0.0045). Similarly, HAART-nai've children with high CD4+ T-cell percentages had 
higher frequencies of activated mature B cells when compared with their HAART· 
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treated counterparts who had high CD4+ T-cell percentages (8.3% [IQR, 4.8%-12.2%] 
versus 2.9% [IQR, 1.8%-7.8%] P=O.O I 72), suggesting that HAART greatly affected the 
frequencies of this activated subset ofB cells. 
Frequencies of atypical memory B cells were elevated in the group that had low CD4+ 
T-cell percentages (29.8% [IQR, 17.7%-40.0%]) when compared with the group that 
had high CD4+ T-cell percentag~s (16% [IQR, 10.8%-24.2%] P=0.0002) and 
community controls (12.6% [IQR, 10.4%-16.4%] P<0.00005). Similar to observations 
above, further stratification of the children revealed that those who had low CD4+ T-cell 
percentages and were HAART -na"ive had higher frequencies of atypical memory B cells 
when compared with HAART-treated children with low CD4+ T-cell percentages 
(35.3% [IQR, 22.0%-47.1%] versus 21.4% [IQR, 13.9%-31.2%] P=0.0231). The same 
was observed within the high CD4+ T-cell percentage group whereby HAART na"ive 
children had higher frequencies of atypical memory B cells when compared with 
HAART treated children (20.5% [IQR, 11.8%-29.4%] versus 14.9% [IQR, 8.4%-
21.1%] P=O.0433), suggesting that HAART treatment had some impact on the 
frequencies ofatypical memory B cells regardless of immunological profile. 
Of note, there were no differences in frequencies of plasmablasts among the various 
groups of children after their stratification on the basis of CD4+ T-cell percentages. 
However, further stratification of the children revealed that HAART -na"ive children who 
had high CD4+ T-cell percentages also had higher frequencies of plasmablasts when 
compared to HAART-treated children who had high CD4+ T-cell percentages (3.8% 
[IQR, 2.3%-6.4%] versus 1.8% [IQR, 0.9%-3.3%] P=0.0259). There were no 
differences between the HAART-na"ive and HAART-treated children in the low CD4+ 
T-cell percentage group with regard to frequencies of plasma blasts. 
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Similarly, there were no differences in frequencies of immature/transitional B cells 
among the various groups of children after their stratification on the basis of C04+ T-
cell percentages. However, further stratification of the children revealed that HAART-
na'ive children who had high CD4+ T-cell percentages also had higher frequencies of 
immature/transitional B cells when compared with HAART-treated children who had 
high CD4+ T-cell percentages (11.6% [IQR, 9.1%-15.0%] versus 7.1% [lQR, 4.5%-
11.9%] P=0.0115). There were no differences between the HAART-na'ive and HAART-
treated children in the low C04+ T-cell percentage groups with regard to frequencies of 
immature/transitional B cells. 
Further analysis of the resting memory B-cell compartment revealed low frequencies of 
IgO+ resting memory 8 cells in low C04+ T-cell percentage group (1.7% [IQR, 1.1%-
3.0%]) and high CD4+ T-cell percentage group (2.8% [IQR, 1.6%-3.6%]) when 
compared with community controls (4.1% [IQR, 3.4%-5.5%] P<0.00005 and P=O.OOOI 
respectively). There was also a significant but partial recovery/preservation of IgD+ 
resting memory B cells in the group that had high CD4+ T-cell percentages when 
compared with the group that had low CD4+ T-cell percentages (P=O.0344). Similarly, 
IgD- resting memory B cells were in low frequencies in both low and high CD4+ T-cell 
percentage groups (2.6% [IQR, 1.1 %-3.5%] and 3.6% [IQR, 1.7%-5.2%] respectively) 
when compared with community controls (6.6% [4.7%-7.9%] P<0.00005 and P=O.OOOt 
respectively). However, there was only a statistically non-significant trend towards 
partial recovery/preservation of this compartment in the high CD4+ T-cell percentage 
group (P=0.0702). Upon further stratification of the children on the basis of their 
HAART treatment status, there were no differences between the HAART -na'ive and 
HAART -treated children with regard to IgO- or IgO+ resting memory B cells within 
both low and high CD4+ T-cell percentage groups. 
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chi ldren who were HAART na'ive and brown triangles represent the community controls. HOJ'iwntalline 
shows the medianfi'equency for each sub-group. Low CD4 percentage group: <25% and high CD4 
percentage group: >/=25%. Statistical test used: Wilcoxon rank-sum test. * represents p<O.05. 
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3.4.5 Summary 
Virological classification Immunological classification 
High Low viraemia Low CD4+ High CD4+ 
viraemia T-cell % T-cell % 
No BAART 0 BAART No HAART No HAART 
HAART IMART IIAART IIAART 
Nlli've U U <:::> ~ U ~ U ~ 
Resting memory U U U U U U U U 
Actlvlltell mature ft ¢:> ¢:> ¢:> ft ¢:> ft ¢:> 
Atypical memol'Y ft ft ft ¢:> ft ft ft <:::> 
Plasmllblast ft ~ <:::> ¢:> ¢:> ¢:> ft ¢:> 
Immature/transitional ¢:> ¢:> ¢:> ¢:> ¢:> <=> <=> <=> 
IgO+ resting memory U U U U U U U U 
IgO' re ting memory U U U U U U U U 
Table 3.2: Summary of the effect of HIV on the various subsets of B cell s when the HI V - In fected 
children are compared with community control ch ildren. The HIV-infected ch ildren can be stratified 
virologically or immunologically wi th further stratification on the basis of their HAART treatment status. 
Symbols represent: U-reduced trequency, <=>-similar frequency and ll-increased fi'equency of the 
respective B-cell subset in the group of HIV-infected children when they are compared wi th community 
controls. Groups were compares using Wilcoxon rank-sum test (Mann-Whitney test) wi th p<O.OOS 
considered as signifi cant. 
When compared with commun ity contro ls, all HIV-infected subgroups of children, 
regard less of mode of class ification, had decreased frequencies of total resting memory 
B cells, unswitched resting memory B ce lls and switched memory B cells. They also all 
had unaffected frequencies of immature/transitional B ce lls. Low frequencies of na'ive B 
ce lls were observed in all high viraemia groups upon viro logical classification and in 
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HAART na'(ve groups upon immunological classification, suggesting that viral load and 
absence of HAART, and not CD4+ T-cell depletion, were important in determining the 
frequencies of na'ive B cells. Elevated frequencies of activated mature B cells were 
observed in HAART na'ive highly viraemic children upon virological classification and 
in all HAART na'(ve groups upon immunological classification, suggesting that viral 
load and absence of HAART were the major determinants of frequencies of this subset. 
Elevated frequencies of plasmablasts in HAART na'ive highly viraemic children and 
HAART na'ive children with high CD4+ T-cell percentages also suggest that viral load 
and HAART treatment are impOltant determinants of frequencies of plasmablasts. 
Atypical memory B cells were increased in all subgroups upon both virological and 
immunological classification with the exception of the HAART-treated low viraemia 
group and the HAART treated high CD4+ T-cell percentage group, suggesting some 
dependence on disease progression. 
3.4.6 Statistical interaction (effect modification) between various HIV states and age 
in the acquisition of resting memory B cells 
To test for interaction between age, treatment with HAART and high viraemia or low 
CD4+ T-cell percentage with regard to the age-related changes in frequencies of resting 
memory B-cell subsets, a predictive linear regression model was used with the predicted 
frequency of resting memory B cells as the dependent variable and age and level of 
viraemia or level of CD4+ T-cell percentage with/without HAART as independent 
variables. Adjustment was done for gender. hemoglobin content and total lymphocyte 
counts. The F statistic for the interaction term and significance level were reported 
[235]. The F statistic was an indication of the strength of effect modification by 
viraemia and treatment. It is a function of the differences in the regression lines of the 
different groups of children. 
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3.4.7 Statistical interaction after stratifying the children on the basis of v irael11ia and 
HAART 
When the various groups were compared with regard to accumulation of resting 
memory B cells, notable trends were observed. As would be expected, the community 
controls showed a gradual increase in predicted frequencies of resting memory B cells 
with increase in age, probably due to exposure to environmental antigens and pathogens 
with advancement in age. Similarly, the low viraemia groups, with and without 
HAART, showed parallel increments of predicted frequencies of resting memory B 
cells with age, though they remained consistently lower than the community controls. 
However, the high viraemia groups did not show a similar increase with age but instead 
showed an age-dependent (hence HIV -exposure dependent) decrease of total resting 
memory B cells. The interaction was statistically significant when the high viraemia 
HAART-na'ive group was compared with community controls. Significant interactions 
were also observed when the high viraemia HAART -na'ive group was compared with 
the low viraemia groups, suggesting that controlling viraemia could enable HIV-
infected children to accumulate resting memory B cells as they advance in age. 
82 
High viremia + No HMRT 
High viremia + HMRT 
Low viremia + No HAART 
Low viremia + HAART 
Community controls 
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Age (months) 
Figure 3.5: Predicted frequencies of resting memory B-cell compartmen t after stratifying the I-IIV-
intected children on th e basis of their level of viraemia and HAART treatment status. The Predxcon 
STAT A package was used to make linear regression predictions that were th en plotted. 
High viraemia High vi raemia Low viraemia Low viraem ia Community F statistic + + + + 
NoHAART HAART No HAART HAART Controls 
Hi gh viraemia F( 1.25)= 1.09 1'( I.D)- 5. IO F( I.-t I ) 6.0R I'( U I) 6.51 
+No HAART 
High viraemia F( 1, 13)= 1.24 F( 1,31 )=0.52 F( I,3 I)=3.09 
+HAART 
Low viraemia F( 1.29)=0. II F( 1.29)=0.28 
+No HAART 
Low viraemia F(I,47)=O.05 
+HAART 
Community 
Control s 
Table 3.3: The F statI stI cs for the IIlteractlOn ofage*(vlI·aem.a wIth/wIthout HAART) wIth regard to 
accumulation of resting memory B cells. Children were stratified on the basis of viraemia and HAART 
treatment. Pairwise comparisons were done between the various groups using the Predixcon STAT A 
package for linear regression prediction. Significant results are in red text. 
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High viraemia Iligh viraem ia 1,011' viraL:l11ia Lo\\ viraemia 
COl 11 I 11l1lliI)' P va lue + + + + 
No HAI\RT HAI\RT No I IAI\RT II I\I\RT Conlrols 
lIi gh viraemia 0.306X ()(l ~3x (I.OI7'} lUll IS 
-+No HAI\RT 
High viraemia 0.2862 0.4777 0.0888 
+HAART 
Low viraemia 0.74 15 0.5987 
+No HAI\RT 
Low viraemia 0.82 19 
+HAART 
Community 
Controls 
Table 3.4: The P values for the interactIOn ofage*(vlraeml3 with/without I-IAART) with regard to the 
accumulation of resting memory B cell s. Children were strati tied on the basis ofvi raemia and I-IAART 
treatment. Pairwi se comparisons were done between the various groups using the predixcon stata package 
for linear regression prediction, P values less than 0.05 were con sidered as sign ifi cant tor interaction . 
Significant resu lts are in red text. 
Statist ical interaction was also observed in IgO- (switched) resting memory B ce lls 
whereby both community controls and low viraemia groups showed a ga in with age 
while the high viraemia groups showed no age-related ga in of predicted frequencies. 
Statistically significant interactions were observed when the HAART -narve high 
viraemia group was compared with community contro ls, low viraemia HAART narve 
group and low viraemia HAART -treated group. Similar significant interaction was 
observed when high viraemia HAART -treated children were compared with low 
viraemia HAART-narve children, suggesting that viraemia and not HAART could be 
the main determinant on whether these children gained frequencies of IgO- resting 
memory B cells. 
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High viremia + No HMRT 
High viremia + HMRT 
Low viremia + No HAART 
Low viremia + HMRT 
Community controls 
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Figure 3.6: Predicted frequencies of IgO' resting memory B-cell compartment after strati tying the HIV-
infected children on the basis of their level of viraemia and HAART treatment status. 
The predxcon stata package was lIsed to make linear regression predictions that were then plotted. 
High viraemia High viraemia Low viraemia Low viraemia Community F statistic + + + + 
No HAART HAART No HAART HAART Controls 
High viraemia F( I. I() 5.90 1'( 1.1 5) 21.,n F( UO) 5.X4 1'( 1.36) 10.6 +No HAART 
High viraemia F( 1,6)=9.86 F( 1,2 1 )=0.0 I F(I ,27)=3. 14 +HAART 
Low viraemia 
J'( 1.20)-"4 75 F( 1.26)=0.30 +No HAART 
Low viraemia F(I ,41)= 1.52 
+HAART 
Community 
Controls 
Table 3.5: The F statistiCS for the interactIOn of age*(vlraemla with/without HAART) with regard to 
accumulation of IgO' resting memory B cells . Chi ldren were stratified on the basis of viraemia and 
HAART treatment. Pairwise comparisons were done between the various groups using the predixcon 
stata package tbr linear regression prediction. Significant results are in red text. 
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High viracmia Iligh \'iracm ia Low \·i nlCI11 ia Lo\\' vi nl~ 1ll ia COllllllllllity I' va lue + + + + 
No I-I AA RT HA ART No HAA RT HA!\ RT Controls 
I li gh viraemi a o.o:n:; o.nno,' O.(J 22() (J .OO:!.' 
+No HAA RT 
Hi gh viraemia 0.020 1 0.9 198 0.0876 
+HAART 
Low viraemia n.1l I I ~ 0.51183 
+No IMART 
Low viraemia 0.2247 
+HAART 
COlllmunity 
Controls 
Table 3.6: The P values for the mteractlOn of age*(vlraemla with/without HAART) with regard to the 
accumulation of IgD- resting memory B cell s. Children were strati tied on the basis of viraemia and 
HAART treatment. Pai rwise comparisons were done between the various groups using the predixcon 
stata package for linear regression predi ction. P values less than 0.05 were considered as signiticant lor 
interaction. Signi ficant resul ts are in red text. 
There was no interact ion between age and leve l of viraemia with regard to the 
acquisition of IgO+ (unswitched) rest ing memory B cells. Further stratification of the 
HIV-infected children on the bas is of HAART treatment did not revea l any interaction 
between the various sub-groups. 
!E. 15 
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High viremia + No HAART 
High viremia + HAART 
Low viremia + No HAART 
Low viremia + HMRT 
Community controls 
Figure 3.7: Pred icted fi'eq uencies of IgD+ resting memory B cells atler stratifY ing the HIV-intected 
ch ildren on the basis ofthei r level of viraemia and HAART treatment status.The predxcon stata package 
was used to make linear regression predictions that were then plotted. 
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High viraemia High viraemia Low viraemia Low viraemiu CommunilY r stalislic + + + + 
No I-IAART HAART No HAART 1-1 AA RT Conlrol s 
High viraemia F( 1.16)=0.35 r( 1.1 5)=0.44 F( 1.30)=1.00 r( 1.36)=0. 13 
+No HAART 
High viraemia F( 1,6)=0.01 F( 1,21 )=0.0 I F( 1,27)=0.09 
+HAART 
Low viraemia F( 1.20)=0.17 F(I .26)=O.02 
+No HAART 
Low viraemia F(I ,41)= 1.18 
+HAART 
Community 
Controls 
Table 3.7: The F stat istics tor the interactIOn of age*(vmlemm with/without HAART) with regard to the 
accumu lation oflgD+ resting memory 8 cells. Children were stratified on the basis of viraemia and 
HAART treatment. Pairwise comparisons were done between the various groups using the predixcon 
stata package for linear regression prediction. Significant resu lts are in red text. 
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High virae11li" Hi gh virac lllin Low viraemia Low vir<lellliu COlllll1unity P value + + + + 
No HAART HAART No HAART HAART Controls 
Hi gh viraemia 0.5635 0.5195 0.3264 0.7207 +No IIAART 
Hi gh viraemia 0.9 100 0.9067 0.7667 +HAART 
1,01·" viraemia 0.6839 O.902(i +No HAART 
Low viraemia 0.2843 
+HAART 
Community 
Controls 
" Table 3.8: The P val ues for the tnteractlOn of age*(vtraemta wtth/wtthout HAARl ) wtth regard to the 
accumulation of IgD+ resting memory B cell s. Children were stratified on the basis of iraemia and 
HAART treatment. Pairwise comparisons were done between the various groups using the predixcon 
stata package for linear regression prediction. P val Lies less than 0.05 were considered as significant tor 
interaction . There were no significan t differences between the groups of children. 
3.4.8 Statistical interaction after stratifying the children on the basis ofCD4+ T-cell 
percentages and HAART 
Similar trends were observed between predicted frequencies of resting memory B cells, 
age and CD4+ T-ce ll percentage with/without HAART when the children were 
classified based on their immunological profile and HAART treatment status. Similar to 
community controls, the high CD4+ T-ce ll percentages groups showed an increase of 
predicted frequencies of resting memory B cells with age, though consistently lower 
than the community controls. The low CD4+ T-cell groups did not show a similar 
increase with age but instead showed an age-dependent (hence exposure-dependent) 
decrease of total resting memory B cells. The interaction was statistically significant 
when HAART-narve children with low CD4+ T-cell percentages were compared with 
community controls with regard to frequencies of resting memory B cells. All other 
pair-wise comparisons were not statistically significant. 
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Figure 3.8: Predicted frequencies of resting memory B cells after stratifying the HIY-infected children on 
the basis of their CD4+ T-cell percentages with/without HAART. The predxcon stata package was used 
to make linear regression predictions that were then plotted. 
Low CD4 Low CD4 High CD4 High CD4 Community F statistic + + + + 
No HAART HAART No HAART HAART Controls 
LowCD4 F( 1.23 )=0.29 F( 1,23)= 1.22 F( 1.33)=3.64 I"( 1.36)0 6.02 
+No HAART 
LowCD4 F( 1.2 1 )=0.23 F( 1.31 )=0.50 F( I ,34)= 1.52 
+HAART 
High CD4 F( 1.31 )=0.27 F( 1.34)=0.63 
+NoHAART 
High CD4 F( 1,44)=0.0 I 
+HAART 
Community 
Controls 
Table 3.9: The F statistiCS for the IIlteractlOn of age*(CD4% With/Without HAART) With regard to 
accumulation of resting memory B cells. Children were strati tied on the basis ofCD4+ T-cell percentages 
and HAART treatment. Pairwise comparisons were done between the various groups using the predixcon 
stata package for linear regression prediction. Significant results are in red text. 
89 
Low CD4 Low CD~ lIigh CD4 Il igh CD4 Commun ity P va lue + + + + 
No HAART IIAART No IIAART HAART Cont rols 
LowCD4 0.5934 0.2802 0.0650 0.0192 
+No HAART 
Low CD4 0.6336 0.4840 0.2266 
+HAART 
High CD4 0.6102 0.433 1 
+No HAART 
High CD4 0.9388 
+I IAART 
Community 
Controls 
. Table 3. 10: rhe P va lues for th e IIlteractlOn 01 age*(CD4% with/ without HAA R r ) w ith regard to the 
accumulation of resting memory B cell s. Children were strati fi ed on the basis of their CD4+ T -ccll 
perccntages and I IAART treatment. Pairwise compari sons were done between the va rious groups using 
the pred ixcon stata packagc for linear regression prcdict ion. P va lucs Ics than 0.05 were con idered as 
signifi cant for interacti on. Sign ificant results are in red tex t. 
A similar trend was observed in IgO- (sw itched) resting memory B cells whereby both 
community controls and high C0 4+ T-ce ll percentage groups showed a gain of 
predicted frequencies. Interestingly, the HAA RT-treated group with low C0 4+ T-cell 
percentages did not show any age-dependent (exposure dependent) reduction in 
predicted frequencies of IgO- resting memory B ce lls. However, the HAA RT-naive 
group with low C0 4+ T-cell percentages showed an age-dependent (exposure 
dependent) reduction in predicted frequencies of IgO- resting memory B cells. The 
interaction was statistica lly significant when the HAA RT-na'ive group with low C0 4+ 
T-cell percentages was co mpared with community contro ls. 
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Figurc 3.9: Predicted frequencies of' IgD- resting memory B ecl ls allcr stratifying thc III Y-infectcd 
childrcn on the basis of thcir CD4 ' T -cell percl!ntagcs and IIAART tn:atmcnt status. Thc predxeon stata 
packagc was uscd to make linear regrcs ion prcdictions that were then plol\ed. 
LowCD4 Low CD4 High CD4 Iligh CD4 Community 
F statistic + + + + 
NollAART HAART No I IAART I IAART Controls 
Low CD4 F(I,14)=2.32 F( 1,15)=2.36 F( 1,24)=3.75 i'( 1,32) 9.11 
+No HAART 
Low CD4 F( 1,12)=0.20 F( 1.2 1 )=0. 17 F( 1,29)= 1.62 
+IIAART 
High CD4 F( 1,22)=0.67 F( 1,30)= 1.43 
+No HAART 
High D4 F( I ,39)= 1.34 
+HAART 
COllllllunity 
Controls 
Table 3. II : The F staltsltcs lor the tntcractton of age*(CD4% Wtth/wtthout HAART) wtth regard to 
accumulation of lgD- resting memory B cell s. Chi ldren were strat i fied on the basis ofCD4+ T-ce ll 
percentages and HAART treatment. Pai rwise compari sons wcrc done between the various groups using 
the predixcon stata package for l inear regression prediction. Significant results are in rcd text. 
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LuwCD4 Low CD4 lI igh CD4 lI igh CD4 Comlllun ity P va lue + + + + 
No IIAART I IAART No IIAART HAART Controls 
LowCD4 0.1497 0.145 1 0.0647 00050 
+No HAART 
LowCD4 0.6599 068 12 0.2133 
+IIAART 
High CD4 0.4208 0.24 15 
+No HAART 
High CD4 0.254 1 
+I IAART 
Community 
Controls 
Table 3. 12: 1 he P va lues for the tnteractton 01 age*(C0 4% wtth/m thoutl lAA R1 ) wtth regard to th e 
accumulation of IgO- re ting memory B cells. Children were strati ti ed on the basis of their C04 ' T-cell 
percentages and IIAA RT treattll ent. Pairwi e comparisons were done between the var iolls grollps lI si ng 
the prcdixcon stata packagc for linear regre ion prediction. P valucs Ic s than 0.05 \l ere considered as 
ignifieant fo r interaction. ignifiemll re ults arc in red text. 
Similar to observat ions after virolog ical stratification, there was no interaction with 
regard to IgO+ resting memory B ce lls when the children were stratified based on their 
immunological profile and HAART treatment. 
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Figurc 3. 10: Prcdictcd frcqucncics of IgD+ resting memory 13 cells ancr stratif)'ing thc IIIY-infectcd 
childrcn on thc basis of their CD4+ T-ccll pcreen tages and IIAAR r treatment statlls.The predxeon stata 
packagc wa used to makc linear regrcs ' ion prcdictions that \\ere then plotted. 
Low CD4 Low CD4 High CD4 Iligh CD4 Community F statistic + + + + 
No IIAART IIAART No HAART IIAART ontrols 
Low CD4 F( 1,14)=0.22 F( 1,15)=0.04 F( 1,24)=2.65 F( 1,32)=0.35 
+No HAART 
Low CD4 F( 1. 12)=0.0 I F( 1,21 )=0.40 F( 1.29)=0.04 
+IIAART 
lIigh D4 F( 1,22)=0.00 F( 1,30)=0.02 
+NoHAART 
Iligh crn F( 1,39)=2.44 
+IIAART 
ommunity 
Controls 
Table 3. 13: Thc F tatt SllCs for the II1teraclton of agc*CCD4% wtth/wtthout IIAART) w tth regard to thc 
accumu lation of IgD+ re ting mcmory 13 cc ll s. Children were strat i fied on the basis of CD4+ T-ccll 
percenlages and HAART treatment. Pairwise comparison were done between the var iou group u ing 
the predixeon stata package for linear regression prediction. There were no ignifican l diflerences 
between the group of children . 
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LoIVC~ LowCD4 Iligh CD4 Il igh CD4 Community P va luc + + + + 
No IIAART IIAART No IIi\ART IIAART Controls 
LowCD4 0.6468 0.8432 0. 11 69 0.56 10 
+No IIAART 
Low C~ 0.9332 0.5363 0.8480 
+IIAART 
High D4 0.9446 0.895 1 
+No HAART 
lIigh D4 0.1267 
+IIAART 
COl11munity 
Controls 
Table 3. 14 : The P va lucs tor the interacti on of a c*(CD4% with/withollt HA ART) with rc ard to the g g 
accul11ulation of IgO+ re ting memory () cell s. Children IVcrc tratified on the ba is or their 0 4+ T -cc ll 
perccntagc and HAA RT treatment. Pairwisc compari sons were done between thc vsriou groups u ing 
the predixcon stats package tor linear regrcss ion prediction. P value Ics than 0.05 werc con idcred as 
signifi cant ror interaction. There were no sign ificantdifTerenccs between the groups or children. 
3.4.9 Correlation of B-cell subsets with population characteri tics among the HIV-
infected children 
Since B-cell defects could be as a resu lt of either CD4+ T-cell depletion, direct effect of 
viral factors or advancement in age, correlations between frequencies of various B-cell 
subsets and viral load, CD4+ T-cell percentages, treatment with HAART and age among 
the HIV-illfected children were checked. 
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Resting Activated Atypical Immature/ 
IgD+ IgD- I 
Na'ive Plasmablasts Resting Restin g 
memory mature memory Transitional 
memory memory 
Age(Months) 0.0875 0.0986 -0. 1676 -0.1 054 -0.2026 -0.1 454 0.0842 0.204 1 
( 1.00) ( 1.00) ( 1.00) (1.00) ( 1.00) ( 1.00) ( 1.00) ( 1.00) 
Viral load -0.5856 -0.1952 0.5488 0.5265 0.306 1 0. 1423 -0.3326 -0.2577 
«0.05) ( 1.00) «0.05) «0.05) ( 1.00) ( 1.00) (0.48) ( 1.00) 
C D4+ T-cell % 0.4071 0.351 4 -0.2057 -0.4413 -0.1674 -0. 181 0.3499 0.3079 
«0.05) (0.09) ( 1.0000) «0.05) ( 1.00) ( 1.00) (0.33) (0.80) 
HAART 0.3896 0.0958 -0.4173 -0.413 -0.2264 -0.1 583 0. 1437 0. 1809 
«0.05) ( 1.00) «0.05) «0.05) ( 1.00) ( 1.00) ( 1.00) ( 1.00) 
Table 3. 15: Spearman's rho (P value) for corre lation between the frequencies of various 8 -cell subsets and the population characteri stics (age. vira l load. C04+ T-cell 
percentages and HAART treatment). Spearman corre lation with Bonferroni adj ustment wcre used. Adjusted P values be low 0.05 were considered as significant. 
Sign ifican t results are in red text. 
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Frequencies of nal've B cells correlated inversely with viral load, directly with CD4 + T-
cell percentages and directly with HAART treatment, suggesting that viraemic states, 
low CD4+ T-cell percentages and untreated state are associated with reduced 
frequencies of naiVe B cells. There was no significant correlation between resting 
memory B cells and any of the considered population characteristics. However, there 
was a trend towards a direct correlation between resting memory B cells and CD4+ T-
cell percentages (rho=O.35, P=O.09), implying that recovery/maintenance of CD4+ T 
cells could be associated with accumulation/maintenance of resting memory B cells. 
Frequencies of activated mature B cells correlated directly with viral load, inversely 
with CD4+ T-cell percentages and inversely with HAART treatment, suggesting that 
controlling viraemia with HAART and subsequent recovery ofCD4+ T-cell percentages 
could be important in the contraction of this compartment. Interestingly, the correlation 
trends observed with atypical memory B cells were a mirror image of those observed 
with naYve B cells, suggesting that the reduction of frequencies of na'(ve B ceIls in 
viraemic, untreated or CD4+ T-celllymphopenic states could be as a result of expansion 
of the atypical memory B cells compartment. Namely, the frequencies of atypical 
memory B cells correlated directly with viral load, inversely with CD4+ T-cell 
percentages and inversely with HAART treatment. While the exact origin of atypical 
memory B cells remains unknown, the naIVe B-cell compartment remains as the most 
likely source. Atypical memory B cells have been shown to have immunoglobulin gene 
somatic hyper mutations and replication histories that are higher than those of naiVe B 
cells but lower than those of classical memory B cells, making classical memory B cells 
an unlikely source and naiVe B cells a likely source. However, the existence of low 
frequencies of atypical memory B cells in healthy individuals raises the possibility of 
them being a unique lineage that just expands upon chronic exposure to high HIV 
viraemia [227]. 
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No significant correlations were observed within other B-cell subsets. 
Notably, the correlation results should be interpreted with caution since viral load, 
CD4+ T-ce ll percentages and HA ART treatment are not entirely independent variables. 
Treatment with HA ART could control viraemia which in turn could allow the CD4 + T-
ce ll percentages to recover. Indeed, the three variables showed some degree of 
mult ico II inearity. 
HIV status Viral load CD4+ T-cell % HAART 
HIV status I 
Viral load -0.5988 I 
«0.00005) 
CD4+ T-cell % 0.3929 -0.5152 I 
«0.00005) «0.00005) 
HAART 0.8163 -0.6658 0.4326 I 
«0.00005) «0.00005) «0.00005) 
, Table 3. 16: Mul ticoll inearity between HI V -tnfectlon. viral loads, CD4+ r-cell percentages and II AART 
treatment. pearman' s rho(p va lues) for corre lation between the variolls population characteristics. 
Spearman's correlation with Bonferroni adjustm ents were done. P values be lolV 0.05 were considered as 
significant. Significant results are in red text. 
3.4.1 0 Correlation of the various B-ce ll subsets with other B cell subsets 
Since a defect in one B-ce ll subset could be related to defects in other B-cell subsets, 
probably due to being driven by the same factors, correlations were checked amongst 
the various B-cell subsets. I nterestingly, frequencies of narve B cells correlated 
inversely with frequencies of activated phenotypes namely activated mature B cells, 
atypical memory B cells and plasmablasts. The frequencies of activated mature B cells 
correlated directly with frequencies of atypical memory B ce lls and plasmablasts. 
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However, frequencies of atypical memory B cells did not correlate with frequencies of 
plasmablasts. The frequencies of resting memory B cells correlated directly with the 
frequencies of its subsets i.e. IgO- and IgO+ resting memory B cells. Similarly, the 
frequencies of IgO- resting memory B cells correlated directly with the frequencies if 
IgO+ resting memory B cells, suggesting that the same factors probably affected them in 
the same way in HIV patients. 
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Resting Activated Atypical Immature/ 
IgD+ IgD-
Naive Plasmablasts Resting Resting 
memory mature memory transitional 
memor memor 
Naive 
Resting 0.1006 
memory (1.0000) 
Activated -0.8248 0.0462 
mature «0.00005) (1.0000) 
Atypical -0.8267 -0.3088 0.6294 
memory «0.00005) 0.1129 «0.00005) 
Plasmablasts -0.4949 0.0826 0.5456 0.2453 
«0.00005) (1.0000) «0.00005) 0.6626 
Immature/ -0.1114 -0.323 -0.0216 -0.1097 -0.0259 
transitional ( 1.0000) 0.0718 ( 1.0000) (1.0000) (1.0000) 
IgD+ resting 0.1201 0 .7685 -0.0 171 -0.2948 -0 .0094 -0. 1143 
memory ( 1.0000) «0.00005) (1.0000) 0.1724 ( 1.0000) ( \.0000) 
IgD- resting 0.0096 0.8508 0.0905 -0.2146 0.1052 -0.1915 0.6826 
memory (1.0000) «0.00005) (1.0000) ( 1.0000) ( 1.0000) (\.0000) «0.00005) 
Table 3.17: Spearman's rho (P values) for correlations between various B-cell subsets. Speannan·s correlation with Bonferroni adj ustments were done. P \ alues belo\\ 
0.05 were considered as significant. Significant results are in red te:\1. 
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3.4.11 Multivariate analysis of effect of various population characteristics on B-cell 
subset distribution with adjustment for age 
The distribution of lymphocytes subsets in children can vary with age. As a result, 
immunological studies of children try to age-match the different groups of children. In 
this study, though an effort was done to match the different treatment groups of children 
by age, subsequent stratification of the children on the basis of viral loads and CD4+ T-
cell percentages gave groups that were not perfectly matched. Furthermore, the 
community controls were slightly older than the HIV-infected children, though the 
differences in age were not statistically significant. To eliminate any possible bias, 
additional regression analyses with adjustment for age were done. Since most of the 
data on frequencies of B-cell subsets were skewed, quantile regression models were 
used. 
The first set of analyses was done to evaluate the effect of HIV infection (HIV status) 
on the frequencies of various B-cell subsets. This was done on all children. Subsequent 
analyses were restricted to the HI V-infected children to evaluate the predictive ability of 
viral loads, CD4+ T-cell percentages and HAART treatment on the frequencies of 
various B-cell subsets. Since the three variables (i.e. viral loads, CD4+ T-cell 
percentages and HAART treatment) showed multicollinearity, they were run on 
separate models. A generalized quantile regression model was also used to evaluate the 
effect of each variable after adjusting for all other variables. 
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B-celJ subset Age HIV status 
~ P value ~ P value 
Coefficient Coefticien t 
Na'ive 0.10(0.06) 0.1 7.94(4. 11 } 0.056 
Resting memory 0.04(0.02} 0.064 .f .69( 1.23) < 0.0005 
Activated mature -0.01(0.02) 0.557 -2. 12( 1.40) 0. 127 
Atypical memory -0 .08(0.03 ) 0.0 18 -5 .690.20) 0.0 11 
Plasmablasts -0.02(0.0 I) 0.074 -0.54(0.78} 0.489 
I mmatu re/transitional -0.03(0.03 ) 0.358 0.14( 1.81) 0.939 
IgD+ Re ting memory 0.008(0.0 I } 0.438 1.90(0.63 ) 0.004 
IgD- Resting memory 0.02(0.02} 0.313 3A8( 1.08) 0.002 
Table 3. 18 : Estimated ch,Ulge 111 frcq ucnc les 01 V<1 nous l3-cell subsets III relalloll to vanatlollS III age and 
HIV statu (beta codlicients). Every 8-cell subset was independently run in a quantile regression model 
containing HIV status and age. P values <0.05 were considered significan t. Significant results are in red 
text. 
B-cell sub et Age Viral load 
~ P value ~ P value 
Coefticien t Coefficien t 
Na'ive -0.03(0.05) 0.500 -6.25(0.67) 0.0005 
Resting memory 
-
-0.0 I (0.02) 0.683 -0.45(0.27) 0. 105 
Activated mature 0.00(0.02) 0.975 1.45(0.26) 0.0005 
-
Atypical memory 
-
0.0 I (0.07) 0.886 3.53(0.88) <0.0005 
Pia mablasts -0.01(0.01) 0.245 0.30(0.17) 0.079 
Immature/transitional -0.0 I (0 .04) 0.889 0.48(0.56) 0.392 
IgD+ Resting memory 0.00(0.00) 0.913 -0.3 1(0. 14} 0.032 
IgD- Resting memory 0.00(0.02) 0.982 -0.45(0.26) 0.086 
Table 3. 19: Estllnated change 111 frequencle of vanou B-cell sub ets III relatIOn to variations III age and 
vi ral load (beta coefficients) among the IIIV-in fected children only. Every l3-cell subset was 
independently run in a quantile regression model containing age and viral load. P values <0.05 were 
considered significant. Significant result are in red text. 
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B-cell subset Age HAART 
p P value p P value 
Coefficien t Coefficient 
NaIve 0.02(0. 14) 0.882 20.32(8 . J 3) 0.015 
Resting memory 0.0 I (0 .02) 0.807 0.35( 1.29) 0.789 
Activated mature -0.0 I (0.02) 0.739 -5 . 73( 1.07) <0.0005 
Atypical memory -0 .025(0.08) 0.756 -12 .65(4.40) 0.005 
-
Plasma blasts -0 .0 I (0.0 I) 0.359 -2 .63(0.80) 0.045 
I mmatu re/transitional -0 .00(0.04) 0.967 -2.3 1 (2 .1 4) 0.284 
IgD+ Resting memory 0.00(0.00) 0.61 3 0.87(0.55 ) 0. 117 
IgD- Resting memory 0.00(0.0 I) 0.988 1.23(0.79) 0. 127 
rable 3.20: Estllnated change III freq uencies of various B-cell subsets III re lation to variati ons In age and 
IIAA RT treatment (beta coe rfieients) among thc I-IIV -in fccted chi Idren. Every l3-cell subset was 
independently run in a quantile regression model containing I-IAART treatment and age. P va lucs <0.05 
were considered significant. Signifi cant results are in red text. 
B-cell subset Age CD4+ T-cell 
percentages 
J3 P value p P value 
Coefficient Coefficient 
Na'ive 0.09(0.12) 0.465 1.04(0.29) 0.001 
Resting memory -0.0 I (0.02) 0.611 0.10(0.04) 0.015 
Activated mature -0.03(0.03) 0.331 -0.15(0.07) 0.049 
Atypical memory -0.08(0.07) 0.288 -0.56(0.17) 0.002 
Plasmablasts -0.03(0.0 I) 0.019 -0.04(0.03) 0.080 
Immature/transitional -0.02(0.03) 0.472 -0. 10(0.08) 0.252 
IgD+ Resting memory 0.01(0.01) 0.566 0.06(0.03) 0.039 
IgD- Resting memory -0.01 (0.0 I) 0.487 0.05(0.03) 0.076 
Table 3.2 1: Estim ated change in frequencies of various B-cell subsets in relation to variations in agc and 
C0 4+ T-ce ll percentage (beta coe ffi cients) among the 1-11 V -in fec ted children. Every B-cell subset was 
independently run in a quantile regression model containing age and C04+ T-ccll percentage. P values 
<0.05 were considered signifi cant. Significant results are in red text. 
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B-cell subset Age I-HV status Viral load CD4+ T-cell IIAART 
percentages 
P Coefficient P value P Coefficient P value P Coefficielll P value P Coefficient P value P Coefficient P value 
Na'ive -0.06(0.05) 0.265 2 1.25(9.39) 0.026 -5.7 1(0.96) <0.0005 0.17(0. 14) 0.209 4.84(3.82) 0.208 
-
Resting memory 0.02(0.02) 0.4 16 -3.43(3.97) 0.390 -0.02(0.4 1 ) 0.959 0.08(0.06) 0. 185 0. 15(1.6) 0.928 
--
Activated mature 0.01(0.01) 0.690 -6.71(2.3 1 ) 0.005 
-~ 
1.20(0.23) <0.0005 -0.00(0.04) 0.901 -2.32(0.96) 0.018 
Atypical memory 0.0 1(0.05) 0.783 -1 6.33(8.51 ) 0.058 1.98(0.89) 0.027 -0.27(0. 13) 0.0.f0 -6.94(3.53) 0.052 
--
Plasmablasts 0.00(0.01) 0.609 -3.04( 1.61) 0.062 
-
0.33(0. 16) 0.045 0.02(0.03) 0.427 -1 .08(0.66) 0. 109 
Immature/transitional -0.0 1(0.03) 0.760 -6.87(5.27) 0. 196 0.22(0.56) 0.69 1 -0.09(0.08) 0.256 -2. 13(2. 19) 0.333 
-IgD+ Resting memory 
-
0.00(0.0 1) 0.750 -0. 76( 1.71) 0.660 -0.29(0. 19) 0. 133 0.01(0.02) 0.696 0.14(0.72) 0.84 1 
IgD- Resting memory 0.02(0.02) 0.246 -1.35(3.59) 0.709 -0. 11 (0.41) 0.788 0.03(0.05) 0.507 0.43(1.5 1 ) 0.779 
Table 3.22: Estimated change in /Tequencies of various B-cell subsets in relation to variations in age. HIV status. viral load. CD4+ T-cell percentage and HAART treatment (beta 
coefficients). Every B-cell subset was independently run in a generalized quantile regression model con taini ng age, HIV status. viral load, CD4+ T-cell percentage and HAA RT 
treatment. P values <0.05 were considered sign ifi cant. Significant results are in red text. 
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When the predictive significance of HIV status on the frequencies of various B-cell 
subsets was assessed among alI children after adjusting for age, HIV infection was a 
significant predictor of low frequencies of resting memory B cells, IgO' resting memory 
B cells and IgO+ resting memory B cells. Being HIV infected was also a significant 
predictor of high frequencies of atypical memory B cells. None of the other B-cell 
subsets were predictable by HIV status, probably due to heterogeneity in the 
frequencies of those subsets between different sub-groups (based on viraemia, C04+ T-
cell percentages and HAART treatment) within the HlV-infected cohort. 
When the predictive significance of viral load on the frequencies of various B-cell 
subsets was assessed among the HIV-infected children after adjusting for age, viral load 
was a significant predictor oflow frequencies ofnarve B cells and IgD+ resting memory 
B cells. It also turned out to be a significant predictor of high frequencies of activated 
mature B cells and atypical memory B cells. Notably, there was a non-significant trend 
towards some predictive power of viral load on high frequencies of plasmablasts 
(P=O.079) and low frequencies ofIgO' resting memory B cells (P=O.086). 
High C04+ T-cell percentages significantly predicted high frequencies ofna'ive B cells, 
resting memory B cells and IgO+ resting memory B cells after adjusting for age in HIV-
infected children. On the other hand, it predicted low frequencies of activated mature B 
cells and atypical memory B cells, suggesting that CD4+ T-cell depletion in HIV could 
be associated with the expansion of some of these subsets. 
Treatment with HAART, after adjusting for age, was a predictor of high frequencies of 
na1've B cells in HIV-infected children. It also predicted low frequencies of activated 
mature B cells, atypical memory B cells and plasmablasts. 
In a generalized model that included all the predictor variables (Le. age, HIV status, 
viral load, C04+ T-cell percentage and HAART treatment), the effect of each predictor 
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variable after adjustment for all other variables was assessed. HIV infection was a 
significant predictor of low frequencies of naiVe B cells and high frequencies of 
activated mature B cells. Viral load appeared to be the most important predictor of B-
cell defects in most B-cell subsets. It significantly predicted low frequencies of na'ive B 
cells and high frequencies of activated mature B cells, atypical memory B cells and 
plasmablasts. Interestingly, CD4+ T-cell percentage was a significant predictor of only 
atypical memory B cells, suggesting that lymphopenia could directly affect atypical 
memory B cells compartment but has minimal direct effects on other subsets. Treatment 
with HAART was a significant predictor of low frequencies of activated mature B cells. 
3.5 Discussion 
In this study, the B-cell subset distribution in HIV-infected children was similar to that 
observed in HIV -infected adults but with minor differences [215, 236]. There was 
general expansion of B-cell subsets that are associated with generalized immune 
activation, namely activated mature B cells, atypical memory B cells and plasmablasts. 
This expansion appeared to be dependent mainly on viral loads, with low CD4 + T-cell 
percentages and absence of HAART treatment also playing some role, suggesting that 
some viral factors could be directly activating B cells. Interestingly, treatment with 
HAART was associated with reduced frequencies of activated mature B cells among 
highly viraemic children. 
HIV gp 120 is one HIV factor that has been shown to polyclonally activate B cells via 
DC-SIGN and the B-cell receptor (BCR) [132,225]. Moreover, BAFF, a cytokine that 
promotes B-ce\l survival, has been shown to be elevated in HIV viraemic patients and 
could be playing a role in maintaining some of these activated subsets [237]. In 
addition, ferritin released by macro phages in response to HIV Nefprotein has also been 
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suggested to contribute to the pathogenic activation of B cells [133]. Therefore, the 
cause of expansion ofthese activated subsets is probably multifactorial. 
Of note, unlike in HlV-infected adults and similar to one previous study in children, we 
did not detect differences in frequencies of immature/transitional B cells between the 
different groups of children [226,234]. Any HIV-associated effects in this compartment 
could have been blunted by the fact that children usually have high frequencies of 
immature/transitional B cells that decrease with age [233], a factor that could lead to 
high variability and probably a large noise:signal ratio. 
The low frequency ofresting memory B cells, an observation that has been reported by 
previous studies in adults and children with HIV, was also seen here [84, 230-232, 234, 
236]. It would be difficult to disentangle depletion of existing resting memory B cells 
from failure to induce new B-cell memory in children infected with HIV. This is 
because most HIV-infected children are infected early in life and therefore build their 
immune memory in the presence of the infection. In viraemic HIV-infected adults, 
depletion of existing B-cell memory has been shown to occur [228]. In addition, poor 
humeral response to vaccines has been reported in untreated HIV patients, suggesting 
that HIV viraemia could also impair induction of new B-cell memory [238]. Therefore, 
HIV-viraemic children could be experiencing both failure to induce adequate B-cell 
memory and depletion of the limited memory that they acquire. Notably, the low 
frequency of resting memory B cells was in both low viraemia and high viraemia 
children, suggesting some independence from viral loads as at that time. 
Interestingly, we found significant interaction between age and level of viraemia 
with/without HAART with regard to accumulation of resting memory B cells. The same 
interaction was also observed between age and CD4+ T-cell percentages with/without 
HAART. Normally, children are expected to acquire memory B cells with age due to 
the continued exposure to environmental and vaccine antigens as they advance in age. 
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Indeed, healthy children in this study showed an increase in frequencies of resting 
memory B cells with age. HIV-infected children who had low viraemia or high CD4+ T-
cell percentages too showed a similar expansion of the resting memory B-cell 
compartment with age, though the predicted frequencies remained consistently lower 
than those of healthy controls. However, HIV-infected children who had high viraemia 
or low CD4+ T-cell percentages showed an age dependent (hence exposure dependent) 
decrease in frequencies of resting memory B cells. This finding suggests that, in the 
long run, having low viraemia could allow the HIV-infected children to slowly build up 
their B-cell memory. This emphasizes the possible advantages of putting children and 
even adults on HAART as soon as they are diagnosed with HIV. Indeed, children and 
adults on HAART with controlled viraemia or improved CD4+ T-cell counts make 
better antibody responses to vaccines when compared with untreated patients [239]. 
Such observation can be extrapolated to the many other antigens that these people 
encounter in the environment over time, explaining the observed association of higher 
frequencies of resting memory B cells with older age among some of the groups of 
children. 
The viral loads correlated with the frequencies of all B-cell subsets with the exception 
of resting memory B cells and immature/transitional B cells, suggesting that viral 
factors could be playing a major direct role in the deregulation of B-cell subset 
distribution. On the other hand, frequencies of resting memory B cells correlated 
positively with CD4+ T-cell percentages, implying a strong connection between 
availability of T-cell help and the generation of memory B cells. However, a role for 
viral factors in depletion or prevention of gene rat ion of memory B cells cannot be ruled 
out since a good number of these children had a history of high viral loads that were 
controlled with HAART, hence abolishing any correlation that could have previously 
existed. Moreover, direct effect of viral factors could significantly affect frequencies of 
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resting memory B cells only at early days of infection when viral load is very high and 
germinal centers get extensively damaged. All the same, the significant inverse 
correlation between viral loads and CD4+ T-cell percentages makes it difficult to 
disentangle the effect of each. 
The significant inverse correlation between nal've B cells and the activated phenotypes 
suggests that the reduction in frequencies of naive B cells could be as a result of the 
polyclonal activation. Indeed, some of the activated phenotypes could have been 
derived from the naive B-cell compartment, leading to reduced frequencies of naive B 
cells. For instance, atypical memory B cells have been shown to lie between classical 
memory B cells and naive B cells with regard to replication histories and somatic 
hypermutations, suggesting that they cannot originate from the classical memory 
compartments hence leaving the na'ive compartment as their likely source. However, 
this does not negate the possibility of them originating from a totally different 
compartment that is probably underrepresented in healthy individuals and only 
expanded in disease. The activating effect of gp 120 on na'ive B cells also supports the 
possibility that some of the activated phenotypes could be originating from the naive 
compartment [132]. 
The significant correlations amongst the activated compartments suggest possible 
shared etiology or shared driving factors, though the generalized regression model 
suggests that atypical memory B cells are sensitive to CD4+ T-cell percentages while 
activated mature B cells are not. Notably, the three activated phenotypes (activated 
mature B cells, atypical memory 8 cells and plasmablasts) and naive B cells were 
significantly dependent on viral loads in the generalized regression model, suggesting a 
shared direct or indirect role of viral load in causing deregulation of all of them. The 
possibility of plasmablasts being derived from the activated mature B cells could 
explain the correlation between plasmablasts and activated mature B cells. 
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In summary, this study evaluated the subset distribution of B cells in HIV -infected 
children and how various factors relate with that subset distribution. 
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Chapter 4 Function of B cells in children 
infected with HIV 
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4.1 Literature review 
Functional defects ofB cells in HIV-infected adults have been described since the early 
days of the HIV epidemic. Most notable is hypergammaglobulinaemia, the polyclonal 
production of large amounts of immunoglobulins that are not targeted to any particular 
antigen and that are assumed to be of little use to the patient [122]. This is considered 
the classical indication of the aberrant activation of the B-cell compartment in untreated 
HIV. Other indicators of aberrant activation ofB cells in untreated HIV adults are: 
• The increased susceptibility to B-celllymphomas [240]. 
• The production of auto reactive antibodies [241]. 
• Production of antibodies spontaneously when lymphocytes are cultured in the 
absence of stimulants [242]. 
• Terminal differentiation ofB cells [123]. 
Paradoxically, despite the aberrant activation, B cells from untreated adults are 
relatively unresponsive to B-cell mitogens in vitro [122]. More importantly, untreated 
adults make poor B-cell responses to vaccines and pathogens. For instance, several 
studies have shown that they have low antibody levels against vaccines and pathogens 
[229,243,244]. Several other studies have shown depletion of antigen-specific memory 
B cells in such patients [84, 229]. However, little attention has been directed towards 
determination of antibodies' avidity maturation, with one study suggesting that the 
avidity of pre-existing anti-measles antibodies remains unaffected in HIV-infected 
adults [245]. 
The low levels of anti-vaccine antibodies and memory B cells in adults who were 
vaccinated before acquiring HIV suggests that HIV can deplete pre-existing B-cell 
responses. On the other hand, the poor response to vaccines administered to already 
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HIV-infected adults indicates that HIV-infection can also impair acquisition of new B-
cell responses [238, 246]. 
Several factors could contribute to the aberrant activation of B cells in HIV. For 
instance, HIV infection is characterized by high concentrations of BAFF, a B-cell 
cytokine that could contribute to maintenance of activated B cells [237]. Gp 120 has also 
been shown to cause polyclonal activation of B cells [132]. On the other hand, the poor 
B-cell responses to newly encountered antigens could be explained by the depletion of 
CD4+ T cells that could be crucial for providing help to the responding B cells in an 
immune reaction. The ability of HIV patients' B cells to harness the available T-cell 
help has also been put to question [247]. In addition, some HIV factors, like HIV Nef 
protein, have been implicated in inhibiting isotype switching and therefore limiting the 
production of switched isotypes like IgG and IgA [25]. Induction of B-cell apoptosis in 
HIV infection has been shown to contribute to the loss of B-cell responses that were 
present before the individual was infected with HIV [248-251]. 
Controlling viraemia following initiation ofHAART appears to reverse most functional 
B-cell defects that are attributable to polyclonal activation. As a result, most HAART-
treated adults experience a reduction in levels of total immunoglobulins upon control of 
viraemia [252]. However, controlling viraemia does not restore antibody and memory 
B-cell responses to previously encountered vaccine antigens and pathogens, suggesting 
that such patients may remain susceptible to infections [215, 229]. Revaccination after 
successfully initiating HAART leads to attainment of protective antibody responses to 
most vaccines, though the magnitude of the responses is not as high as that in 
revaccinated healthy controls [253-256]. Partial restoration of the CD4+ T-cell 
compartment and the elimination of detrimental HIV factors (e.g gp 120 and Net) could 
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explain the partial recovery in ability to make B-cell responses when viraemia is 
controlled with HAART. 
Vertically infected children differ from adults in that their immune system develops in 
the presence of HIV. Since they mostly become infected in utero, at birth or during 
breast-feeding, they receive most childhood immunizations and infections when they 
are already HIV-infected, raising the question of whether HIV may impair induction of 
B-cell responses as well as deplete any induced responses. In addition, the interaction of 
the virus with an immature immune system could result in different outcomes, 
especially with regard to polyclonal activation. As a result, many studies have been 
conducted to investigate the effect of HIV-infection on the quantitative antibody 
response to vaccine antigens in HIV -infected children [245, 257-268]. However, few 
studies have been done to characterize avidity maturation and the 
acquisition/maintenance of memory B cells in these children [232, 245, 261]. 
Similar to adults, untreated H1V -infected children have shown elevated levels of total 
immunoglobulins [269]. In addition, they have low levels of specific antibodies to 
vaccine antigens; many ofthem fail to maintain protective titres despite going through 
the usual childhood immunization programs [245, 257-263]. They also have lower 
frequencies of antigen-specific memory B cells when compared with healthy children 
[232]. Unlike in adults, antibodies' avidity maturation to measles antigen is impaired in 
HIV -infected children [245, 261]. Controlling viraemia using HAART normalizes total 
immunoglobulin levels but does not restore prior anti-vaccine antibody responses [269, 
270]. Subsequent revaccination induces protective titres that are long lasting, but its 
effect on antibody avidity maturation and generation of memory B cells has not been 
evaluated [257, 264-268]. Notably, initiation of HAART treatment in the first year of 
life has been shown to preserve the integrity of the memory B-cell compartment [232]. 
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Untreated lilY patients have been shown to have disruptions of the structures of their 
germinal centres in various lymphoid organs [271]. Consequently, and in consensus 
with the literature reviewed above, it is possible that HIY affects most, if not all, of the 
processes that are attributable to the genninal centre reaction. In this chapter, I further 
investigate the effect of paediatric HIY infection on the outcomes of germinal centre 
reaction namely antibody avidity maturation, generation and maintenance of long-lived 
plasma cells (as measured by maintenance of plasma antibodies) and generation and 
maintenance of memory B cells. I evaluated B-cell responses to some components of 
routine childhood vaccines namely tetanus toxoid, diphtheria toxoid and measles virus 
lysate. I also evaluated responses to pneumococcal capsular polysaccharides to 
determine responses upon natural exposure to pneumococcal pathogens in the 
community. Of note, a pneumococcal conjugate vaccine was introduced in the 
community during this study. Therefore, the analysis of pneumococcal responses in this 
chapter was limited to the children that had not received the pneumococcal vaccine. 
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Vaccinc Full namc Components Age of administration 
Bacillus Live attenuated 
BCG Calmette- Mycobacterium bovi At birth Guerin 
OPV Oral polio Live attenuated polio At birth, 6 weeks, 10 weeks and 
vaccine virus 14 weeks 
Diphtheria toxoid, 
Diphtheria, Tetanus toxoid. 
Pertussis, Bordetella pertussis 
DPT- Tetanus, 
toxins and adhesins, 
HepB- Hepatiti B 
Hepatiti B surface 6 weeks, 10 weeks and 14 
and antigen, Hemophilus weeks 
Hib Hemophilus influenza 
influenza type po Iysaccharides 
B conjugated to carrier 
protein 
Decavalent Pneumococcal capsular 
PCV 10 pneumococcal po Iysaccharides 
6 weeks, 10 weeks and 14 
conjugate conjugated to carrier weeks 
vaccine proteins 
Measles Live attenuated 9 month 
vaccine measles virus 
Table 4.1: ummary of the roulIm: childhood vaccines that arc part of the Kenya Expanded Programme 
011 Immunisation (KEPI) . Thc vaccines components th at were evaluated arc in rcd lex \. 
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4.2 Objectives 
I determined the function ofB cells in children infected with HIV with regard to various 
antigens. The specific objectives were: 
1. To determine the levels of antibodies to common childhood vaccines and 
infections in HIV-infected children. 
2. To determine the avidity of antibodies to common childhood vaccines and 
infections in HIV-infected children. 
3. To determine the frequencies of memory B cells to common childhood vaccines 
and infections in HIV-infected children. 
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4.3 Results 
The population characteristics of the HIV-infected children and community control 
that were studied in thi chapter are shown in table 4. I. 
Va lue P value 
(vcrsu community 
controls) 
Number (N) 174 
ommunity controls 58 
I II V-infected 116 
Low viraem ia 64 
High viraemia 52 
High 04+ T-cell percentage 49 
Low 04+ T-cell percentage 67 
Median age in months 55 (35-80) 
ommunity controls 55 (43-81) 
HIV-infected 53 (31-79) 0.2617 " 
Low viraemia 58 (29-86) 0.5623 " 
High viraemia 49 (33-72) 0. 1580 · 
High 04+ T-cell percentage 59 (35-82) 0.7386· 
Low 04+ T-cell percentage 47(3 1-71) 0.0758 • 
% Female (n) 50 (87) 
ommunity controls 48 (28) 
HIV-infected 5 1 (59) 0.707 b 
Low viraemia 56 (35) 0.423 b 
Iligh viraemia 46 (24) 0.824 b 
High C04+ T-cell percentage 58 (38) 0.300 b 
Low 04+ T-cell percentage 43 (21) 0.575 b 
% on IIAART(n) N/A 
ommllnity control N/A 
I-IIV-infected 61 (71) 
Low viraemia 78 (50) 
High viraemia 40 (21) 
High C04+ T-cell percentage 73 (49) 
Low 04+ T-cell percentage 45 (22) 
Viral load, 10glO RNA COllics/mL N/A 
ommunity controls N/A 
IIIV-infected 3.4 (0-4.6) 
Low viraemia 1.4 (0-3.2) 
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High viraemia 
High C04+ T-cell percentage 
Low C04+ T-cell percentage 
CD4+ T cells (percentage) 
Community control 
HIY- infecled 
Low viraemia 
High viraemia 
High 04+ T-cel! percentage 
Low 04+ T-cell percentage 
% PlliD-CV vaccinated (n) 
Comillunity controls 
HIY-infected 
4.7 (4.4-5.2) 
2.7(0-4. 1) 
4.4 (3.2-4.9) 
27.7 (19.6-34.5) 
33.8 (28. 1-39.3) 
26.2 (18. 1-32.9) 
29.4 (22.5-34.5) 
2 1.3 (9.4-27.4) 
32.0 (28. 1-37.8) 
16.5 (8.7-22.0) 
28 (49) 
15 (9) 
35 (40) 
0.000 I · 
0.0069 • 
<0.0005 • 
0.3757 " 
<0.0005 • 
Low viraemia 38 (24) 0.005 b 
High viraemia 31 ( 16) 0.049 b 
High 04+ T-cel! percentage 42 (28) 0.00 I b 
Low 04+ T-cell percentage 26 (12) 0.202 b 
Table 4. 1: Baseline characteristics of the children who participated in the evaluation or B-cell runction in 
I flY-infected children. Yalues hO\'\11 are medians (inter-quartile range) un les otherwise tated. 
Statisti cal tests usedl: ' Wilcoxon rank-sum test (Mann Whitney te t), b hi-squared test. 
However some of the children were not considered in the analysis in this chapter. 
Fourty nine children were omitted from the evaluation of anti-pneumococcal response 
because they had participated in the community catch-up campaign for introduction ofa 
pneumococcal conjugate vaccine Synflorix®, wh ich was introduced into the childhood 
immunization sched ule when this study was ongoing. As a result, orne older children 
in the community received the vaccine in the community. ince the evaluation of 
pneumococcal responses in this tudy was aimed at asse sing the responses ITom natural 
exposure to pneumococcal antigens, children who had received the vaccine were left out 
in the analysis of responses to pneumococcal capsular polysaccharide in thi chapter. 
Furthermore, two of the polysaccharides in the vaccine were conjugated to tetanu 
toxoid and diphtheria toxoid. The vaccine therefore acted as a booster to pre-exi ting 
anti-tetanus and anti-diphtheria response. Since the ana lyses of the anti-tetanus and 
anti-diphtheria response in thi chapter were aimed at de cribing the respon es that 
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were attributable to the OPT vaccination in the first months of life, such children who 
received the pneumococcal conjugate vaccine in the community were also excluded 
from the analyses. Eleven children whose OPT vaccination information was not 
available were also excluded from the analyses on tetanus toxoid and diphtheria toxoid 
responses. Other children were omitted from the various analyses because their samples 
had not been collected at the time when the assays were carried out. 
After stratification of the 174 total children on the basis of viral loads and C04+ T-cell 
percentages, differences in age were revealed amongst the various HIV -infected 
subgroups and community controls. Initial statistical analyses were done using 
univariate nonparametric tests, mainly Wilcoxon rank-sum test (Mann-Whitney test). 
Subsequent analyses were performed using multivariate regression models whereby 
adjustments for age and other covariates were done. 
119 
4.3.1 Quantities of antibodies to vaccines and natural infections 
Similar to previous reports, HIV-infected children had lower levels of IgG to vaccine 
antigens when compared with community control children. The whole HIV -infected 
cohort had lower median levels oflgG against tetanus toxoid (47.5 [lOR, 29.6 -112.4] 
AU versus 174.3 [lOR, 52.5 -653.7] AU, P=0.0122), diphtheria toxoid (230.9 [lOR, 
144.2-349.8] AU versus 890.5 [lOR, 531.4-1537.9] AU, P<0.00005) and measles 
antigen (19.3 [lOR, 10.4-44.6] AU versus 51.7 [lOR, 25.5-103.5] AU, P<0.00005) 
when compared with community controls. Following further classification of the HIV-
infected children into high viraemia and low viraemia groups, the two groups still had 
comparably low median levels of anti-tetanus toxoid (high viraemia, 46.5 [lOR, 28.5-
87.2] AU P=0.0236; low viremia, 54.0 [lOR, 26.3-117.8] AU, P=0.0281), anti-
diphtheria toxoid (high viraemia, 244.0 [lOR, 175.5-422.4] AU P<0.00005; low 
viraemia, 205.0 [lOR, 133.9-327.0] AU P<0.00005) and anti-measles (high viraemia, 
18.5 [lOR, 11.2-35.1] AU P=O.OOOI; low viraemia, 21.6 [lOR, 9.7-48.0] AU P=0.0005) 
IgG when compared with community controls, suggesting that the level of viraemia at 
that time did not influence the acquisition/maintenance of plasma anti-vaccine IgO 
concentrations. Stratification of the HIV -infected children on the basis of CD4 + T-cell 
percentages yielded similar results with both low and high CD4+ T-cell percentage 
groups having low anti-tetanus toxoid (low CD4+ T-cell percentage group, 46.8 [lOR, 
30.1-113.0] AU, P=0.0222; High CD4+ T-cell percentage group, 51.3 [lOR, 52.5-653.7] 
AU, P=0.0296), anti-diphtheria toxoid (low CD4+ T-cell percentage group, 219.5 [lOR, 
175.1-318.4] AU, P<0.00005; High CD4+ T-cell percentage group, 244.7 [lOR, 141.3-
427.7] AU, P<O.OOOOS) and anti-measles (low CD4+ T-cell percentage group, 18.6 
[IQR, 11.6-45.0] AU, P=0.0005; High CD4+ T-cell percentage group, 19.9 [lOR, 9.8-
43.7] AU, P=0.0002) IgG when compared with community controls. Interestingly, there 
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were no differences between the community controls and the HIV -infected children 
with regard to IgO against pneumococcal capsular polysaccharides. 
Further stratification of the high and low viraemia children on the basis of their 
HAART-treatment status did not reveal any differences between the HAART-narve and 
the HAART-treated children with regard to levels of JgG against any of the antigens. 
Notably, only the HAART -treated subgroups had lower quantities of anti-TT JgO while 
all subgroups had lower anti-DT JgO when compared with community controls. In 
addition, all subgroups, except the low viraemia sub-group, had lower anti-measles IgO 
when compared with community controls. None of the sub-groups differed from 
community controls with regard to IgO levels against pneumococcal capsular 
polysaccharides. 
Further stratification of the low and high CD4+ T-cell percentage groups on the basis of 
treatment also revealed no differences between HAART-narve and HAART-treated 
subgroups within both low and high CD4+ T-cell percentage groups with regard to all 
antigens. However, the HAART-treated subgroups showed lower ant-TT JgO levels 
when compared with community controls. All subgroups had lower levels of IgO 
against DT and measles when compared with community controls. None differed from 
community controls with regard to IgO against pneumococcal capsular polysaccharides. 
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Notably, plasma IgM levels against tetanus toxoid were similar in HIV -infected and 
community control children. However, plasma IgM levels against diphtheria toxoid 
were lower in the HIV-infected cohort when compared with community controls (594.5 
[lOR, 393.5-828.8] AU versus 2276.6 [lOR, 1135.5-3409.1] AU P<0.00005). Further 
classification of the HIV-infected children showed that both high viraemia (649.3 [lOR, 
375.7-830.3] AU, P<0.00005) and low viraemia (581.0 [lOR, 412.6-844.5] AU, 
P<0.00005) children had lower anti-diphtheria IgM levels than community controls. 
The same observation was made after stratifying the children based on their CD4+ T-
cell percentages with both low and high CD4+ T-cell percentage groups having lower 
anti-diphtheria toxoid IgM levels (651.7[IQR, 384.7-776.7] AU and 554.7 [lOR, 412.6-
844.5] AU respectively, P<0.00005 in both cases) when compared with community 
controls. 
Further stratification of the children on the basis of their HAART treatment status did 
not reveal any differences between the HAART -naiVe and HAART treated children 
within the low viraemia, high viraemia, low CD4+ T-cell percentage and high CD4+ T-
cell percentage groups. However, while all HIV -infected subgroups were similar to 
community controls with regard to levels of anti-TT IgM, they all had lower levels of 
anti-DT IgM than community controls. 
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Figure 4.2: Pia rna concentration in arbitrary units (AU) oflgM again t tetanu toxoid (n') and 
diphtheria toxoid (DT). Blue symbols represent chi ldren who were treated with IIAART. red symbol 
represent children who were I-IAART naive and brown symbol represent the community control s. 
I-Iorizontalline shows the median concentration tor each sub-group. High viraemia group: >/=5000 RNA 
copies/ml, low viraemia group: < 5000 RNA copie /ml. low CD4 pereentage group: <25% and hi gh CD4 
percentage group: >/=25%. Statistical test u ed: Wilcoxon rank-sum test. • represent p<O.05. 
In summary, HIV-infected children had lower vaccine-derived ant ibody levels when 
compared with community contro ls. However, they were not any different with regard 
to naturally acqu ired antibodies again t pneumococcal antigens. 
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4.3.2 Avidities oflgG to vaccine antigens and natural infections 
Antibody avidity index is a measure of the strength of the interaction between an 
antibody molecule and its cognate antigen. Avidity maturation is the process by which 
the produced antibodies are modified in the course of an immune reaction so that 
antibodies that bind more strongly to the antigen are produced at later stages of the 
immune response. The process occurs in the germinal centre. It involves somatic 
hypermutation and Darwinian selection of B-cell clones that interact more strongly with 
the available antigen. The whole process is important in ensuring high quality of 
antibodies that are produced [272]. To assess if HIV affects avidity maturation of 
antibodies produced against non-HIV antigens in HIV-intected children, the avidity 
indices of IgG against TT, DT, measles and pneumococcal capsular polysaccharides 
were assessed. 
The avidity indices of antibodies against tetanus toxoid were lower among the lIlV 
infected children (0.22 [lOR, 0.14-0.34]) when compared with community control 
children (0.38 [lOR, 0.27-0.51], P=0.0143). Further stratification of the HIV-infected 
children revealed that the impairment was in both high viraemia group (0.21 [lOR, 
0.15-0.32], P=0.0152) and low CD4+ T-cell percentage group (0.19 [lOR, 0.13-0.32], 
P=O.O 1 to). The same effect was also observed for avidity indices of antibodies against 
diphtheria toxoid when the whole HIV -infected cohort (0.34 [lOR, 0.28-0.43], 
P=0.0006), high viraemia group (0.37 [lOR, 0.29-0.43], P=O.OOIO), low viraemia group 
(0.34 [lOR, 0.26-0.44], P=0.0042), low CD4+ T-cell percentage group (0.37 [lOR, 0.30-
0.44], P=0.0016) and high CD4+ T-cell percentage group (0.32 [lOR, 0.26-0.44], 
P=0.0028) were compared with community controls (0.51 [lOR, 0.41-0.57]). The 
avidity indices against measles antigen were also lower in the whole HIV -infected 
cohort (0.22 [lOR, 0.16-0.27], P<0.00005), low viraemia (0.22 [lOR, 0.16-0.30], 
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P=0.0002), high viraemia (0.21 [IQR, 0.16-0.24], P<0.00005), low CD4+ T-cell 
percentage (0.21 [IQR, 0.16-0.28], P=0.0002) and high CD4+ T-cell percentage (0.22 
[IQR, 0.16-0.26], P<0.00005) groups when compared with community controls (0.30 
[IQR, 0.23-0.38]), suggesting that HIV infection generally impairs the process of 
avidity maturation to routine vaccines in children. Notably, the HIV -infected children 
did not differ from community controls with regard to anti-pneumococcal capsular 
polysaccharides IgG avidity indices. 
Further stratification of the children on the basis of their HAART treatment status did 
not reveal any differences between the HAART-nai've and HAART-treated children 
within the low viraemia, high viraemia, low CD4+ T-cell percentage and high CD4+ T-
cell percentage groups with regard to avidity indices against any of the antigens. For 
TT, the HAART-treated subgroups had lower avidity indices when compared with 
community controls. For DT, all subgroups, except the low viraemia HAART-nai've and 
low CD4+ T-cell percentage HAART-narve subgroups, had lower avidity indices when 
they were compared with community controls. All subgroups, except the low viraemia 
HAART-narve subgroup, had lower avidity indices of anti-measles IgG. However, none 
of the sub-groups differed from community controls with regard to avidity indices of 
anti-pneumococcallgG. 
In summary, HIV-infected children had lower avidity indices for IgG against vaccine 
antigens when compared with community controls. However, the same was not 
observed with regard to avidity indices for IgG against pneumococcal antigens. 
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Figure 4.3: Avidity indices of pl asma IgO against tetanu toxoid (TI), diph theria toxoid (DT). meas le 
and pneumococca l capsular polysaccharides (PP ). Blue ymbol represent children who \\ere treated 
with HAART, red symbol represent children who were I IAART nai've and bro"'" ymbols represent the 
community controls. Horizontal line show the median concentration for each sub-group. lligh viraemia 
group: >/=5000 RNA copics/ml. low iraemia group: < 5000 RNA copies/ml. low D4 perccntage 
group: <25% and high CD4 percentage group: >/=25%. tati stica l Ie I u ed: Wi lcoxon rank· um te t. • 
repre enls p<0.05. 
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4.3.3 Frequencies of memory B cells to vaccine antigens 
One of the products of a germinal centre reaction is long-lived memory B cells against 
the cognate antigen. Such memory B cells enable the individual to mount a quicker and 
stronger antibody response in the event ofre-exposure to the same antigen. Assessment 
of frequencies of antigen specific memory B cells is done by first activating PBMCs 
polyclonally with B-cell mitogens that are known to drive terminal differentiation of 
preferentially memory B cells. The polyclonal activation is followed by an antigen 
specific enzyme linked immunospot assay to detect the number of antibody secreting 
cells [221]. 
Similar to previous studies in children and adults, the HIV-infected children had lower 
frequencies of memory B cells to measles and pneumococcal capsular polysaccharides 
when compared with community controls (measles antigen; 3.8 [lOR, 0.1-17.5] 
ASCII M PBMCs versus 20 [lOR, 5-35] AU P=0.0051, pneumococcal capsular 
polysaccharides; 5.0 [lOR, 0.0-17.5] ASCII M PBMCs versus 13.8 [lOR, 6.3-40] AU 
P=0.028I ). However, no differences were observed with regard to anti-TT memory B 
cells when the HIV cohort was compared with community controls. Further 
stratification of the HIV-infected children into high viraemia and low viraemia groups 
revealed that the low viraemia group had low frequencies of memory B cells against 
measles antigen when compared with community controls. Stratification into high and 
low CD4+ T-cell percentage groups revealed that both groups had lower frequencies of 
anti-measles memory B cells when compared with community controls. For 
pneumococcal antigens, both low viraemia and high CD4+ T-cell percentage groups had 
low frequencies of memory B cells when compared with community controls. No 
differences were observed between the HIV -infected groups and community controls 
with regard to ant i-TT memory B cells. 
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When further stratification of the children on the basis of their treatment with HAA RT 
was done, the HAART-treated children with low viraemia had higher frequencies of 
memory B cells against measles antigen and pneumococcal capsular polysaccharides 
when compared with HAART-narve children who also had low viraemia. No other 
differences were observed between HAART-narve and HAART-treated children within 
any other groups with regard to any of the antigens. Notably, for measles antigen, all 
HAART-nai've subgroups had lower frequencies of memory B cells when compared 
with community controls. For IT, only the HAART-treated children who had low CD4+ 
T-cell percentages showed lower frequencies of anti-TT memory B cells when 
compared with community controls. For pneumococcal antigens, the high viraemia 
HAART-treated, low viraemia HAART-nai've and low CD4+ T-cell percentage 
HAART-nai've groups had lower frequencies of anti-pneumococcal memory B cells 
when compared with community controls. 
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Figure 4.4: Frequencies of antigen- pecific IgG memory B cell in peripheral blood again t tetanu toxoid 
(TI), mea les and pneumococcal capsular pol ysaccharide (PPS) expressed as IgG antibody-secreting 
eells(ASC) per I mi ll ion PBMC . Blue symbol represent chi ldren who were treated with HI\ 1\ RT. red 
symbols represent chi ldren who were HAART naIve and brown symbols represent the community 
controls. lIorizontal line sho\ the median concentration for each sub-group. High viraemia group: 
>/=sooo RNA copies/ml, low viraemia group: < 5000 RNA copies/ml, low CD4 percentage group: 
<25% and high CD4 percentage group : >/=25%. Statistical test used: Wilcoxon rank-sum test. • 
represents p<O.OS. 
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Multivariate regression analysis with adjustment for age 
B-cell responses to vaccine antigens and natural infections vary with age. Responses 
against vaccine antigens are expected to wane over time, as the children grow older. On 
the other hand, responses to environmental antigens and natural infections are expected 
to increase over time with exposure, as children grow older. After stratifYing the 
children on the basis of their viral loads, CD4+ T-cell percentages and HAART 
treatment, it was noted that the various subgroups differed in age amongst the HlV-
infected children and also when compared with community. Consequently, further 
analysis was done with adjustment for age to analyse the effect of various population 
characteristics on B-cell responses to the antigens of interest. Since most of the data 
were not normally distributed, quantile regression models were used. 
The first set of analyses was done to evaluate the effect of HIV infection (HIV status) 
on the B-cell responses to the various antigens. This was done on all children. 
Subsequent analyses were restricted to the HIV-infected children to evaluate the 
predictive ability of viral loads, CD4+ T-cell percentages and HAART treatment on B-
cell responses to the antigens of interest. Since the three variables (i.e. viral loads, CD4 + 
T-cell percentages and HAART treatment) showed multicollinearity, they were first run 
on separate models then later run together on a generalized model. 
When the predictive ability of HIV status was evaluated with adjustment for age alone, 
HIV infection was a significant predictor of low IgG responses against TT, DT and 
measles antigen. It also significantly predicted low levels of anti-DT IgM. In addition, 
HIV significantly predicted low avidity indices for JgG against TT, DT and measles 
antigen and low frequencies of memory B cells against measles antigen. It did not 
predict any B-cell responses against pneumococcal capsular polysaccharides, 
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suggesting that HIV infection does not affect the acquisition of B-cell responses against 
environmental pneumococcal antigens. 
Interestingly, when the effect of viral load was assessed among the HIV-infected 
children after adjustment for age, viral load came out as a significant negative predictor 
of IgO against pneumococcal capsular polysaccharides, suggesting that even though 
HIV-infection does not affect acquisition of anti-pneumococcal responses, viral load 
does. The other B-cell responses were not affected by viral load at the time, suggesting 
that it had no effect for as long as a child was infected. 
When the effect ofCD4+ T-cel1 percentage was assessed with adjustment for age among 
the HIV-infected children, it did not affect any of the B-cell responses, suggesting that 
CD4+ T-cell percentages at the chronic phase of HIV-infection do not influence 
responses to historically encountered antigens. 
Surprisingly, HAART treatment was a predictor of low anti-DT IgM and low avidity 
indices of IgO against TT after adjustment for age, probably because the children on 
HAART are the same ones whose disease had progressed more in the first months of 
life, hence them being put on HAART. HAART treatment did not predict any other B-
cel1 response. 
In the generalized quantile regression model where age, HIV status, viral loads, CD4 + 
T-cell percentages and HAART treatment were included, the effect of each variable 
with adjustment for the other variables was assessed. HIV infection was still a 
significant predictor of low levels of IgO against TT, DT and measles as well as low 
levels of IgM against DT. It also significantly predicted for low avidity indices of IgO 
against DT and measles antigen, but not TT. Interestingly, it did not significantly 
predict frequencies of memory B cells against any of the antigens. Viral load and CD4 + 
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T-cell percentages did not sign ificantly predict any of the B-cell responses. HAART 
treatment significantly predicted for higher frequencies of anti-measles memory B cells, 
suggesting that treatment with HAART in children can indeed influence memory B-cell 
responses against some vaccines. Notably, age was a significant predictor of anti-TT 
IgG levels and anti-pneumococcal IgG avidity indices, suggesting that age could only 
influence some of the B-cell responses. 
B-cell respon e 
Anti-TT IgG 
Anti-DT IgG 
Anti-Measles IgG 
Anti-PPS IgG 
Anti-TT IgM 
Anti-DT IgM 
Anti-TT IgG AI 
Anti-DT IgG AI 
Anti-Measles IgG 
AI 
Anti-PPS IgG AI 
Anti-TT IgG 
ASCII MPBMCs 
Anti-Measle 
IgG 
ASC/IMPBMCs 
Anti-PPS IgG 
ASCIIMPBMCs 
HIV statu 
13 Coefficient 
-14-l.83( 13.95) 
-720. [3(79.84) 
-36.22( 4.40) 
-31.25(28.87) 
-272 .82( 1298.99) 
-1596.00(158. (9) 
-0.17(0.06) 
-0.17(0.05 ) 
-0.08(0.02) 
-0.0 I (0.04) 
-5.23(3.24) 
- [8.81(6.0 [) 
-10.00 (6.73) 
P value 
0.000 
0.000 
0.000 
0.282 
0.834 
0.000 
0.006 
0.000 
0.000 
0.890 
0.112 
0.003 
0.143 
Age(Month) 
13 Coefficient 
-0.72(0.22) 
-I. 19( 1.23) 
-0.18(0.07) 
0.87(0.52) 
8.93(20.50) 
2.69(2.50) 
-0.00(0.00) 
-0.00(0.00) 
0.00(0.00) 
0.00(0.00) 
-0.04(0.05) 
-0.05(0. 10) 
0.00(0. (0) 
P value 
0.002 
0.338 
0.011 
0.098 
0.664 
0.286 
0.832 
0.389 
0.996 
0.204 
0.473 
0.589 
1.000 
Tablc 4.2: Estimated change in B-cell re ponses in relation 10 variations in age and III V tatu (beta 
coemcient ). Every B-cell re pon e was independently run in a quantile regression model containing HIV 
status and age. P val ues <0.05 were considered significant. TT-tetanus toxoid ; DT-diphtheria toxoid; 
PPS-pneumococcal eap ul ar polysaccharide; AI-avidity index; ASCII MPBM s-antibody ecreting cell 
per 1 million PBM s. ignificant results arc in red text. 
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B-cell r e po nse 
A nti-TT IgG 
Anti- DT IgG 
A nti-Meas les IgG 
A nti-PP IgG 
A nti-TT IgM 
A nti- DT IgM 
A nti-TT IgG AI 
Anti-DT IgG A I 
A nti-Meas les IgG 
A I 
A nti- PP IgG A I 
Vira l load 
l} Coeffi cie nt 
-1 .22(3.6 1 ) 
10.9 1( 15.3 1) 
-0042(0.95) 
-10.68(4.93) 
3 11.98(225.19) 
1.75(29.56) 
0.00(0.0 1 ) 
0.0 I (0.0 I) 
-0.00(0.00) 
0.00(0.0 1) 
A nti-TT IgG 0.28(0.92) 
A C/ I M PBM 
Anti-M easles 
Ig G 
A CIIMPBM Cs 
A nti- PP IgG 
A Cl I M PBMCs 
-0.34( 104 1) 
0.70(1.75) 
Age(Mo nths) 
P va lue l} Coeffici ent 
0.736 
00479 
0.662 
0.034 
0. 172 
0.953 
0.972 
0.3 14 
0.811 
0.794 
0.76 1 
0.809 
0.69 1 
-0.79(0.30) 
- 1.1 5( 1.24) 
-0.2 1(0.06) 
-0. 15(0.39) 
27.00( 18.3 1) 
0.85(2045) 
-0.00(0.00) 
-0.00(0.00) 
0.00(0.00) 
-0.00(0.00) 
-0.06(0.08) 
0.20(0. 11 ) 
-0 .06(0.1 I) 
P va lue 
0.0 11 
0.358 
0.00 1 
0.700 
0. 146 
0.73 1 
0.8 19 
0.704 
0.934 
0. 105 
00469 
0.096 
0.596 
Table 4.3: Estimated change in B-cell response in relation to va ri ation in age and viral load (beta 
coe ffi cient ) am ong the III V-infected childrcn only. Every B-cell re ponse was independently rlln in a 
quantile regre ion model containing age and viral load. P value <0.0' were c n idcrcd ignifi ctlnt. r r-
tetanu toxoid; DT-diphtheria toxoid: PP -pneumococcal cap lIlar poly accharides: I-avidity index: 
A C/I MPBM C -anlibody ecrcling cell per I million PBM ignificant rc ult are in red text. 
134 
B-cell response CD4+ T-cell percentage Age(Months) 
J3 Coefficient P va lue J3 Coefficient P vll lue 
Anti-TT IgG 0.30(0.51) 0.551 -0.74(0.22) 0.001 
--Anti-DT IgG 
-1.34(2.51 ) 0.597 -1.21 ( 1.09) 0.272 
-
Anti-Measles IgG 
-0.08(0.21 ) 0.713 -0.19(0.08) 0.023 
-Anti-PPS IgG 
-1.27( I. 90) 0.507 0.70(0.77) 0.363 
-
Anti-TT IgM 
-30.14(27.36) 0.276 20.00( 11.75) 0.095 
~ 
Anti-DT IgM 3.22(5 .76) 0.578 2.49(2.50) 0.324 
-
Anti-TT IgG AI 0.00(0.00) 0.502 -0.00(0.00) 0.743 
-
Anti-DT IgG AI 
-0.00(0.00) 0.207 -0.00(0.00) 0.486 
-
Anti-Meas les IgG 
AI 0.00(0.00) 0.206 0.00(0.00) 0.635 
-
Anti-PPS IgG AI 
-0.00(0.00) 0.565 -0.00(0.00) 0.075 
-
Anti-TT IgG 0.07(0.10) 0.486 -0.06(0.04) 0.156 ASC/ IMPBMCs 
-
Anti-Measles 
IgG 0.11 (0.26) 0.677 0.16(0.12) 0.204 
ASC/IMPBMCs 
-
Anti-PPS IgG 
-0. 10(0.3 I) 0.759 -0.06(0. 1 I) 0.610 
ASC/IMPBMCs 
T ab Ie 4.4: Estimated chan e in B-cell res g po n es in relation to variation in a e and C04 g T-cell 
percentage (beta coefficients) among the IIIV-infected children only. Every B-cell re pon e was 
independently run in a quantile regre ion model containing age and 04+ T-cell percentage. P values 
<0.05 were considered significant. Tr-tetanus toxoid; DT-diphtheria toxoid; PP -pneumococcal cap ular 
polysaccharide: AI-avidity index; A el l MPBM s-antibody ecreting cells per I million PBM s. 
Significant results are in red text. 
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B-cell respo nse HAA RT Age(Months) 
13 Coeffi cient P va lue 13 Coeffi cient P va lue 
Anti-TT IgG 2.62( I 1.05) 0.813 -0.71(0.22) 0.002 
-Anti-DT IgG 
-37.44(83 .82) 0.657 -0.85( 1.66) 0.6 11 
Anti-Meas le IgG 2.50(4.24) 0.557 -0.20(0.07) 0.004 
-Anti-PPS IgG I. 12(3 I. 7) 0.972 0.5 1(0.57) 0.37 1 
Anti-TT IgM 
-597. 18(94 1.24) 0.529 13.89( 18.22) 0.450 
Anti-DT IgM 
-246.35( 121. 72) 0.048 4.6 1(2.44) 0.064 
-
Anti-TT IgG AI 
-0. 11 (0.05) 0.050 0.00(0.00) 0.473 
---Anti-DT IgG AI 
-0.07(0.05) 0. 14 1 -0.00(0.00) 0.7 14 
-
Anti-Mea Ie IgG 
AI 0.00(0.02) 0.907 0.00(0.00) 0.899 
-
Anti-PPS IgG AI 0.07(0.05) 0.1 86 0.00(0.00) 0.025 
-
Anti-TT IgG 
ASC/ IMPBMCs -0.67(3 .03) 0.826 -0.04(0.06) 0.522 
-
Anti-Measle 
IgG 8.43(6.09) 0.1 80 0. 12(0.11 ) 0.324 
ASCIIMPBMC 
-
Anti-PP IgG 7.5(5 .99) 0.2 18 -0.00(0. 10) 1.000 ASCII M PBMCs 
. . 1 able 4.5: Est Imated change In vanou l3-cell rcspon e 111 relatIon to vanatlOn. 111 age and IIAARl , 
treatment (beta coemcicnt ) among the I II V-infected children. Every B-eell re pon c wa independent ly 
run in a quantile regres ion model containing I IAART treatment and age. P value <0.05 were con idercd 
significant. IT-tetanus toxoid; DT-diphtheria toxoid: PP -pneumococcal cap ular polysaccharides: AI-
avidity index: ASCI I MPBM s-antibody secreting cell per I mi ll ion PBM . ignilicant results are in 
red text. 
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Age HIV status Viral load C04+ T-cell % H AA RT 
B-cell J3 Coefficient P value J3 Coefficient P value 13 Coefficient P value J3 Coefficient P value J3 Coefficient P value 
response 
Anti -TI IgG 
-0.82(0.3 1 ) 0.010 -163.42(47.04) 0.001 -1.30(4.78) 0.786 0.34(0.73) 0.645 -8.25( 19.98) 0.68 1 
-Anti-DT lgG 
- 1.45( 1.33) 0.280 0.000 4.58(20.32) 0.822 -0.98(3 .20) 0.760 12.05(87.53) 0.89 1 
-855 .6(205 8) 
- -Anti-Measles 
-0.22(0. 11) Ip{, 0.058 -41.38( 18.69) 0.029 0.1 1( 1. 89) 0.952 -0.08(0.3 1 ) 0.794 4.60(7.76) 0.554 
Anti-PPS IgO 0.76(0.96) 0.433 -n ll ( 153.87) 0.6 18 -3.78(15.67) 0.8 10 -1.98(2.45) 0.423 0.3 1(6 1.76) 0.996 
Anti-TT lgM 19.25(20.64) 0.354 665.7 1(3 148.9 1 0.833 ) 72.56(320.34) 0.822 -32.9 1 (49.32) 0.507 496.34( 1354.80) 0.7 15 
Anti-DT IgM 3.69(3.32) 0.269 -1863.9(4866) 0.000 -6.80(46.99) 0.885 5.78(7.68) 0.454 -229.4(205.4) 0.268 
Ant i-TT IgO Al 0.00(0.00) 0.889 -0.25(0. 19) 0. 196 -0.0 I (0. 02) 0.754 0.00(0.00) 0.687 -0.06(0.08) 0.475 
Anti-DT IgO AI 
-0.00(0.00) 0.806 -0.30(009) 0.001 0.00(0.01) 0.683 -0.00(0.00) 0. 18 1 -0.03(0.04) 0.397 
--
Anti-Measles 0.00(0.00) 0.58 1 -0.14(0.07) 0.048 0.00(0.01) 0.983 0.00(0.00) 0. 126 -0.03(0.03) 0.325 IpC; AI 
-Anti-PPS IgG 
-0.00,0.00) 0.028 0. 14(0. 12) 0.240 0.00(0.0 1) 0.9 16 -0.00(0.00) 0. 190 0.08(0.05) 0. 122 
AI 
Anti-TT IgG 
-0.02(0.08) 0.759 -3.33( 11.87) 0.780 1.68( 1.14) 0. 148 0.23(0. 19) 0.240 1.02(5.04) 0.84 1 
ASCII MPRMC 
Anti-Measles 
-0. 16(0. 11 ) 0. 138 27.54(22.33) 0.225 -0.76(2.17) 0.728 -0.44(0.3 I) 0. 162 20.16(9.02) 0.032 1 pC; 
Anti-PPS IgO 
-0.04(0. 14) 
A <\(,1 I MPRM(, 0.745 4.79(24.94) 0.848 1.79(2.71) 0.513 0. 11 (0.40) 0.780 6. 13( 10.59) 0.565 i 
Table 4.6: Estimated change in various B-cell responses in relation to variations in age. HIV status. viral loads. CD4 T T-cell percentage and HAART treatment (beta 
coefficients). Every B-cell response was independently run in a generalized quantile regression model containing age. HIV status. viral load. CD4 T T-cell percentage 
and HAART treatment. P values <0.05 were considered significant. TI-tetanus toxoid: DT-diphtheria toxoid: PPS-pneurnococcal capsular polysaccharides: AI -avidity 
index: ASCII MPBMCs-antibody secreting cells per I million PBMCs. Significant results are in red text. 
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4.3.4 Correlations between plasma antibody concentrations, antibody avidity indices 
and frequencies oflgG memory B cel\s. 
Among the community controls, significant direct correlations were observed with 
regard to plasma IgG and avidity indices against TT. DT and measles. Similar 
correlations between plasma IgG and avidity indices were observed among HIV-
infected children with regard to IT and DT only. There were also direct correlations 
between avidity indices and trequencies of memory B cells against TT and measles 
antigen among the HIV-infected children, but similar trends were not seen among the 
community controls. Interestingly, there was a direct correlation between plasma IgG 
and frequencies of memory B cells against pneumococcal capsular polysaccharides 
among the community controls. 
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Community controls 1I1\,-infccted 
Plasmll IgC AI Plas ma IgC AI 
T T' 
I 0.8298 0.3887 
«0.00005) (0.0053) 
ASC/ IM PBMC 0.3792 -0.0333 0.4620 0.4642 
(0. 1207) (0.8955) (0.001 1) (0.00 15) 
OT 
AI 0.72 14 0.3804 
(0.0007) (0.0038) 
Measles 
AI 0.3779 0.0537 
(0.0 105) (0.577 1) 
A CIIM PBMC 0.3835 0. 1003 0.0537 0.5032 
(0. 1426) (0.692 1) (0.786 1) (0.0054) 
PI'S 
AI -0.0326 0. 1034 
(0.8398) (0.4085) 
A CIIM PBMC 0.7608 -0.0445 0.2625 0. 12 11 
(0.0065) (0.8654) (0.093 1) (0.428 1) 
Table 4.7: S pc arman's correlation coellicients rho (P valucs) Ix:twccn plasma IgG Icv el . IgG avidity 
indicc and rrequcncic ormemory B cell s again t variou antigens. The IIIV- infcctcd children and 
community controls havc Ix:en evaluated separately. P valucs <0.05 wcre considcrcd ignificant. TT-
tetanus toxoid: DT-diphtheria toxoid: PP -pneumococcal capsul ar polysaccharide: AI-avidi ty index: 
ASCI I MPBMCs-anti body secreting ce lls per I million PI3MC. ignifican l re liltS are in red text. 
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4.4 Discussion 
Similar to previous studies in children, in our study, HIV infection was associated with 
lower IgG levels against the childhood vaccine antigens tetanus toxoid, diphtheria 
toxoid and measles antigen[232, 245, 257-263]. In addition, HIV infection was 
associated with low avidity indices to TT, DT and measles antigens, confirming the 
results of a study that showed that HlV-infected children had lower avidity maturation 
of anti-measles IgG [261]. HIV infection was also associated with low frequencies of 
memory B cells against measles antigen, replicating the outcome in a study that showed 
that HIV-infected children who were started on HAART late had low memory B cell 
responses to measles regardless of subsequent control of viraemia [232]. Interestingly, 
HIV infection did not affect frequencies of anti-TT memory B cells, probably because 
of the small sample size that was left after omitting the children who had received the 
pneumococcal conjugate vaccine in the community. Furthermore, HIV infection had no 
effect on any anti-pneumococcal response, suggesting that it was not a good predictor of 
B-cell responses against environmental antigens. This could be due to an interaction 
between pneumococcal exposure and HIV infection. HIV-infected children could be 
exposed to more pneumococcal infections due to their impaired immune function or due 
to presence of sick HIV-infected parents in the household. As a result, the higher 
frequency of pneumococcal exposure could boost their anti-pneumococcal responses, 
making them comparable with HIV-uninfected children. Alternatively, HIV could be 
having no effect on B-cell responses against pneumococcal capsular polysaccharides. 
From the results, it was concluded that HIV-infection is associated with low antibody 
levels, poor avidity maturation and low frequencies of memory B cells to some of the 
childhood vaccines. Unlike most older studies, the current study had the strength of 
evaluating different types of B-cell responses (plasma IgG & IgM levels, IgG avidity 
indices and frequencies of memory B cells) against a variety of antigens that differed in 
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nature (i.e. subunit vaccines [toxoids], whole virus Iysates [measles antigen] and 
polysaccharides) on the same children. Studies in adults have shown similar results with 
the exception of antibody avidity maturation that is relatively left intact in adults who 
get HIV-infected later in life after they have already been exposed to most antigens [84, 
229, 243-245]. This is probably because antibody avidity maturation is a historical 
event that is relatively irreversible. As a result, adults would retain the antibody-avidity 
that they acquire prior to infection with HIV. On the other hand, children become 
infected with HIV in the first months of life and are exposed to most vaccines and 
environmental antigens when they are already HIV -infected. Their primary response 
(and any subsequent secondary responses) to most antigens would therefore take place 
in the presence of the HIV infection, leading to poor antibody avidity maturation. 
Of note is the similarity between the various HI V -infected groups with regard to all 
measures of 8-cell function, suggesting that control of viraemia (and the resultant 
recovery of CD4+ T-cell counts) is not sufficient to restore the functionality of the 
compartment. Furthermore, in the multivariate analyses, viral load and CD4 + T-cell 
percentages did not significantly predict any of the 8-cell responses to vaccines, 
suggesting that the virological and immunological statuses at the chronic phase have 
little effect on the 8-cell responses to historically encountered antigens. Interestingly, 
HAART treatment was a significant predictor of anti-measles memory 8 cells. In the 
univariate analysis, the HAART-treated children who had low viraemia showed higher 
frequencies of anti-measles and anti-pneumococcal memory 8 cells when compared 
with low viraemia HAART-na'ive children, suggesting that initiation of HAART can 
influence at least some 8 cell responses. In agreement, another study showed that 
initiation ofHAART in children in the first year of life helps to maintain the integrity of 
the memory 8-cell compartment [232]. Furthermore, revaccination of successfully 
treated children and adults has been shown to elicit adequate responses [257, 264-268]. 
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CD4+ T-cell depletion provides a possible and straightforward explanation to the failure 
of HIV-infected patients to induce optimal B-cell responses. Since the quality and 
magnitude of a B-cell response is very dependent on the germinal centre reaction where 
CD4+ T-cell help is crucial, depletion of CD4+ T cells would arguably reduce the 
amount of T-cell help, resulting into a low quality and low magnitude of B-cell 
response. However, evidence suggests that the perturbation of the B-T cell interactions 
in HIV goes beyond mere depletion of helper T cells. For instance, B cells from 
viraemic HIV-infected people have been shown to respond poorly to CD4+ T-cell help 
when compared with B cells from healthy uninfected and aviraemic HIV -infected 
people [247]. Such B cells are also inefficient in providing co-stimulation to CD4+ T 
cells, suggesting that the CD4+ T cells in viraemic patients might be poorly 
programmed to in turn give T-cell help [273]. Indeed, a more recent study showed that 
follicular helper T cells that are exposed to B cells from viraemic HIV patients are 
defective in performing their helper functions. The defects were shown to be a result of 
enhanced PDI-PD-L1 interaction that renders the follicular helper T cells incapable of 
producing adequate IL21 among other helper signals [274]. 
Alternatively, some HIV factors could directly affect the quality and magnitude of B-
cell response. One such factor is HIV Nefthat has been shown to impair class switching 
of naiVe B cells in vitro by inhibiting CD40L dependent intracellular signaling via 
NFKB pathway. Considering that NFKB plays a central role in many other B-cell 
pathways, HIV Nef could therefore also affect other aspects of the B-cell response [25]. 
The mechanism for depletion of pre-existing antibody and memory B-cell responses to 
non-HIV antigens in HIV infection is poorly understood. Increased susceptibility of B 
cells to apoptosis has been reported and associated with increased expression of Fas in 
both chronic and primary HIV viraemic states [248-250]. The increased Fas mediated 
apoptosis of B cells has been attributed to a concerted effect of lymphopenia, viraemia 
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and T-cell activation [251]. Altered expression of receptors to BAFF on some B-cell 
subsets in HlV patients has also been implicated in permitting the Fas mediated 
apoptosis [275]. In addition, Fox03a- and TRAIL- mediated apoptosis has been 
reported, suggesting that mUltiple pathways could contribute to the increased 
susceptibility to apoptosis that is seen in B cells from HIV -infected patients [276]. 
Finally, in this study, there was a notable direct correlation between the three measures 
of B-cell function in some of the groups of the children for some of the antigens. For 
instance, significant direct correlations were observed between all measures of ant i-TT 
responses among the HIV-infected children. This could be an indication of the 
efficiency of the immune response that each child had experienced at the time of 
immunisation; a good responder is likely to generate more long-lived plasma cells and 
memory B cells while experiencing more antibody avidity maturation. On the other 
hand, the correlation could be an indicator of the dependency on the memory B-cell 
pool for the maintenance of the plasma-cell pool, as suggested by Bernasconi and 
colleagues [277). However, the reason for absence of such correlations of anti-TT 
responses among the community controls is not clear. Notably, there were no 
correlations between various responses against pneumococcal capsular polysaccharides, 
probably due to the complex interactions between exposure, HIV disease progression 
and the complex biological properties of pneumococcal bacteria. 
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Chapter 5 Memory B-cell responses in healthy 
children who received a to-valent Pneumococcal 
non-typeable Haemopltilus Influenza protein D 
conjugate vaccine (PHiD-CYl 
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5.1 Literature review 
Streptococcus pneumoniae is a major cause of morbidity and mortality in the world, 
accounting for an estimated 14.5 million cases of serious illness and 735000 deaths in 
HIY -negative children below five years of age in the year 2000 [278]. In Kenya, it has 
been shown to be the leading cause of invasive bacterial disease in children [279, 280]. 
Introduction of pneumococcal conjugate vaccine in some countries' childhood 
immunization schedules has led to a dramatic reduction of the incidence of Invasive 
Pneumococcal Disease (IPD) among the vaccinated children [281]. It has also had an 
indirect effect of reducing pneumococcal disease in the general population, probably by 
reducing transmission of disease from vaccinated children to unvaccinated children and 
adults [282, 283]. 
Synflorixtm is a 10-valent Pneumococcal non-typeable Haemophilus Influenza protein 
D conjugate vaccine (PHiD-CY). It contains ten pneumococcal capsular 
polysaccharides that are conjugated to protein D (for serotypes 1,4,5, 6B, 7F, 9Y, 14 
and 23F), tetanus toxoid (for serotype 18C) and diphtheria toxoid (for serotype 19F). 
The protein D is derived from a cell-surface lipoprotein that is conserved among both 
capsulated and unencapsulated strains of Haemophilus injlllenzae. PHiD-CY targets 
additional serotypes I, 5 and 7F that are not targeted by the 7-valent pneumococcal 
conjugate vaccine (PCY7) that has been used in many developed countries since 200 I, 
but has now been replaced with a 13-valent version. These three serotypes are 
important causes oflPD in developing countries [284, 285]. In general, the 10 serotypes 
targeted by PHiD-CY are responsible for approximately 70% ofIPD in Kenyan children 
below the age of five years [286]. 
Studies in Europe, South America and Asia have shown that PHiD-CY is comparably 
immunogenic when compared with PCY7 and when co-administered with other 
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childhood vaccinations [287-290], leading to its licensure in more than 100 countries 
for use in children below 2 years of age. Based on recent data, the age limit for the 
administration of the vaccine has been extended to 5 years in the European Union [291]. 
These immunogenicity studies have been done by measuring serum IgG (by ELISA) 
and opsonophagocytic activity (OPA). Notably, the antibody titres and 
opsonophagocytic activity after vaccination wane over time but increase markedly after 
booster vaccination, suggesting that priming after the primary vaccination induces 
immunological memory. However, direct evaluation of the generation of serotype-
specific memory B cells after administration of PHiD-CV needs to be done. 
In this study, I determined the generation of memory B cells against pneumococcal 
capsular polysaccharides and the conjugating proteins (tetanus toxoid and diphtheria 
toxoid) after administration of PHiD-CV among community children aged 12-24 
months. The study was part of a larger clinical trial that evaluated the immunogenicity 
and reactogenicity of the vaccine among children aged 12-59 months. Due to the limited 
amount of sample that could be obtained from the children, the assays were limited to 
serotypes I, 6B, 14, 19F and 23F. These serotypes were chosen based on available data 
on their contribution to IPD and nasopharyngeal carriage. A previous study had shown 
the rate of isolation of various vaccine type serotypes from children presenting with IPD 
in Kilifi district to rank as follows: serotypes 1>14>6B>6A>5>23F>4 [286]. Another 
study on nasopharyngeal pneumococcal carriage showed that the rate of serotype-
specific carriage in Kilifi district ranked as follows: serotypes 
I 9F>6A>6B>23F> I 4>9V>7C> 1>4 [292]. 
Determination of memory B cells at day 0 informed on the effect of pre-existing 
naturally acquired memory B-cell responses on the response to PHiD-CV while 
determination of frequencies of memory B cells at day 30 (30 days after first dose of 
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PH iD-CV) and at day 210 (30 days after the second dose of PH iD-CV) informed on the 
ability of the PHiD-CV to elicit memory B cells against the various antigens. 
Determination of pneumococcal carriage on day 0 was important in determining the 
effect of nasopharyngeal carriage on responses to PHiD-CV while determination of 
carriage on day 180 was done to determine if responses elicited after a single dose of 
PHiD-CV affected subsequent nasopharyngeal carriage. 
The frequencies of antigen-specific memory B cells in the children in this study were 
then compared with those of HIV-infected children (CCRC) and community controls 
(Ngerenya) that had either received or not received the PHiD-CV vaccine (some of the 
children were reported in chapter 4). Of particular importance was the comparison 
between the PHiD-CV vaccinated children before they received the PHiD-CV vaccine 
and the HIV-infected children from CCRC who did not receive the PHiD-CV vaccine. 
Notably, the PHiD-CV vaccinated children were younger than the children from CCRC 
and community controls from Ngerenya. Nevertheless, a comparison between older 
HIV-infected children and younger community children would be worthwhile 
especially if HIV-infection causes immunological stunting with regard to natural 
acquisition of immunity against environmental pathogens like Streptococcus 
pneumoniae. Indeed, HIV has been shown to interfere with the age-related natural 
acquisition of anti-malarial responses in children [293]. 
5.2 Objectives 
1. To determine the frequencies of memory B cells against various antigens before 
PHiD-CV vaccination and at follow-up among healthy children. 
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2. To determine the relationship between frequencies of memory B celIs and 
plasma antibodies against the pneumococcal capsular polysaccharides 
3. To determine the relationship between nasopharyngeal carriage and frequencies 
of memory B cells with regard to the various serotypes. 
4. To compare frequencies of memory B cells in the healthy children in the PRISM 
study with HIV-infected children from CCRC and healthy children from 
r 
Ngerenya. 
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5.3 Results 
5.3. 1 Population characteristics 
600 children were recruited into the PH iD-CV randomized clinical trial, 200 into each 
arm of the study. PBMC samples collected from 35 children in group B (those who 
rece ived the PHiD-CV vaccine at enrollment and on day 180 as per table 2. 1) were used 
for determination of memory B cells aga inst pneumococca l capsu lar polysaccharides, 
tetanus toxo id and diphtheria toxoid. They were selected based on their age ( 12-24 
months) in order to limit the sample size due to the labo rious nature of the assay . Data 
on pneumococcal nasopharyngea l carriage and plasma antibody leve ls were obtained 
from the principal investigator of the PHiD-CV randomized clinical trial. The 
population characteristics of the 35 children are shown in table 5.1 . 
Characteristic Value 
Total number 35 
Median age IQR) in months 20 (16-22) 
Females (%) 19(54%) 
-Median Children in household (range) 
-
3 1-6) 
Smokers in household (%) 11(31 %) 
Had 3 doses of Pentavalent vaccine (DTaP+HB+HiB) - ,- 91.4% 
Had at least I dose of Pentavalent vaccine 100.0% 
- -
. . . . 
rable :>. 1: Popul ation charactenstlcs of the children who participated," the memory B cells substlldy . 
IQR-Interqllartile range. 
Among the 35 children who participated in the memory B cell substudy, there was a 
decline in total carriage when baseline pneumococcal carriage was co mpared with 
pneumococcal carriage at day 180 (From 88.6% to 71.4%). There was also a marked 
reduction in carriage of vaccine-type serotypes (including serotype 6A) when the two 
time points were considered (From 51.4% to 35.3%). The carriage rate of non-vaccine 
serotypes remained unchanged at 37. 1 %. 
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When thc various pneumococcal serotypes were considered, there was a decline in 
carriage for serotypes 19F and 23F among t the sub-study's participant when day zero 
(0) was compared with day 180. Carriage of serotype 68 remained unchanged wh ile 
that of serotypes 14 and I rema ined low at the two time points. Carriage 0 find ividual 
non-vaccine serotypes was low, with a ll being carried by Ie than 6% of the children at 
the two time points. 
Baseline Day 180 
Serotype Number (%) Numbe r (%) 
lOA 1(2.9%) 0(0.0%) 
IIA 1(2.9%) 1(2.9%) 
13 1(2.9%) 0(0.0%) 
14 1(2.9%) 1(2.9°'0) 
15A 1(2.9%) 2(5.7%) 
158 1(2.9%) 0(0.0%) 
15C 1(2.9%) 2(5 .7%) 
16A 1(2.9%) 0(0.0%) 
16F 1(2.9%) 1(2.9%) 
19A 1(2.9%) 0(0.0%) 
198 1(2.9%) 0(0.0%) 
19F 6( 17. 1%) 1(2.9°'0) 
20 0(0.0%) 1(2 .9%) 
21 1(2.9%) 2(5.7%) 
23 8 1(2.9%) 1(2.9%) 
23F 4( 11 .4%) 1(2.9° '0) 
3 1 1(2.9%) 0(0.0%) 
34 0(0.0%) 2(5.7%) 
358 0(0.0%) 1(2.9%) 
6A 3(8.6%) 3(8.6%) 
6B 4(11 .4%) 4( 11 .4%) 
9V 0(0.0%) 2(5.7%) 
I 0(0.0%) 0(0.0%) 
18C 0(0.0°'0) 0(0.0%) 
7F 0(0.00 '0) O(O.O~o) 
.. 0(0.0%) 0(0.00 0) 
5 0(0.0%) 0(0.0%) 
Total 31(88.6%) 25(71.4%) 
Vaccine serotypes 18(5 1.4% ) 12(35.3%) 
Non vaccine type 13(37. 1 %) 13(37.1 %) 
Table 5.2: FrequencIes of nasopharyngeal carnage of va no us pneumococca l serotypes at baseline and at 
day 180 orthe tud)'. Vaccine rotype have been hown in red text. Serotype 6A has been included 
among the vaccine erotype becau e orthe antigenic ero s-reactivity between it and serotype 6B. 
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When the IgG levels against the 5 polysaccharide that were evaluated in the memory B 
cells sub-study were considered, there was a significant increase in IgG concentrations 
against capsular polysaccharides for all five serotypes after each vaccination with 91-
100% of the children attaining at least 0.26 Ilglml of anti-capsular poly accharide IgG 
aga inst the various pneumococcal capsular polysaccharide after the second dose. 
Serotype Time point I'values 
OilY 30 On 210 
vs \ ' 
Day 0 Day 30 Day 210 Day 0 OilY 0 
% of 
responder 
- - -
,-
-19F 23,}o 80,}o 94% 
- - -
! -
14 29% 86% 100% 
1- 68 34% 
~ 
- 74% -
,-
97% 
1- 23F 11 % 
~ 
- 63% -
!-
91% 
I 9% 100% 97%. 
Median 
(IQR) IgG 
level 
-
,- I- ~ 
-19F 0. 11 3.22 19,50 
(0.06-0.24) (0.47-10.82) (2.70-33.50) <0.000 I <"0.000 1 
I~ 
-14 0.02 1.05 4.80 
<0.0001 <0.0001 (0.022-0.39) (0.47-2.46) (2.21-11.75) 
1- 68 0.21 0.60 1.57 -
(0.10-0.38) (0.25-1. IS) (0.86-3.57) <;.0.0001 '- 0.0001 
I~ - -23F 0.03 0.50 1.02 
<0.000 1 <0.000 I (0.00-0,09) (0. 13-0.94) (0.44- 1,83) 
I- I 0.08 - 1.06 2.05 -1-
(0.04-0.15) (0.48-2. 12) ( 1.43-4.40) <"0.0001 <0.0001 
Table 5.3: IgG response to various pneumococcal capsular polysac haride .Wilcoxon signed-rank test 
wa u ed to compare level orantibodie at different time point. 
5.3.2 Frequencies of antigen- pecific memory B cells 
Serotype 19F exemplified the highest baseline and vaccine induced frequencies of 
memory B cells. After the first dose ofpHiD-CY, there was a significant increa e in the 
151 
frequency of memory B cells against serotype 19F (From 0 [IQR, 0-4] ASCII M 
PBMCs to 15 [IQR, 0-28] ASCII M PBMCs, P=0.0046). Similarly, there was a 
significant increase in frequencies of memory B cells against serotype 19F after the 
second dose of PHiD-CV (From 15 [IQR, 0-27.5] ASCII M PBMCs to 22 [IQR, 0-61] 
ASCIl M PBMCs, P=O.0275). For serotype 14, the frequencies of memory B cells did 
not significantly change after the first dose of PHiD-CV (From 0 [IQR, 0-3] ASCII M 
PBMCs to 0 [IQR, 0-8] ASCII M PBMCs, P=0.1242), but did increase significantly 
after the second dose of PHiD-CV (From 0 [IQR, 0-8] ASCII M PBMCs to 5 [IQR, 0-
21] ASCII M PBMCs, P=0.0294). Notably, there was no significant increase in the 
frequencies of anti-PS6B memory B cells after the first (From 0 [IQR, 0-5] ASCII M 
PBMCs to 3 [IQR, 0-6] Asci 1M PBMCs, P=0.2596) and second (From 3 [IQR, 0-6] 
ASCIIM PBMCs to 2.5[IQR, 0-12] ASC/IM PBMCs, P=0.0867) doses ofPHiD-CV. 
Also, the frequencies of anti-PS6B memory B-cell after the two doses of PHiD-CV did 
not differ from baseline frequencies (P=0.2417). On the other hand, whi Ie there was no 
significant increase of anti-PS23F memory B cells after the first (From 0 [IQR, 0-3] 
ASCII M PBMCs to 0 [IQR, 0-4] ASCII M PBMCs, P=0.3027) and the second (From 0 
[IQR, 0-4] ASCIlM PBMCs to 2.5 [IQR, 0-14] ASC/IM PBMCs, P=0.1269) doses of 
PHiD-CV, there was a significant difference when frequencies of memory B cells after 
the two doses were compared with baseline frequencies (P=0.0068). Anti-PS I memory 
B--cell frequencies were higher after the first (5 [IQR, 0- 10] ASCIl M PBMCs, 
P=0.0005) and second (4 [lOR, 0-15] ASCIlM PBMCs, P=0.0006) doses ofPHiD-CV 
when compared with baseline (0 [IQR, 0-0] ASCII M PBMCs). However, there was no 
difference between frequencies at day 30 and day 180 (P=0.1024), implying that a 
single dose of PHiD-CV had an effect that was similar to two doses with regard to this 
serotype. 
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In this vaccine, all capsular polysaccharides were conjugated to protein D from non-
typeable Haemophilus Influenza. with the exception of serotypes 18C and 19F that were 
conjugated to tetanus toxoid and diphtheria toxoid respectively. Furthermore, the 
children in this sub-study received a booster dose of DTaP on day 60. Almost all of 
them had received three doses of the pentavalent (DTaP+HB+HiB) immunization in 
their first year of life. The PHiD-CV vaccination had not been introduced into the 
childhood vaccination schedule at the time when these children were receiving the 
pentavalent immunization. We therefore aimed to also determine the effect of the study 
on the frequencies of memory B cells to tetanus toxoid and diphtheria toxoid. After the 
first dose of PHiD-CV, there was a significant increase in frequencies of memory B 
cells against tetanus toxoid (From 20 [lOR, 5-33] ASCI 1M PBMCs to 45 [lOR, 10-119] 
ASC/IM PBMCs, P=O.OI05) and diphtheria toxoid (From II [lOR, 0-33] ASC/IM 
PBMCs to 65 [lOR, 35-115] ASCII M PBMCs, P=0.0087). However, there was no 
further increase following a booster dose of DTaP on day 60 and a second dose of 
PHiD-CV on day 180 with regard to both proteins (Tetanus toxoid: trom 45 [lOR, 10-
119] ASCII M PBMCs to 58 [lOR, 24-127] ASCII M PBMCs, P=0.6494; Diphtheria 
toxoid: trom 65 [lOR, 35- I 15] ASCII M PBMCs) to 66 [lOR, 38- I 66] ASCI 1M 
PBMCs, P=0.2238). 
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Figure 5. I : Frequencies of antigen specific memory B cells against various pneumococcal capsular polysaccharides (PS). tetanus toxoid (TI") and diphtheria toxoid 
(DT). The vaccine induced significant increase in frequencies of memory B cells against all constituent antigens tested with the exception of serotype 6B. Horizontal 
line represents median. Statistical test used: Wilcoxon signed-rank test. 
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5.3.3 Correlation between anti-pneumococcal plasma IgG and frequencies of anti-
pneumococcal memory 8 cells 
There was no correlation between plasma IgG levels and frequencies of memory B cells 
at baseline for the various capsular polysaccharides. However, a direct correlation 
emerged for serotype 19F at day 30 (rho=0.55, P=O.0069) and day 210 (rho=0.68, 
P<O.00005). A similar direct correlation was also observed for serotype 1 at day 210 
(rho=0.55, P=O.OO 19). Weaker non-significant direct correlations were observed for 
serotypes 14 (rho=0.30, P=O.1116), 68 (rho=0,35, P=0.0545) and 23F (rho=0.30, 
P=0.0936) at day 210. 
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were also seen for the other antigens at day 210. Statistical test: Spearman' s correlations. 
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5.3.4 Effect of baseline pneumococcal carriage on the frequencies of anti-
pneumococcal memory B cells 
When the children were classified on the basis of their baseline nasopharyngeal carriage 
for the various serotypes, the six children that had serotype 19F carriage at day 0 also 
had significantly lower frequencies of anti-PS 19F memory B cells at days 30 (0 [IQR, 
0-0] ASC/IM PBMCs versus 18 [lOR. 10-43] ASC/IM PBMCs, P=O.OOJ3) and 210 (0 
[lOR, 0-9] ASCIl M PBMCs versus 35 [lOR, 4-66] ASCII M PBMCs, P=O.O 114) when 
compared with children who did not have carriage for serotype 19F at day 0, suggesting 
that baseline carriage was associated with lower frequencies of memory B-cell to the 
vaccine. However, there was no difference between the two groups with regard to 
baseline anti-PS 19F memory B-cell responses (0 [lOR, 0-9] ASCII M PBMCs versus 0 
[lOR, 0-5] ASCIl M PBMCs, P=0.6946). Interestingly, the same trend was observed 
with regard to anti-PS 19F plasma IgG levels whereby children who had serotype 19F 
carriage on day 0 had lower IgG responses against PS 19F when they were compared 
with children who had no carriage on day O. On the other hand. there was no difference 
in anti-PS6B memory B-cell response between the serotype 6B/6A baseline carriers and 
non-carriers at all time points; baseline carriage of serotype 6B/6A did not affect the 
frequencies of memory B cells against PS6B (Day 0, 0 [IQR, 0-48] ASCII M PBMCs 
versus 0 [IQR, 0-5] ASCII M PBMCs, P=0.9570; Day 30, 3 [lOR, 0-5] ASCII M 
PBMCs versus 3 [IQR, 0-42] ASC/IM PBMCs, P=0.4351; Day 210, 3 [IQR, 0-11] 
ASCII M PBMCs versus 3 [IQR, 0-20] ASCII M PBMCs. P=0.8505). The frequency of 
baseline carriage of the other serotypes was very low in our cohort and comparison 
between baseline carriers and non-carriers could therefore not be done. 
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Figure 5.3: Frequencies of ant igen specific memory B cells against the various pneumococcal capsular polysaccharides (PS) after stratif)ing the study participants on 
the basis of their baseline pneumococcal carriage of the respective serotypes. Baseline carriage of serotype 19F was associated wi th weaker subsequent anti -PS 19F 
memory B-cell responses. Anti -PS6B memory B-cell responses did not differ bel\\een baseline serotype 6B carriers and non -carriers. Horizontal line represents 
median. Statistical test used: Wilcoxon rank-sum test. 
158 
On day 180, there was little or no nasopharyngeal carriage for serotypes 19F, 14, 23F 
and I. Consequently, the effect of the memory B-cell response on level of carriage 
could not be assessed for these serotypes. However, for serotypes 6B/6A whose day 180 
nasopharyngeal carriage was 20%, there were no differences when day 180 carriers 
were compared with non-carriers with regard to their frequencies of anti-PS6B memory 
B cells for day 0 (0 [lOR, 0-5] ASCIIM PBMCs versus 0 [lOR, 0-8] ASCIIM PBMCs, 
P=0.7877) , day 30 (3 [lOR, 0-5] ASCII M PBMCs versus 3 [lOR, 0-36] ASCII M 
PBMCs, P=0.5378) and day 210 (3 [lOR, 0-14] ASC/IM PBMCs versus 3 [lOR, 0-10] 
ASCII M PBMCs, P=0.7956). This suggests that the level of memory B-cell response 
before and after the first dose ofPHiD-CV (memory B cell responses on days 0 and 30) 
did not affect the level of serotype 6B/6A nasopharyngeal carriage on day 180 and the 
carriage rate on day 180 did not affect the memory B cell responses on day 210 (30 
days after the administration of the second dose ofPHiD-CV on day 180). 
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5.3.5 Comparison of hea lth v children in the PRI M study with HIV-infected children 
from CCRC and healthy chi ldren from Ngerenya 
The 35 chi ldren in the memory B ce lls sub-study were then compared to HIV-infected 
chi ldren from the CCRC HIV clinic and community control children from Ngerenya 
with regard to their frequencies of memory B cells against tetanu toxoid and 
pneumococcal antigens. For this ana lysi • children who had not received the pentavalent 
vaccine in the first year of life were omitted. C Rand Ngerenya children who 
rece ived the PHiD-CV vaccine as part of the catch-up campaign in the community were 
con idered in separate groups. Of note, there were huge age differences between the 
various groups hence need to exerci e caution when interpreting the re ult . This is 
becau e naturally acquired anti-pneumococcal re ponse would be expected to increase 
with age while anti-TT and anti-DT re ponses would be expected to wane over time 
after receiving the DTaP immunizations in th fir t year of life. 
PRISM NGERENYA NGERENYA mv HIV 
+ 
PHiD- V + 
PHiD-CV 
N 35 18 9 46 4 
Median age 12-24 78.5 33.7 48.5 2 1 (months) 
Table 5.4: Median a e or children in difTerent groups that were compared \ ith regard to rrequencies of g 
memory B cells. 
The ELlSpots for evaluation of frequencies of ant i-pneumococcal memory B cell in 
CCRC and Ngerenya children were done u ing a pool of pneumococcal capsu lar 
polysaccharides for serotypes I, 5, 6B, 14 19F and 23F. n the other hand, frequencies 
of anti-pneumococca l memory B cell in the PRISM study were done in a serotype-
specific manner for serotypes I, 6B, 14, 19F and 23 F. Therefore, evaluation for 
erotype 5 was only done in the RC and Ngerenya ch ildren. As a result, compari on 
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of the different groups of children were done with the awareness that response aga inst 
serotype 5 had been done for ome groups only. Frequencies of memory B cell against 
the various pneumococcal capsu lar po lysaccharides in the PRISM children were 
summed up and compared with fTequencies of memory B cell again t the pool of 
polysaccharides that was used for the CCRC and Ngerenya children. 
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Figure 5.5: omparison of PRISM children with CCRC HIV-infected childrcn and community controls 
from gerenya with regard to Frequencic of memory () cells again t tetanu toxoid. 1I0rizontal lines 
show mcdian. ·P<O.05. n! -no sign ificant difference (i.e. P>O.05). 
When the different children were compared with regard to frequencies of memory B 
cells against tetanus toxoid, the PRI M children at day 0 were comparable with the 
Ngerenya community controls who had not received the PHiD- V vaccine. However, 
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the PRISM children at day 0 had higher frequencies of memory B cells against TT 
when they were compared with HIV-infected children who had not received the PHiD-
CV vaccine, suggesting that the HIV -infected children had experienced faster waning of 
anti-TT memory B cells when compared with the Ngerenya healthy children. As would 
be expected, the Ngerenya community controls who had received the PHiD-CV had 
higher frequencies of anti-TT memory B cells when compared with those who had not 
received the PHiD-CV, suggesting that administration of the PHiD-CV vaccine in the 
community indeed boosted anti-TT and probably also anti-DT responses. The PRISM 
children at day 30 were comparable with the Ngerenya community controls who had 
received the PHiD-CV in the catch up campaign with regard to frequencies of anti-TT 
memory B cells, suggesting that a single dose of PHiD-CV elicited similar responses in 
the clinical trial and in the community. 
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Figure 5.6: ompari son or PRISM children with CRC HIV-inrected children and commun ity controls 
from Ngerenya with regard to frequencies or memory B eell against pneumococcal eap ul ar 
poly aechar ides. Horizontal line how median. · 1'<0.05. n/s-no ignifieant difference (i.e. I 0.05). 
When the different children were compared with regard to frequenci es of memory B 
cells against pneumococcal capsular polysaccharides, the PRISM children at day 0 were 
comparable with the Ngerenya community control who had not received the PHiD-CV 
vaccine. Similarly, the PRISM children at day 0 were comparable with HIV -infected 
children who had not received the PHiD-CV vaccine with regard to frequencies of 
memory B cells against pneumococcal capsular polysaccharides. As would be expected, 
the Ngerenya community controls who had received the PHiD-CV had higher 
frequencies of anti-pneumococcal memory B cells when compared with those who had 
not received the PHiD-CV, suggesting that administration of the PHiD-CV vaccine in 
the community indeed elicited anti-pneumococcal memory B-cell responses. The 
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PRISM children at day 30 were comparable with the Ngerenya community controls 
who had received the PHiD-CV in the catch up campaign with regard to frequencies of 
anti-pneumococcal memory B cells, suggesting that a single dose of PHiD-CV elicited 
similar responses in the clinical trial and in the community. 
5.4 Discussion 
In our study, the induction of memory B-cell responses to the studied pneumococcal 
capsular polysaccharides differed between the antigens. 
In general, the presence of some baseline responses against all serotypes in some of the 
children suggests that natural exposure can induce the formation of memory B cells 
against the capsular polysaccharides. Indeed, antibody responses against pneumococcal 
capsular polysaccharides increase upon natural exposure and are thought to contribute 
to the age-dependent naturally acquired immunity to pneumococcal disease [294]. 
Notably, the baseline memory B-cell responses against serotype 19F were much higher 
than those against any of the other four serotypes. suggesting that the children had 
encountered more natural exposure to serotype 19F prior to vaccination. Previous 
studies in Kenya have shown that there is more nasopharyngeal carriage of serotype 
19F in the community when compared to carriage of the other four serotypes [292]. 
Another important observation was the fact that memory B-cell responses against 
serotype 19F after vaccination with PHiD-CV were stronger than those of any other 
serotype measured. This could be attributed to the high baseline responses due to higher 
previous exposure to PS 19F. This could have primed the children against PS 19F. hence 
making them to have higher vaccine-induced responses to PS 19P when compared with 
other serotypes. On the other hand, the conjugat ion of PS 19F to diphtheria toxoid, an 
antigen that the children had experienced during their childhood pentavalent 
(DTaP+HB+HiB) vaccination series. could have influenced the amount of T-cell help 
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available to PS 19F specific B cells. This is because DTaP vaccination would be 
expected to have induced formation of helper T cells against diphtheria toxoid peptides 
that would be presented by PS 19F specific B cells after the vaccination. 
From our results, a single dose of the vaccine induced a significant increase in 
frequencies of anti-PS 19F memory B cells while a second dose induced a further 
increase, suggesting that every successive dose had a beneficial etTect on this 
compartment. The first dose was essentially a boost of the pre-existing high natural 
responses against PS 19F. On the other hand, the first dose was ineffective in inducing 
anti-PS 14 memory B cells. A second dose successfully induced an increase of anti-
PS 14 memory B cells; two doses would be required to have an effect on this 
compartment. The same effect was observed with regard to serotype 23F whereby a 
significant increase of anti-PS23F memory B cells was only detected after the second 
dose. For serotype I, the first dose induced a significant increase in anti-PS I memory B 
cells but the second dose was ineffective in inducing a further increase, suggesting that 
one dose was required whereas a subsequent dose conferred no additional benefit. Of 
note was the inability of the vaccine to induce anti-PS6B memory B cells, a fact that 
resonated with the inability to reduce nasopharyngeal carriage against serotypes 6B/6A 
in our cohort and the entire cohort of the larger vaccine trial. 
Frequencies of memory B cells against tetanus toxoid and diphtheria toxoid also 
increased after the first dose. The vaccine can therefore confer an additional benefit of 
boosting B-cell responses against the DPT vaccine. 
The direct correlation between the antibody levels and the frequencies of memory B 
cells against PS 19F and PS 1 at day 210 could be an indication of the strength of the 
children's germinal centre reaction to the antigens. Arguably, a child who makes a 
strong germinal centre reaction would be expected to concurrently induce higher 
antibody levels and more memory B cells when compared with a child who makes a 
166 
weaker germinal centre reaction, though differentiation into either memory B cells or 
plasma cells could also occur independently since they are driven by different factors. 
Similar correlations and explanations have been observed and discussed in chapter four 
with regard to B-cell responses against tetanus toxoid and measles antigen. Considering 
that similar but non-significant trends were observed for the other serotypes at day 210, 
it could be a universal phenomenon that was only missed out in some serotypes due to 
the limited number of our study subjects and the varying immunogenicity of the 
antigens. However, polysaccharide antigens have been reported to induce T-
independent antibody responses that are independent of the germinal centre reaction. As 
a result, even though the capsular polysaccharides in the vaccine were conjugated to 
proteins to give them the ability to induce T-dependent responses, they could have 
retained their ability to also cross-link BCR and induce T-independent responses, 
leading to generation of antibodies with limited induction of memory B cells via that 
route. Such an effect could be an explanation to the poor correlation between levels of 
plasma IgO and frequencies of memory B cells. 
Surprisingly, the children who had baseline nasopharyngeal carriage of serotype 19F 
also had lower anti-PS 19F antibody and memory B-cell responses to the vaccine. 
Previously, nasal carriage has been shown to induce plasma antibody responses to some 
capsular polysaccharides [294]. In addition, pneumococcal nasal challenge without 
carriage has been shown to induce mucosallgG against protein antigens but not against 
capsular polysaccharides, implying that priming and boosting of immune responses can 
occur in the absence of active carriage as long as an individual gets exposed to the 
bacteria in the community [295]. The natural exposure of our participants to 
pneumococcal challenge (and whether it resulted in carriage or no carriage) was not 
determined. It is possible that both carriers and non-carriers had experienced natural 
challenge, with the non-carriers eliciting better priming of systemic B-cell responses 
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while also making better mucosal responses that would prevent carriage. Such priming 
in the children without nasopharyngeal carriage would explain their better responses to 
the vaccine when compared with children who had baseline carriage. 
Day 180 serotype 6BI A carriage was not associated with the level of anti-PS6B memory 
B-cell responses. This could be interpreted to mean that anti-PS68 B-cell responses did 
not protect against carriage. an argument that fits well with the fact that there was no 
reduction in carriage of serotype 68 in the larger vaccine trial despite the attainment of 
adequate anti-68 IgG levels. 
The observation that Ngerenya community controls who received the PHiD-CV vaccine 
had higher anti-TT and anti-pneumococcal memory B-cell responses when compared 
with Ngerenya community controls who did not receive PHiD-CV proves that the 
vaccine was effective in inducing memory 8 cells when administered in the community. 
The similarity of the Ngerenya PHiD-CV vaccinated children with the PRISM children 
at day 30 (after 1 dose of PHiD-CV) implies that the effectiveness of PlliD-CV was 
similar in the clinical trial and in the catch-up campaign in the community. 
Interestingly, older HIV-infected children were comparable to younger healthy children 
in the absence of PHiD-CV, suggesting that HIV had impaired their ability to acquire 
anti-pneumococcal memory B cells naturally with age. Due to the small numbers of 
HI V-infected PHiD-CV vaccinated children, I was unable to evaluate the effectiveness 
of the vaccine amongst HlV-infected children. 
In summary. I have shown that immunization with PHiD-CV elicits memory B-cell 
responses against pneumococcal capsular polysaccharides in the setting of a controlled 
clinical trial as well as in the community setting. I have also shown that the vaccine 
boosts anti-TT and anti-DT memory 8-cell responses. The similarity of older HIV-
infected children to younger healthy children with regard to naturally acquired anti-
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pneumococcal responses suggests that HIV infection could be impairing the natural 
acquisition of memory B cells to pneumococcal antigens. 
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Chapter 6 Effect of different combinations of 
B-cell stimulants and the in vitro effect of 
recombinant HIV -1 Ner on B-cell responses 
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6.1 Literature review 
Even though most pathogens are able to elicit/carryall four signals that activate B cells, 
i.e BCR Ligand (antigen), TLR ligand (e.g pathogen genetic material), C040L and 
cytokines, some antigens may not elicit some of the signals. For instance, immunisation 
with a recombinant protein that is devoid ofTLR ligation may elicit BCR signalling and 
T-cell help without TLR signalling, though adjuvant can be used to trigger innate 
signals in such scenarios. Also, T-independent antibody responses have been proposed 
to occur in the absence of T-cell help [296]. Furthermore, bystander activation of 
memory B cells with irrelevant specificities has been proposed as a means by which the 
body maintains long lasting antibody responses to historically encountered antigens, 
suggesting that activation of some B cells can occur in the absence of BCR signalling 
[277]. All these possibilities point towards the importance of understanding the etTect of 
all permutations of combinations of different signals on B cells. There is also a need to 
understand how various pathogens manipulate these B-cell stimulatory signals, singly 
or in combinations, as a means of blunting the antibody responses against themselves. 
Indeed, most viruses have evolved ways of modulating the immune system. H1V is one 
such virus that, in addition to depleting host's C04+ T cells, causes many other defects 
in the immune system so as to evade clearance. As a result, HIV -infection is associated 
with a wide range of defects in all lymphocyte compartments. Some of the defects are 
thought to be due to the depletion of C04+ T cells. The observed impairment of the 
function of follicular helper T cells could also playa role in causing defects in the S-
cell compartment [274]. Other defects could be due to the direct effect of virion factors 
such as viral proteins and viral RNA. 
HIV-I Nef is an accessory protein that has been linked to several immune-cell defects 
in HIV-infection. It is a 27-kOa protein that is expressed early in the replication 
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cycle of the virus [297]. Originally named 'negative factor', it was thought to negatively 
regulate viral replication [298]. However, subsequent studies showed its importance in 
HIV-I pathogenesis and viral replication in vivo. For instance, a cohort of blood 
products recipients who acquired a Nef-mutant HIV-I variant became long-term non-
progressors [299]. Also, a SIV strain that was attenuated by mutating the nef gene 
proved to be a safe live attenuated vaccine in adult macaques, though a similar strain 
was pathogenic to neonatal macaques [300, 301]. In another study, neftransgenic mice 
developed AIDS-like presentation (immune suppression, wasting etc), suggesting that 
Nef could playa role in causing some of the AIDS-associated clinical manifestations 
[302]. 
Most of the effects ofNefhave been attributed to either manipulation of the expression 
level of surface markers on or activation of immune cells. 
Among the effects on surface marker expression, most notable is the downregulation of 
surface C04 levels in infected CD4+ T cells, a process that could enable efficient 
release of new viral particles [303]. Nef also downregulates MHC-I expression on 
infected T cells, leading to impaired killing of infected cells by cytotoxic T cells [304]. 
In fact, HLA-B. which has been shown to be more protective against HIV than HLA-A, 
has also been shown to be less susceptible to Nef-mediated downregulation, suggesting 
that the effect of Nef on HLA could be significant in vivo [305]. In addition to the 
above effects on C04+ T cells, Nef affects expression of MHC-II, C080 and C086 on 
infected antigen presenting cells (APCs), an effect that could compromise the activation 
of T cells by the APCs [306, 307]. It also upregulates the expression of DC-SIGN on 
infected dendritic cells and therefore promotes lymphocyte clustering and viral spread 
[308]. 
Additionally, HIV-I Nef has been shown to modulate the activation of immune 
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cells. This has been mainly attributed to its ability to interact with the NFKB pathway in 
T cells and macro phages. Most important are the direct and indirect activation signals 
that it delivers to T cells hence increasing viral infectivity and viral replication. The 
protein has been shown to lower the threshold for TCR and C028 mediated activation 
of T cells [21]. It also mediates the release of soluble inflammatory factors from 
macrophages that in turn act as chemokines and activation signals to T cells, drawing 
the T cells to sites of HIV replication and activating them to make them permissive to 
infection [309, 310]. Additional soluble factors such as soluble ICAM and soluble 
C023 are released from Nef expressing macrophages and render B cells stimulatory to 
T cells [311]. 
In addition, HIV-I Nefhas been shown to reduce host T-cell actin dynamics following 
TCR engagement [312]. That finding concurs with the observed defective homing of 
Nef-expressing T cells to lymph nodes in a mouse model [313]. Other effects include 
cytotoxicity on un infected T cells (effect of exogenous Net) [314] and impairment of 
phagocytosis in macrophages [315]. 
HIV-l Nefhas also been shown to indirectly contribute to B-cell activation by inducing 
the release offerritin from infected macrophages. The ferritin then interacts with B cells 
to cause polyclonal activation [133]. On the other hand, it has been shown to impair 
C040L mediated class switching in vitro, implying that it could benefit the virus by 
blunting the antiviral antibody response. The ability to impair class switching while 
activating the NFKB pathway of immune cells is somehow contradictory. However, it 
was shown that the activation ofNFKB pathway on Nef-exposed B cells was relatively 
inefficient, leading to engagement ofnegative feedback ·mechanisms that rendered the B 
cells refractory to subsequent C040L stimulation [25]. Indeed, expression of Nef in 
drosophila inhibits relic NFKB dependent innate immune responses [316]. 
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This chapter presents experiments that were done with the aim of determining the effect 
of various combinations of stimulants on B cells and the in vitro effect of exogenous 
HIV-I Nefon B-celJ responses to such stimulant-combinations. 
6.2 Results 
6.2.1 Titration of reagents 
All stimulants were individually titrated to establish optimal stimulant concentrations 
for the experiment. Concentrations of stimulants were plotted against the magnitude of 
the various B cell responses that they elicited. The concentrations that were chosen were 
those that lay on the part of the curve where a unit increment in stimulant concentration 
corresponded with maximal increment in B-celJ response i.e. the exponential part of the 
curve. This was done to enable the combination of different stimulants without eliciting 
saturating responses that would mask any effect of adding other stimulants in the 
combination or mask any immunomodulatory effects of recombinant HIV -I Ner. 
Titration ofCpG-B (ODN-20061 
Oligodeoxynucleotide (ODN) 2006 was used in the reported experiments. It is a CpG-
B/K-type ODN that has a full phosphorothioate backbone that protects it from 
degradation by nucleases. Its sequence is 5' -tcgtcgttttgtcgttttgtcgtt-3' whereby bold 
letters represent the CpG dinucleotides and the regular letters represent 
phosphorothioate linkage. ODN-2006 is a potent ligand for TLR9. The TLR9 generally 
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detects unmethylated cytosine-phosphate-guanosine (CpG) motifs that are common 
within bacterial DNA but relatively underrepresented in mammalian DNA. Like other 
compounds containing CpG motifs, ODN-2006 is highly effective in stimulating B cells 
/Tom humans and mice among other animals and can therefore be used to asse s the 
effect of bacterial DNA on B cells [317, 318]. 
In the titration experiments the optimal concentration of the ODN-2006, simply 
referred to as CpG, as determined on the basis of day 8 IgG and IgM ELI A optical 
density values was l/-lg/ml. The flow cytometry assays for determination of 
proliferation and differentiation of B cells into plasmablasts had not been optimi ed as 
at that time. 
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Figure 6.1: Titration of CpG. The 1110 t sui table concentration of pG IVa establi hed at I ~lgll11l. Data 
represents two experiments. Symbols how l11ean ±SEM. 
Titration of R848 
R848 is a low molecu lar weight imidazoquinoline molecule that that has a molecular 
weight of314 glmole and a molecular formula C17HnN402. It was initially investigated 
for its potent antiviral and antitumor activity, and has since been shown to be a potent 
activator of immune cells via the TLR7 and TLR8 receptors who e natural ligand is 
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viral single stranded RNA [319]. R848 is particularly effective for activating B cells and 
can be used to mimic the effect of HI V-I single stranded RNA [320]. 
NH2 
~)"ryoJ 
~OH 
Figure 6.2: Chemical structure of R848 
The optimal concentration of R848 was determined on the basis of proliferation of B 
cells (day 5), differentiation of B cells (day 5), and secretion of IgG and IgM into 
culture supernatants (day 8). It was determined to be 0. 1 ~g/m l of R848. 
Concentnllon of R848 )A9lm1 Conc:entnllon of R848 ",,*"1 
-I .. • D~1 B~ 
-1 1~1 IIlB lleD I!~ !~ II#. 
.. £= 
~ ~ 
0.0 0.1 0.2 0.3 2 3 0.0 0.1 0.2 0.3 2 3 
R848 tilralon ughnl R848 oonoentnltion ugknl 
Figure 6.3: Titration of R848. The most suitable concentration of R848 was establi hed at 0.1 ~1g/mL 
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Data represents t\\O experiments. S.\11lbols show mean ±SEM. 
Titration ofCD40L 
As discussed ear lier in this chapter CD40L (CD 154) i the natural ligand for CD40 
[189]. Even though it is naturally expressed on the surface of activated helper T cells to 
provide contact signals to cognate B cells, a recombinant biologically active soluble 
version can be generated. The one used in these experiments was generated in E. coli 
and consists of the extracellular domain fused at the N-terminus to a linker peptide and 
a FLAG-tag. It was used together with a cross-linking enhancer. 
The optimal concentration of the CD40L was detemlined on the basis of proliferation of 
B cell (day 5) and secretion of IgG and IgM into culture supernatants (day 8). It wa 
determined to be 125 ng/ml. There was neither detectable differentiation into 
plasmablasts as measured by flow cytometry nor secretion of detectable IgM into 
culture supernatants when PBMCs were stimulated with CD40L alone. 
o 100 200 300 400 500 600 o 100 200 300 400 500 600 
C040L concentration nghnI C040L concenntion nghnI 
o 100 200 300 400 500 600 
C 040L concen In! on nglml 
Figure 6.4: Titration of CD40L. The mo t suitable concentration of D40L was establi shed at 125177 
nglml. Data represents two experiments. )mbol show mean ± EM. 
Titration ofanti- Igs CBCR ligand) 
F(ab')2 fragment goat anti-human IgA+lgG+lgM were used to stimulate the B cell Via 
the BCR. The optimal concentration of the anti- Igs (BCR ligand) was determined on the 
basis of proliferation of B cells (day 5) and secretion of IgM into culture supernatants 
(day 8). It was determined to be 1.25 ~lglml. There was neither detectable ecretion of 
IgG into supernatants nor detectable differentiation into plasmabla ts as mea ured by 
flow cytometry when PBMCs were stimulated with anti-I g alone. 
o I 2 3 • 5 e 7 8 9 10 
An5-Ig'a concenlnlbOn ,.gknI 
o 1 2 3 • 5 e 7 8 9 10 
An -!g'. Q)flcentnl~on ,.gknI 
o 1 2 3 4 5 e 7 8 9 10 
Anl-Ig'. Q)flatnlrltlon ,.gImI 
Figure 6.5: Titration ofanti- Ig (BCR ligand). The mo t suitable concentration ofanti- Igs was c tabli hed 
at 1.25 Ilglml. Data repre ents two experiment . ymbols how mean ± EM . 
6.2.2 Combinations of different timulants used 
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10 stimulant combinations were then made using the following combinations in order to 
mimic the different circumstances under which B cells may be stimulated in vivo during 
B-cell responses against complex pathogens and antigens. IL21 was used at SOng/ml as 
per previous reports [210]. 
The effects of the various stimulant-combinations on B cells were first assessed by 
comparing samples that were pre-incubated with media alone. The effect of pre-
incubation with recombinant HIV -1 proteins was then assessed by comparing samples 
that were pre-incubated with the wild-type HIV -\ Nef with samples that were pre-
incubated with mutant HIV-l Nefor media alone. 
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Stimulant- BCR-ligand 
IL21 CD40L C pG R848 
combination (anti-Ig ) 
I ~ 
2 ~ ~ 
3 ~ ~ 
4 ~ ~ ~ 
5 ~ ~ 
6 ~ ~ ~ 
7 ~ ~ ~ ~ 
8 ~ ~ 
9 ~ ~ ~ 
\0 ~ ~ ~ ~ 
Table 6. 1: Combinations of st imulants lIsed to make the various stimulant-combinations. 
-I indicates the use or the particular stim ulant in the correspondin g combinat ion. 
6.2.3 Proliferation of B ce lls after 5 days in respon e to the va rious stimulant 
combinations. 
When the proliferation of B ce lls after exposure to the various timulant combinations 
was evaluated by CFSE staining, differential effects were observed. Generally, the 
number of stimulants in culture correlated with the frequency of proliferating B cells, 
suggesting synergistic effect. The combination of CpG+IL21 elicited higher frequencie 
of proliferating B cells when compared with IL2 1 alone. Similarly, the combination of 
CD40L+IL21 elicited a trend of higher fi'equencies of proliferating B cells when 
compared with IL2 1 alone, though the difference was not statistica lly significant. 
R848+CD40L+BCR+IL2 1 elicited significantly higher fi'equencies of proli ferating B 
ce lls than R848+CD40L+1 L21 that in turn elicited ignificantly higher frequencies of 
proliferating B cells than R848+IL2 1, suggesting that addition of each timulant 
synergised the effect of the other stimulants in the combination. The same effect was 
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observed in stimulants that contained CpG whereby CpG+CD40L+BCR+IL2l elicited 
significantly higher frequencies of proliferating B cells than CpG+CD40L+IL2l that in 
tum elicited significantly higher frequencies of proliferating B cells than CpG+IL21. 
The addition ofTLR ligands enhanced proliferation in all cases. For instance, addition 
of R848 onto CD40L+IL2l or CD40L+BCRL+IL2l led to significantly higher 
proliferation. The same was observed upon adding CpG onto CD40L+IL2l or 
CD40L+BCRL+lL2t. However, addition ofBCRL onto CD40L+IL21 had no effect. 
Figure 6.6: Frequencies of proliferating 0 cells after exposure to various stimuhUlt-combinations. Data 
represents four independent experiments. Oars show mean ±SEM. • represents P<O.OS. 
6.2.4 Differentiation ofB cells into plasmablasts after 5 days in response to the 
various stimulant-combinations. 
When the differentiation of B cells into plasmablasts following stimulation with the 
various combinations was evaluated by flow cytometry, differential effects were also 
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observed. Generally, the number of stimulants in culture correlated with the ftequency 
of plasma blasts, suggesting that the stimulants synergized with each other. For instance, 
CD40L+BCRL+IL21 elicited significantly higher ftequencies of plasmablasts than 
BCRL+IL21. Similarly, R848+CD40L+BCRL+IL21 elicited significantly higher 
ftequencies of plasmablasts than R848+CD40L+IL21, which in turn elicited higher 
ftequencies of plasmablasts than R848+IL21. The same was observed with 
combinations that contained CpO whereby CpO+CD40L+IL21 elicited significantly 
higher frequencies of plasmablasts than CpG+IL21, which in turn elicited higher 
ftequencies of plasmablasts than IL21 alone, suggesting that the stimulants synergised 
each other. The addition of TLR ligands enhanced differentiation into plasmablasts in 
all cases. For instance, addition of R848 onto CD40L+IL21 or CD40L+BCRL+IL21 led 
to significantly higher frequencies of plasma blasts. The same was observed upon adding 
CpG onto CD40L+IL21 or CD40L+BCRL+IL21. However, addition of BCRL onto 
CD40L+IL21 had no effect. 
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Figure 6.7: Frequencies of plasmablasts after exposure to variolls stimulant-combinations. Data represents 
four independent experiments. Oars show mean ±SEM. • represents P<O.OS. 
6.2.5 Expression ofCD86 on B cells after 48 hours in response to the various 
stimulant-combinations. 
The expression of CD86 on B cells as a marker of B-cell activation was evaluated by 
flow cytometry. There was differential expression of CD86 after stimulation with the 
various stimulants. The combination of CD40L+BCRL+IL21 elicited significantly 
higher frequencies ofCD86+ B cells when compared with CD40L+IL2I, which in turn 
elicited significantly higher frequencies of CD86+ B cells when compared with IL21 
alone. Similarly, R848+CD40L+IL21 elicited significantly higher frequencies of 
CD86+ B cells when compared with R848+1 L21. The same was observed with 
combinations containing CpG whereby CpG+CD40L+IL21 elicited significantly higher 
frequencies of CD86+ B cells when compared with CpG+IL21, which in turn 
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elicited significantly higher frequencies of CD86+ B cells when compared with I L21 
alone, suggesting that the various stimulants synergised each other. Notably, 
R848+CD40L+BCRL+IL21 was comparable to R848+CD40L+IL21 while 
CpG+CD40L+BCRL+IL21 was comparable to CpG+CD40L+IL21, suggesting that 
addition of BCR ligand to combinations that had TLR ligands and CD40L did not have 
any additional effect on the expression ofCD86 on B cells. 
* 
Figure 6.8: Frequencies of CD86+ B cells after exposure to various stimulant-combinations. Data 
represents four independent experiments. Bars show mean ±SEM .... represents P<O.05. 
6.2.6 Secretion oflgG into culture supernatants after 8 days in response to the various 
stimulant-combinations 
When the secretion ofigG was evaluated by ELISA on culture supernatants, there was a 
notable high variability within each culture condition, probably because numbers of B 
cells vary between donors. This could have in tum resulted in generation of varied 
numbers of antibody secreting cells for samples from different donors. To eliminate 
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this bias, JgG indices, ratios of JgG elicited by various stimulants combinations to JgG 
elicited by a reference stimulant combination were calculated and also used to compare 
the performance of the various stimulants combinations. CD40L+IL21 was chosen as 
the reference stimulant because it is the best-studied model of B-cell responses and 
elicited responses that, unlike IL21 alone or BCRL+JL2I, were not just background 
responses that could wrongly bias the proportions. 
When the actual concentrations of IgG secreted into supernatants were compared 
between different stimulant-conditions, the only significant differences were between 
CpG+CD40L+IL21 and IL21 alone. Trends of differences between other conditions 
were observed but were not statistically significant, probably due to the high variability 
within stimulants. When the IgG indices were compared, differential secretion of IgG 
was observed among the various stimulant-conditions. Notably, addition of BCR ligand 
to any stimulant-combination dampened the secretion of JgG. For instance. BCRL+IL21 
elicited significantly lower JgG indices when compared with IL2l alone, 
CD40L+BCRL+IL2l elicited significantly lower IgG indices when compared with 
CD40L+IL21 and R848+CD40L+BCRL+IL21 elicited significantly lower IgG indices 
when compared with R848+CD40L+IL21. TLR ligands and CD40L synergised with 
JL21 to induce secretion of IgG as shown by significantly higher JgG indices in 
CD40L+IL2I, R848+IL21 and CpG+IL2l when they were compared with IL21 alone. 
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Figure 6.9: Concentrations of IgG secreted into culture supernatants afil..'I' exposure of PBMCs to various 
stimulant-combinations. Data represents four independent experiments. Bars show mean ±SEM. • 
represents P<O.OS. 
Figure 6.10: Indices of concentrations of IgG secreted into culture supernatants aller exposure 01'186 
PBMCs to various stimulant-combinations. Data represents four independent experiments. Bars show 
mean ±SEM. • represents P<O.05. 
6.2.7 Secretion oflgM into culture supernatants after 8 days in response to the variolls 
stimulants combinations 
There was high variability within culture conditions in the amounts of IgM produced, 
probably because of variability of B-cell frequencies in the different donors. To 
minimise this bias, IgM index was calculated as a ratio of concentration of IgM in 
culture supernatants of various stimulant-combinations to concentration of IgM in 
culture supernatants ofa reference condition (CpG+IL21). CpG+IL21 was chosen here 
instead ofCD40L+IL21 as the reference condition because there was no secretion of 
IgM after stimulation with CD40L+IL21. The IgM index was then used to compare the 
performance of different stimulant-combinations. 
There was little or undetectable IgM secretion in the stimulant-conditions that did not 
contain CpG. In those conditions that contained CpG, there were no significant 
differences in IgM secretion between various stimulants combinations. The same was 
observed when IgM indices were compared; there were no differences in IgM indices 
between various stimulants combinations except in the case of CpG+IL21 versus IL21 
alone where the significant difference might have been driven by the lack of variability 
within the reference condition CpG+IL2I(all donors had an IgM index of 1 for 
CpG+IL21). 
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Figure 6.11: Concentrations of IgM secreted into culture supernatlmts afler exposure of PBMCs to 
various stimulant-combinations. Data represents four indcpcnd~'Ilt experiments. Oars show mean ±SEM. • 
represents P<O.05. 
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Figure 6.12: Indices of concentrations oflgM secreted into culture supernatants alh:r exposure of PI3MCs 
to various stimulant-combinations. Data represents four indepcmknt expcrinll.:nts. Bars show mean 
±SEM. • represents P<O.05. 
6.2.8 Secretion ofTNF-alpha into culture supernatants after 48 hours in response to 
the various stimulant-combinations 
TLR ligands and CD40L have been shown to induce secretion ofTNF-alpha by B cells 
[321,322]. Furthermore, the secreted TNF-alpha can synergize with B-cell stimulants in 
inducing further B-cell responses [323]. The secretion of the cytokine upon stimulation 
with various stimulant-combinations was therefore assessed in this study. However, the 
same stimulants have been shown to induce secretion of TNF-alpha by monocytes 
[324], making it likely that the TNF-alpha detected in the culture supernatants came 
trom B cells as well as other cell-types that constitute PBMCs. 
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A TNF-alpha index was calculated for each donor and each stimulant combination as a 
ratio between the concentration of TNF-alpha in culture supernatants of the various 
stimulant-combinations and the concentration ofTNF-alpha in culture supernatants ofa 
reference stimulant condition (CD40L+IL21). When actual TNF -alpha concentrations 
were considered, there was a significant difference between R848+CD40L+IL21 and 
R848+IL21 with regard to secretion of the cytokine into culture supernatants. However, 
no other differences were observed. When TNF -alpha indices were considered, the 
secretion of TNF-alpha was highly dependent on presence of CD40L in the stimulant 
preparation; stimulant combinations that contained CD40L elicited significantly higher 
TNF-alpha indices when compared with those that did not have CD40L. Furthermore, 
there were no statistically significant differences between culture conditions that 
contained CD40L with regard to TNF-alpha indices. 
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Figure 6.13: Concentrations ofTNF-alpha secreted into culture supernatants siler exposure of PBMCs to 
various stimulant-combinations. Duta represents four independent exp,,:ril11ents. Bars show mean 
±SEM. • represents P<O.05. 190 
Figure 6.14: Indices of concentrations of TNF-alpha secreted into culture supernatants aller exposure of 
PBMCs to various stimulant-combinations. Data represents four independent experiments. Bars show 
mean ±SEM. • represents P<O.05. 
6.2.9 Secretion of I L6 into culture supernatants after 48 hours in response to the 
various stimulant-combinations 
TLR ligands and CD40L have also been shown to induce secretion of IL6 by B cells 
[321, 322]. IL6 has been shown to potentiate the effect of B-cell stimulants in inducing 
B-cell responses [325]. The secretion of the cytokine upon stimulation with various 
stimulant-combinations was therefore also assessed in this study. However, stimulation 
of monocytes has been shown to make them secrete IL6 [326, 327]. making it likely 
that the IL6 detected in the culture supernatants came from B cells as well as other 
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cell-types that constitute PBMCs. 
There was high variability in IL6 concentrations in culture supernatants within the 
various stimulant-combinations, probably due to high variability in IL6 producing cells 
between donors. When the levels of IL6 were considered, there were no statistically 
significant differences in IL6 levels between various culture conditions. 
An IL6 index was calculated for each donor and each stimulant-combination as a ratio 
between the concentration of IL6 in culture supernatants of the various stimulant-
combinations and the concentration of IL6 in culture supernatants of a reference 
stimulant condition (CD40L+IL21). Notably, all culture conditions that contained 
CD40L had significantly higher IL6 indices when compared with corresponding culture 
conditions that did not have CD40L. suggesting that CD40L played an important role in 
determining the amount of IL6 produced by the cultured PBMCs. Presence of BCR 
ligand did not appear to affect the amount oflL6 produced. 
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Figure 6. IS: Concentrations of IL6 secreted into culture supernatants alter exposure of PBMCs to 
various stimulant-combinations. Data represents four independent experiments. Oars show mean ±SEM. • 
represents P<O.05. 
5 
Figure 6.16: Indices of concentrations of IL6 secreted into culture slIpemat,mts atlcr exposure of 
POMCs to various stimulant-combinations. Data represents four independcnt experiments. Oars show 
mean ±SEM. • represents P<O.05. 
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6.2.10 Effect of recombinant HIV-I Nefon proliferation ofB cells after stimulation 
with various stimulants for 5 days 
The effect of recombinant HIV -I Nef on B-cel\ proliferation was assessed by 
comparing the proliferative response after pre-incubation with wild-type recombinant 
HIV -1 Nef, mutant non-myristoylated recombinant HIV -I Nef and media alone. 
Notably, across all stimulant-combinations, there was no difference between the 
samples that were pre-incubated with recombinant HIV -I Nef and those pre-incubated 
with mutant (non-myristoylated) HIV-I Nefor media alone. 
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Figure 6. 17: Frequcncics of proliferating 13 cc ll aller prc-incubation with Ill Y proteins and subscqucnt 
cxposurc to various stimulant -combinations. All samplc wcre prc-incubated with rccombinantlllv-I 
cf(red), recombinant mutant (non-myri toylatcd) 1-lI v- 1 ef(Grccn) or mcdia (Bluc). Data rcprc ents 
four independent cxperiments. Bars how mean ± EM. 
Stimulant Mean( tandard error) of P value 
proliferating B cell 
Nef MNef Nil Nef Ncf MNcf 
v v v 
MNef Nil Nil 
NIL+lL21 4.4(2.2) 1.3(0.2) 1.9(0.3) 0.2786 0.300 1 0. 1965 
BCRL+IL21 6.8( 1.5) 8.4(2. 1) 6.3(2.3) 0. 1993 0.6042 0. 1430 
C040L+IL21 21.55(7.4) 21.66(7.0) 21.00(6.9) 0.805 1 0.8893 0.85 12 
C040L+BCRL+IL21 23.2(7. 1) 2 1.7(5.6) 23.4(4.9) 0.5402 0.95 10 0.3743 
R848+IL21 11.4(4.7) 12.6(4.0) 13.9(4.0) 0.36 11 0.05 15 0.1403 
R848+CD40L+IL21 4 1.2( 10.4) 39.0( 11.6) 37.9(9. 1) 0.27 18 0. 1753 0.7 148 
R848+CD40L+BCR+1 L2 1 61.7(9.4) 65.8(6.3) 6 1.1 (6.6) 0.4569 0.8722 0. 188 1 
pG+IL21 15. 1 (2.8) 15. 1(1.2) 15.8(2. I) 0.9886 0.6728 0.7902 
pG +C O.tOL+IL21 56.5(9.7) 59.4(9.0) 56.8(8.2) 0.3976 0.9076 0.4 123 
CpG +C O.tOL+BCRL+IL21 77.8(8.7) 73.7(7.0) 77.8(7.8) 0.4 195 0.9786 0.359 1 
Table 6.2: Mean and standard error of mean) offrequencie of rolifcratin p g B cells for the various 
timulant cocklai ls aller pre-i ncubation wi th wild-type 1-ll v- 1 er(Ncf), mutant non-myri stoylated IlI v-
I Nef(MNel) or med ia (Ni l) and the corresponding P values after pair-wisc COm pari ons. Paired 
Student's T test was used. 
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6.2.11 Effect of recombinant HIV-I Nefon differentiation ofB cells into plasmablasts 
after stimulation with various stimulants for 5 days 
Notably, across all stimulant-combinations, there was no difference in frequencies of 
plasmablasts when samples that were pre-incubated with recombinant HIV-I Nefwere 
compared with those pre-incubated with mutant (non-myristoylated) HIV -I Nef or 
media alone. However, for samples stimulated with CD40L+BCRL+IL21, those pre-
incubated with mutant non-myristoylated HIV -I Nef had lower frequencies of 
plasmablasts than those pre-incubated with media alone (P=O.0052). Similarly, for 
samples stimulated with IL21 alone, those pre-incubated with mutant non-myristoylated 
HIV -I Nef had lower frequencies of plasmablasts when compared with those pre-
incubated with media (P=O.0357). 
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rigure 6.18: Frcqucncics of plasma blasts aller prc-incubation with Ill V proteins and ubscquent ex po ' ure 
to various stim ulant-combinations. All sample were pre-incubated with recombinan t IIIV- I ef (red). 
recombinant mutant (non-m yri stoylated) III V- I ei" (G reen) or media (13Iue). Data rcpre enlS IOll r 
independent experiment . Bars show mean ± EM. 
Stimulant Mea n(s tandard error) % of J> va lue 
(ll as mablas ts 
Nef MNef Nil Nef Nef MNcf 
vs v vs 
MNef Nil Nil 
NIL+IL21 3.05( I. 7) 0.70(0.2) 1.29(0.3 ) 0.2700 0.3587 n.D357 
BCRL+IL21 1.95( 1.\ ) 2.27(0.9) 3.94(2.3) 0.3545 0.5242 0.5954 
CD40L+IL21 16.07(5.5) 16.70(5.3) 16.29(5.1 ) 0.5591 0.937 1 0.8 138 
CD40L+8 RL+IL21 16.20(5.9) 13.43(4.8) 17.07(4 .7) 0.3280 0.7136 n.oo)] 
R848+1L21 9.50(3.3) 13.05(2.3) 10.71(3. 1) 0.2342 0.2734 0.3236 
1~848+CD40L+1 L21 33.60(7.5) 3 1. 75(9.0) 32. 13(6.5) 0.3806 0.2709 0.9035 
R848+CD40L+BCR+IL21 54.73(8 .7) 60.73(5.4) 58.20(4.9) 0.2528 0.4708 0.2083 
CpG+lL21 10.08(2 .4) 9.88(2.4) 9.47( 1.8) 0.9485 0.5468 0.8493 
CpG +CD40L+lL21 39.73(7.9) 39.88(6.5) 35.88(7.7) 0.9572 0.149 1 0.0552 
CpG+CD40L+BCRL+1 L21 48.25(9.2) 51.63(9.1 ) 44.38( I 0.3) 0.5346 0.4734 0.2633 
T ab Ie 6.3: Mean and standard error of mean of fre uencies of lasmablasts for the variou q p timulan t-
com binations after pre-incubation with wild-type HIV -I ef (Nel). mutant non-myri stoylated III V-I Nef 
(MNef) or medi a (N il) and the corresponding P values after pair-wi e comparison . Paired tudent 's T 
test was u ed. Significant P va lues are shown in red text. 
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6.2.12 Effect of recombinant HIV -I Nef on expression of CD86 on B cells after 
stimulation with various stimulants for 48 hours 
With the exception of BCRL+I L21 and CD40L+BCRL+1 L21, there were no differences 
between samples pre-incubated with wild-type HIV-l Nefand those pre-incubated with 
either mutant non-myristoylated HIV-l Nef or media alone. For samples that were 
stimulated with BCRL+IL2I, pre-incubation with wild-type HIV-) Nef resulted in 
higher frequencies of CD86 expressing B cells when compared with pre-incubation 
with mutant non-myristoylated H)V-) Nef. For samples that were stimulated with 
CD40L+BCRL+IL2), pre-incubation with mutant non-myristoylated HIV-) Nef 
resulted into lower frequencies of CD86 expressing B cells when compared with pre-
incubation with either wild-type HIV-) Nef or media alone. 
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Figurc 6.19: Frequcncie of CD86 cxprc ing B cell aller pre-incubation with IllY protcin ' lIno 
sub cqucnt exposure to var iou timulant-combination. All samplcs were pre-incubatcd with 
rccombinant IllY-I Ncf (red). recombinant Illutant (non-Ill)'Ti toylated) IllY-I Ner ( recn) or mcdia 
Stimulant Ican(standard error) % of P va lue 
Nil ef Ncf M cf 
v vs v 
1Ncf Ni l Nil 
NIL+IL21 6. 12( 1.4) 5.65(1.1) 0.4 148 0.6327 0.5337 
B RL+IL21 46.45(3.0) 23.97(8.9) () 00119 0.0725 0.4554 
D40L+IL21 23.18(3.5) 19.10( 1.8) 0.2045 0.1306 0.4032 
CD40L+BCRL+IL21 61.63(3.4) 55.23(6.0) 00-1113 0. 1716 O.O30!! 
R848+1L21 2 1.09(4.6) 19.54(6. 1) 0.5449 0.85 14 0.3026 
R848+C D.JOL+IL21 37. 10(3.0) 39.48(4.8) 0.2762 0.7182 0.7650 
R848+ D.JOL+BCR+lL21 59.40(7.8) 55.58(9.0) 0.8003 0.4027 0.9 145 
pG+IL21 33.43(2.1 ) 25.18(3.6) 0.071 1 0.2423 0.7398 
pG +C D.JOL+IL21 43.50(2.8) 41 .25(0.4) 0.3369 0.4121 0.5569 
0.1671 0. 1295 0.3654 
for the vari us 
timulant-combinations aller pre-incubation with wild-type IllY-I ef(Ncf), mutant non-myri stoylated 
IllY-I Nef(MNef) or media ( il) and the corresponding P values nner pair-wisc comparisons. Paired 
Student's T te t was used. ignificant P values are hown in red text. 
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6.2.13 Effect of recombinant HIV-I Nefon secretion ofIgG by PBMCs after 
stimulation with various stimulants for 8 days 
When the IgG indices were compared, there were no significant differences between 
samples pre-incubated with wild-type HIV-I Nef and those pre-incubated with mutant 
non-myristoylated HIV -I Nef or media alone, suggesting that recombinant HIV -1 Nef 
did not affect the secretion of IgG by PBMCs stimulated with different stimulants 
combinations. Similarly. there were no differences in the IgG indices between samples 
pre-incubated with mutant HIV-I Nefand those pre-incubated with media alone. 
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Figure 6.20: IgG Indices after pre-incubation with IllY proteins and sub equent exposure or PBM s to 
various stimulant-combinations. All sample were pre-incubated with recombinant IIIY-I Ner (red), 
recombinant mutant (non-myristoylated) HIY-I Ner (Green) or media (B lue). Data repre ents four 
independent experiments. Bars show mean ± EM. 
Stimulant Mean (standard error) IgG Index I) \llI lue 
Nef MNef Nil Nef Ner MNef 
\IS \IS \IS 
MNcf Nil Nil 
NIL+IL21 0.06(0.0 1) 0.09(0.03) 0.07(0.0 1) 0. 149 1 0.4003 0.2805 
BCRL+IL21 0.00(0.00) 0.01(0.01) 0.01(0.0 1) 0.2890 0. 1985 0.6767 
CD40L+IL21 0.80(0.2 1 ) 0.82(0. 13) 1.00(0.00) 0.924 1 0.3974 0.2704 
CD40L+BCRL+lL21 0.09(0.04) 0.05(0.02) 0.07(0.03) 0.320 1 0.6497 0.3448 
R848+1L21 0.20(0.08) 0.26(0.05) 0.32(0.08) 0.2320 0.0833 0.3855 
R848+CD40L+IL21 0.99(0. 18) 0.76(0.22) 0.74(0.22) 0. 1407 0. 1495 0.6038 
R848+CD40L+BCR+lL21 0.30(0.19) 0.29(0.08) 0.33(0.12) 0.9838 0.9003 0.6884 
CpG+IL21 0.70(0. 17) 0.80(0.19) 0.95(0. 15) 0.2658 0. 1958 0.2292 
CpG +CD40L+IL21 1.34(0. 14) 1.70(0.51 ) 1.90(0.64) 0.4536 0.3805 0.2479 
CpG+CD40L+BCRL+1 L21 0.35(0. 14) 0.49(0.23) 0.54(0. 16) 0.4897 0.2894 0.6547 
Table 6.5: Mean (and standard error of mean) of IgG II1dlce for the various sllmulant-combll1atlOn afier 
pre-incubation with wi ld-type HIY-I Nef (Nef), mutant non-myri toylated HIV-I Ncr (MNef) or mcdia 
(Ni l) and the corresponding P values after pair-wise comparisons. Paired tudent' s T test was used. 
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6.2.14 Effect of recombinant HIV-I Nefon secretion ofl~M by PBMCs after 
stimulation with various stimulants for 8 days 
Similar to observations in secretion of IgG above, with the exception of CpG+IL21, 
there was no difference between samples that were pre-incubated with wild-type HIV-I 
Nef and those pre-incubated with mutant non-myristoylated HIV- I Nef or media alone 
with regard to IgM indices. Interestingly, samples that were pre-incubated with wild-
type HIV - I Nef and stimulated with CpG+IL21 showed significantly lower IgM ind ices 
when compared with those pre-incubated with media and stimulated with CpG+IL21. 
However, this result should be interpreted with caution since the samples that were pre-
incubated with media and stimulated with CpG+IL21 were used as the reference 
samples in the calculation of IgM indices and therefore all had an IgM index of 1.0, 
with a standard error of 0.00 that could have driven the statistical significance. 
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Figure 6.2 1: IgM indices after pre-incubation with HIV proteins and ub equent expo ure to vari II 
stimulant-combinations. All amples were pre-incubated with recombinant IllV-1 Ncr (red), rceombinant 
mutant (non-m yristoylated) HIV- I Ner (Green) or medi a (Blue). Data represent lour independent 
experiments. Bars show mean ± EM. 
Stimulant-combination Mean(standard error) IgM Index P vlI lue 
Nef MNef Nil Nef Nef MNef 
\ 'S vs vs 
MNef Nil Nil 
NIL+IL21 0 0 0.13(0.13) 0.3910 0.3910 
BCRL+IL21 0 0 0.07(0.07) - 0.3910 0.3910 
040L+IL21 0 0 0 - -
-
C040L+BCRL+lL21 0 0 0.03(0.03) - 0. 3910 0.3910 
R848+IL21 0 0 0.00(0.00) - 0.3910 0.3910 
R848+C0 40L+IL21 0.4 1(0.4 1) 0 0.01(0.01) 0.39 10 0.4004 0.3910 
R848+C0 40L+BCR+1 L21 1.22( 1.22) 0. 14(0.14) 0.78(0.78) 0.39 10 0.8046 0.5021 
CpG+IL21 0.31(0. 12) 1.09(0.48) 1.00(0.00) 0.2675 0.0106 0.8691 
CpG +C0 40L+1L21 3.66(0.94) 3.86( 1.36) 4.40(2.00) 0.8954 0.7278 0.4969 
CpG+CO-lOL+BCRL+IL21 3.06( 1.92) 3.90(2.12) 2.85( 1.13) 0.7783 0.86 13 0.6226 
Table 6.6: Mean (and standard error of mean) of lgM IIldlce for the vanous stimulant-comblllations afler 
pre-incubation with wild-type HIV-I Nef (Ner), l1lutant non-myristoylated IIIV -I Ner (MNe f) or media 
(Nil) and the corresponding P values after pair-wise comparison s. Paired tudent" s T te t IVa used. 
ignifi eant P va lues are shown in red text. 
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6.2.15 Effect of recombinant HIV-I Nefon secretion ofTNF-alpha by PBMCs after 
stimulation with various stimulants for 48 hours 
Pre-incubation with wild-type recombinant HIV-I Nef induced high and comparable 
TNF-alpha indices regardless of the stimulant combination, suggesting that wild-type 
HIV -1 Nef, independently from the stimulants used, causes secretion of TNF -alpha by 
PBMCs. Pre-incubation with wild-type HIV-I Nef elicited higher TNF-alpha indices 
than pre-incubation with mutant non-myristoylated HIV-I Nef but that difference was 
only statistically significant for samples stimulated with NiI+IL21, BCRL+IL21, 
CD40L+IL21, R848+IL21, CpG+IL21, CpG+CD40L+IL21 and 
CpG+CD40L+BCRL+IL21, suggesting that myristoylation was necessary for the 
observed effect. Likewise, pre-incubation with media alone led to significantly higher 
TNF-alpha indices than pre-incubation with mutant non-myristoylated HIV -I Nef with 
regard to all stimulant-conditions except NiI+IL21, BCRL+IL21, R848+IL21 and 
CpG+IL21. Notably, these are the stimulant combinations that did not contain CD40L. 
The results suggest that non-myristoylated HIV-I Nef could be having some inhibitory 
effects on CD40L-mediated activation of PBMCs to secrete the cytokine. Notably, the 
TNF-alpha indices after pre-incubation with media were higher than those induced after 
pre-incubation with wild-type HIV-I Nef under all CD40L-containing stimulant-
conditions although the difference was statistically significant only after simulation with 
R848+CD40L+BCR+IL21. This, coupled with the fact that pre-incubation with wild-
type HIV-I Nef induced higher TNF-alpha indices when compared to pre-incubation 
with media in conditions that did not contain CD40L, suggests that wild-type HIV-I 
Nefprotein induces some immune activation while at the same time inhibiting CD40L-
mediated activation. 
The possibility of contamination of the wild-type HIV-I Nef protein with 
lipopolysaccharide (LPS) provides a possible alternative explanation for the204 
observed effects on TNF-alpha secretion. LPS has been shown to induce secretion of 
prointlammatory cytokines (like TNF-alpha and IL6) by monocytes [327]. Even though 
a previous publication reported that the Nef proteins were free of endotoxin [25], 
presence oftrace amounts of LPS in the particular vials that were used cannot be ruled 
out. 
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Fi gure 6.22: TNF-alpha indices afler pre-incubation with III V protein and suhsequent exposure to 
variou stimulant-combinations. All sample were pre-incubated with re mbinant III V - I ef (red), 
recombinant mutant (non-myri toylated) IIIV-I cf (Green) or media (Blue). Data represents four 
independent experiments. Bar show mean ±. M. 
Stimulant Mcan(standard crror) TNF-u Indcx P value 
Ncf MNcf Nil Ncf Ncf MNcf 
vs v s 
MNcf Ni l ~i l 
NIL+IL21 0.55(0. 13) 0.02(0.0 1) 0. 10(0.03) (J.028 I 0.0504 0. 1038 
BCRL+IL21 0.59(0. 17) 0.0 1(0.01) 0.04(0.02) 0.O.t1 7 0.03 H 0.2418 
O.tOL+lL21 0.67(0. 16) 0. 15(0.05) 1.00(0.00) (l.0277 0. 1208 O. OOO~ 
C040L+BCRL+1 L21 0.68(0. 16) 0.28(0.10) 0.75(0.08) 0.0874 0.6684 0.0 152 
RS.tS+lL21 0.64(0. 11 ) 0.05(0.02) 0. 17(0. 13) O.()()90 O.OOD 0.3698 
RS48+CO.tOL+1 L21 0.83(0.24) 0.50(0.13) 1.1 5(0. 16) 0.2222 0.26 16 001 73 
RS4S+CO.tOL+BCR+IL21 0.70(0. 18) 0.63(0.25) 1.42(0.36) 0.5900 0.02 I () 0162 
pG+IL21 0.62(0. 13) 0.03(0.02) 0.03(0.02) (U) 1 )·t O.OI N 0.8882 
CpG +C0 40L+IL21 0.65(0. 14) 0. 17(0.05) 0.77(0. 14) O . ()..j~ 2 0.5974 0.0362 
CpG+CO.tOL+BCltL+lL21 0.78(0.13) 0.23(0. 10) 0.94(0.14) O.{)O67 0.4936 {Ull 1\ 
Table 6.7 : Mean (and tandard error of mean) of quantities or TNF-alpha produccd for the arious 
timulant conditions after pre-incubation with wild-type HIV-I e i" (Ncl), mutant n n-myristoylated 
HIV- I ef (MNet) or media (Nil) and the corresponding P values afier pair-wi com pari on ' . Paired 
tudent' T te twas u ed. ignificant P values are shown in red text. 
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6.2.16 Effect of recombinant HIV-J Nefon secretion oflL6 by PBMCs after 
stimulation with various stimulants for 48 hours 
There were no statistically significant differences in IL6 indices when samples that were 
pre-incubated with wild-type HIV -I Nef were compared with samples that were pre-
incubated with mutant non-myristoylated HIV-I Nef or media alone. However, 
statistically non-significant trends were observed across all stimulant combinations with 
samples pre-incubated with wild-type Nef having higher IL6 indices than those pre-
incubated with mutant Nef or media. Notably, there was very high variability in IL6 
indices within the samples that were pre-incubated with wild-type HI V -I Ner, hence the 
lack of statistically significant differences even though there were large differences in 
mean values between the samples pre-incubated with wild-type IIIV-\ Nef and the 
other samples. 
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Figure 6.23: IL6 indices after pre-incubation with Ill Y protcin and ubsequent expo ure to variou 
timulant-combinations. All sample were pre-incubated with recombinant Ill Y- I ef (red). recombinant 
mutant (non-myristoylated) HIY-I Ner (Green) or media (Blue). Data represents four independent 
experiments. Bars show mean ± EM. 
S timulant Mean( tandard error) IL6 P value 
index 
Nef MNef Nil Nef Ne f M Nef 
vs v v 
M Nef Nil Nil 
NIL+IL21 13.55(5.39) 0.22(0. 10) 0.07(0.0 I) 0.09 13 0.0873 0.2524 
BCRL+lL21 14.05(5.74) 0.07(0.02) 0.06(0.02) 0.0920 0.0920 0.2542 
C D.tOL+IL21 14.22(5.60) 0. 14(0.04) 1.00(0.00) 0.0854 0.0992 0.0002 
C D40L+BCRL+IL21 14.46(5.6 1) 0. 17(0.06) 0.66(0. 18) 0.0823 0.0936 0. 1070 
R848+IL21 15.47(5.90) 0. 19(0. 11 ) 0.30(0.22) 0.0785 0.0774 0.4022 
R848+C040L+IL21 14.84(5.98) 1.08(0.37) 2.03(0.64) 0.0932 0. 1072 0.2369 
R848+C040L+BC R+I L21 14.75(5.76) 1. 12(0.88) 3. 19(0.97) 0.0733 0. 1074 0.00) -
C pG +IL21 14.82(5.86) 0. 12(0.06) 0.11 (0.06) 0.0850 0.0850 0.6277 
C pG +C040L+IL21 14.75(5.92) 0.26(0. 12) 0.90(0. 16) 0.0893 0. 1006 0.0648 
C pG+C D40L+BC RL+IL21 14.35(6.48) 0.32(0. 17) 0.60(0.27) 0. 11 32 0. 11 35 O. t378 
.. Table 6.8: Mean (and standard elror of mean) of IL6 lIld lCCS for the :mou IImu lant-cond ltlons after 
pre-incubation with wi ld-type HI Y- I ef(Net). mutant non-myri toylated Ill Y-I ef(M ef) or media 
(Ni l) an d the corresponding P values after pair-wise compari ons. Paired ludent ' s T test wa u cd. 
Significant P value are shown in red text. 
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6.3 Discussion 
TLR signalling synergised with CD40L signalling and BCR signalling in inducing 
proliferation, differentiation and activation of B cells in PBMCs. Similar to a previous 
report, addition of CD40L onto TLR ligands led to increased frequencies of 
proliferating B cells, plasmablasts and CD86+ B cells [328]. Further addition of BCR 
ligand led to a significant further increase in frequencies of proliferating B cells and 
plasmablasts, but the increase in frequencies of CD86+ B cells was not significant. 
However, PBMCs stimulated with CD40L+BCRL+1 L21 had higher frequencies of 
CD86+ B cells when compared with those stimulated with CD40L+IL2I, suggesting 
that BCR ligation could synergise with CD40L in induction of markers ofactivation. 
While human memory B cells have been shown to constitutively express TLR7 and 
TLR9, naiVe human B cells express TLR9 only after BCR stimulation [198]. 
Furthermore, TLR ligation has been shown to induce up-regulation of CD40 and IL21 
receptor [209, 329]. These interactions provide a possible explanation to the observed 
synergy between BCR ligand, CD40L and TLR ligands in the induction of proliferation, 
activation and differentiation ofB cells in the presence oflL21 in the current study. 
Interestingly, adding BCR ligand to the stimulant-combinations, though effective in 
inducing differentiation into plasmablasts and proliferation, reduced antibody 
production. This phenomenon has been reported elsewhere [330-332]. Indeed, nCR 
ligation alone induces apoptosis. However, having CD40L or TLR signalling in 
addition to the BCR ligation rescues the B cells from apoptosis. The pro-apoptotic 
effect of BCR-only ligation is thought to be a mechanism to protect against auto-
reactive antibody responses that may be induced by auto-antigens in the absence of 
other B-cell signals [333, 334]. Whether the blunting of antibody responses by BCR 
ligation in presence of CD40L and TLR signalling was due to its pro-apoptotic 
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effects is unclear. Even though the TLR and CD40 ligands are expected to rescue the 
cells from such BCR-induced apoptosis, their signalling might not have been strong 
enough to counteract the magnitude of BCR-induced apoptosis in the cultures. 
Alternatively, stimulation with BCR ligands in absence ofTLR ligands or CD40 ligand 
may drive the B cells to preferentially differentiate into plasmablasts with little clonal 
expansion and little generation of memory B cells, processes that are favoured by TLR 
and CD40 signalling. Such an effect could lead to reduced antibody response in the long 
run in BCR stimulated cultures when compared with cultures that contain CD40L and 
TLR ligands without BCR ligand. 
The TLR ligands R848 and CpG did not induce significant secretion ofTNF-alpha and 
IL6 by PBMCs. However, addition of CD40L significantly increased the secretion of 
the two cytokines. Notably, further addition of BCR ligand did not cause further 
increment in secreted cytokines. Therefore, CD40 ligation seemed to be the only factor 
that significantly influenced secretion ofTNF-alpha and IL6 by the PBMCs. It would be 
difficult to ascertain the cellular source of the cytokines, since both human and mouse B 
cells and monocytes have previously been shown to secrete TNF-alpha and IL6 upon 
stimulation with TLR ligands and CD40L [321,324]. In fact. TLR ligation has been 
shown to synergize with CD40 ligation and BCR ligation in inducing the secretion of 
the·two cytokines by human B cells [322]. It was therefore surprising to see that BCR 
ligation and TLR ligation did not significantly affect the secretion of the two cytokines 
in the current study, probably because PBMCs were used while the previous studies 
used purified B cells or purified monocytes. Differences in concentrations of TLR 
ligands and BCR ligands could have also played a role in the differences. Furthermore, 
considering that secretion of pro-inflammatory cytokines is very sensitive to endotoxin. 
the purity of the recombinant stimulants used in this study could have influenced the 
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secretion ofTNF-alpha and IL6, though such purity was not determined. 
Even though a previous study showed that recombinant HIV -I Nef inhibited CD40L-
mediated class switching of naive B cells [25], the results of the current study do not 
show any effect of the protein on proliferation, differentiation (plasmablasts and 
secretion of antibodies into culture supernatants) and activation (CD86 expression) of B 
cells upon stimulation with various combinations ofCD40L, TLR ligands, BCR ligand 
and IL21. However, pre-incubation with wild-type HIV-I Nef affected the secretion of 
TNF-alpha after exposure to the same stimulants. 
According to the previous study, exposure of the B cells to the recombinant HIV -I Nef 
inefficiently activated the NFlCB pathway, leading to activation of negative feedback 
pathways that rendered the B cells refractory to subsequent NFKB pathway-dependent 
activation with CD40L+IL4 [25]. Since TLR9 and TLR7 too signal via NFKB, 
recombinant HIV-I Nef would be expected to also inhibit the effect of R848 (TLR7 
ligand) and CpG (TLR9 ligand) on B cells in the current study. Several differences in 
the experimental set-up could explain the differences in results between the two studies 
with regard to B-cell proliferation, differentiation and activation. Firstly, the current 
study involved the use of PBMCs while the previous study used purified naive B cells. 
Consequently, there could have been some indirect effect of HIV-I Nef via other 
immune cells in the PBMCs culture. Indeed, as discussed in the previous paragraph and 
in the literature review, HIV -1 Nef has numerous effects on monocytes and T cells [21, 
22, 133, 309-311]. In addition to the secretion of IL6 and TNF-alpha, it induces 
secretion of other soluble factors that could affect B cells. For instance, Nef expressing 
monocytes secrete ferritin that in turn induces polyclonal activation of B cells [133]. 
Moreover, the monocyte-derived TNF-aIpha and I L6 could potentiate the effect of other 
B-cell stimulants [323, 335]. 
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Differences in the source and quality of the reagents could also have contributed to the 
differences in the results of the two studies. For instance, the previous study used 
trimeric CD40L from Immunex whereas the current study used a kit containing 
monomeric CD40L+enhancer for ligands (a reagent that cross links the CD40L to 
enhance its potency) from Enzo Life sciences [25]. Also, even though the identities and 
sources of the recombinant HIV -I proteins used were similar, differences in handling 
and storage conditions could have affected their integrity. However, wild-type HIV-I 
Nef in the current study induced secretion of IL6 and TNF-alpha in PBMCs in 
agreement with a previous study on monocytes, suggesting that it was not defective 
[310]. 
Finally, the previous study focused on the effects of HIV-I Nef on class switching of 
naIve B cells while the current study evaluated effects on proliferation, differentiation 
and activation of B cells. Even though all these processes rely on the NFKB pathway, 
their other differences could have led to the observed differences in the results. 
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Chapter 7 Summary and conclusion 
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The effect of HIV on the B-cell compartment in adults has been well characterized. 
Active viraemia has been shown to cause aberrant polyclonal activation of B cells and 
expansion of certain B-cell subsets that are normally in low frequencies in normal 
uninfected adults [84, 123, 215, 226, 228, 229]. The function of B cells in highly 
viraemic HIV-infected adults has also been shown to be compromised, with such adults 
having low levels of vaccine-specific antibodies and low frequencies of vaccine-specific 
memory B cells [84, 229, 243, 244, 253]. Children differ from adults in that their 
immune system is relatively immature. Furthermore, their B-cell compartment develops 
in a background of HI V infection, unlike adults who get infected later in life when their 
immune system is already mature. The interaction between HIV and the B-cell 
compartment may therefore differ in children when compared with adults. However, 
the phenotype and function of B cells in HIV -infected children has not been studied to 
the same extent as in adults. 
The overall goal of this study was to determine the B-cell defects and their causes in 
HIV-infected children. In particular, I aimed to: 
1. Describe the subset distribution ofB cells in children infected with 1I1V. 
2. Describe the B-cell responses to common childhood vaccines in children 
infected with HIV i.e. 
a. Quantities of antibodies in circulation. 
b. Avidities of antibodies in circulation. 
c. Frequencies of memory B cells in peripheral blood. 
3. Describe the memory B-cell responses to pneumococcal capsular 
polysaccharides in children after natural exposure or vaccination with a 
pneumococcal conjugate vaccine and compare those responses with natural and 
vaccine-induced anti-pneumococcal responses in HIV-infected children from 
HIV clinic and community control children from Ngerenya cohort. 
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4. Determine the in vitro response of B cells to ditferent B-cell stimulant-
combinations and evaluate the in vitro effects of recombinant HIV -1 Nef protein 
on B-cell responses to such stimulant-combinations. 
For the assessment of phenotypes and function of B cells in HIV -infected children, a 
cross-sectional study was done at the HIV clinic (CCRC). These HIV-infected children 
were then compared with community control children from the Ngerenya malaria 
cohort. For determination of memory B-cell responses to pneumococcal capsular 
polysaccharides in children before and after vaccination with a pneumococcal conjugate 
vaccine, children were recruited into a larger clinical trial that evaluated 
immunogenicity and reactogenicity to a PHiD-CV vaccine in children aged 12-59 
months. Memory B-cell responses were evaluated in a subset of the children aged 12-24 
months at enrollment and at 30 days following each of the two doses of the vaccine. 
The responses were then compared to those observed in HIY-infected CCRC children 
and community control Ngerenya children. In vitro experiments were done using 
lymphocytes from buffy coats that had been collected from healthy donors. B-cell 
responses were assessed after stimulating the lymphocytes with various stimuli. Effects 
of HIY -I Nef on the B-cell responses to the stimuli were also assessed after pre-
incubating the lymphocytes with wild-type HIY -1 Nef, mutant non-myristoylated my-
I Nefand media. 
Flow cytometry was used for determination of the expression of surface markers on B 
cells. The surface markers were then used to identify the various B-cell subsets. 
Frequencies of each B-cell subset were compared between different groups of IIIY-
infected children and community control children. Flow cytometry was also used for 
determination of proliferation, differentiation and activation of lymphocytes after 
culture in the in vitro experiments. Enzyme Linked Immunoassay (ELISA) was used 
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to determine the levels of antibodies against vaccine antigens and pneumococcal 
capsular polysaccharides. The same assay was used to determine levels of total 
immunoglobulins in culture supernatants. A modified ELISA was used to determine the 
avidity indices of antibodies against their cognate antigens. Commercial cytokine-
ELISA kits were used in accordance to manufacturers' instructions to determine levels 
of TNF-alpha and IL6 in culture supernatants. Cultured B-cell ELISpots were done to 
determine the frequencies of antigen-specific memory B cells. 
Similar to previous studies in adults, in this study, the frequencies of activated B-cell 
subsets (i.e. activated mature B cells, atypical memory B cells and plasmablsts) were 
higher in the high viraemia HIV-infected children when compared with community 
controls and low viraemia HIV-infected children, suggesting that HIV viraemia was the 
driving force in their expansion [84]. A similar observation was also observed in 
children in a previous study, though the three activated subsets were not differentiated 
[234]. In the generalized quantile regression model, viral load was the common 
predictor of frequencies of all activated subsets. CD4+ T-cell percentages significantly 
predicted frequencies of atypical memory B cells only. On the other hand, frequencies 
of resting memory B cells were lower in the entire HIV -infected cohort when compared 
with community controls. This has been shown to be the case in adults too and has also 
been reported in some studies on children [228, 230, 231, 234]. Notably, unlike 
previous reports on adults, there were no differences in immature transitional B cells in 
the different groups of children in the current study [226]. 
Interestingly, there was a statistical interaction between level of viraemia and age with 
regard to age-related acquisition of resting memory B cells. Similar to community 
controls, the groups of children that had low viraemia showed age-related increase in 
frequencies ofresting memory B cells while those groups that had high viraemia did not 
show the same. This observation has never been reported elsewhere and provides a 
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good reason to consider if all children, regardless of their age, should be put on HAART 
as soon as they are diagnosed with HIV. Currently, according to the WHO 
recommendations, all children who are diagnosed with HIV in the first two years of life 
are to be put on HAART immediately. Until recently, children who are diagnosed with 
HIV after their second birthday and before 5 years of age were to be put on HAART 
only if their CD4+ T-cell counts fell below 750 celis/ilL or below 25% or if they were in 
WHO clinical stage 3 or 4 while children who were above 5 years were to be put on 
HAART only if their CD4+ T-cell counts fell below 350 ce"s/~lL or if they were in 
WHO clinical stage 3 or 4 [80]. A recent revision of the WHO guidelines now 
recommends all children below five years of age to be put on HAART the moment they 
are diagnosed with HIV, but scientific evidence to support that recommendation is 
lacking [76]. Furthermore, the new WHO recommendations are yet to be adopted into 
the national treatment guidelines for the various countries. Considering that 90% of the 
HI V-infected children live in the resource-poor Sub-Saharan Africa where only 28% of 
eligible children were receiving HAART as at the year 201 t [45], many children could 
be missing the opportunity of being started on HAART early. In addition, delivery of 
babies at home is still common in some parts of the region [336, 337], suggesting that a 
significant number of children continue to miss out on PMTCT services and early 
initiation of HAART if they are infected. Such children, if they live long enough, are 
likely to be diagnosed with HIV late and are put on HAART if their CD4+ T-cell 
percentages/counts deteriorate to a certain level in accordance with their country's 
policies. According to this study, high viraemia continues to take a toll on their immune 
system by denying them a chance to accumulate memory B cells with age. Control of 
viraemia by putting all HIV-infected children on HAART may enable them to grow 
immunologically like healthy children. 
Similar to previous studies in adults and children, the HIV-infected children had 
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lower levels of antibodies against childhood vaccines when compared with community 
controls [84. 229. 243-245. 257-264. 266-268]. The HIV-infected children in the current 
study also had lower avidity indices of IgG against the same vaccine antigens and lower 
frequencies of memory B cells against some vaccine antigens when compared with 
community control children. This confirms the few studies that have assessed the effect 
of pediatric HIV on antibody avidity maturation and frequencies of antigen-specific 
memory B cells [232, 245, 261]. However, no differences were observed between the 
two groups of children with regard to naturally acquired responses against 
pneumococcal capsular polysaccharides. This suggests that HIV-infected children 
make sub-optimal B-cell responses to vaccines at the time of immunization or 
experience depletion of the responses that they make, raising the question of whether 
they should be revaccinated after being put on HAART. At the moment, there are no 
programs in place for revaccination of HIV-infected children. The current study, 
together with many other previous reports, suggests that revaccination schedules could 
be beneficial to these children [338]. 
Memory B-cel\ frequencies were also assessed against pneumococcal capsular 
polysaccharides from serotypes 19F, 14, 23F, 6B and 1 among healthy children who 
took part in a clinical trial for a to-valent Pneumococcal non-typable Haemophilus 
Influen=a protein D conjugate vaccine (PHiD-CV). Memory B cells against tetanus 
toxoid and diphtheria toxoid were also evaluated in the same children. The two proteins 
had been used to conjugate some of the polysaccharides in the vaccine. Vaccination of 
healthy children with two doses of PHiD-CV elicited significant increase in frequencies 
memory B cells against all capsular polysaccharides with the exception of serotype 68. 
There was also a significant increase in frequencies of memory B cells against the 
conjugating proteins, i.e. tetanus toxoid and diphtheria toxoid, upon vaccination with 
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PHiD-CV. Similar effects were observed in community control children who received 
the PHiD-CV as part of the catch-up campaign in the community. Notably, children 
who had serotype 19F carriage at enrollment elicited poorer responses against serotype 
19F after vaccination. Importantly, older HIV -infected children at the HIV clinic were 
comparable to younger healthy children in the trial with regard to anti-pneumococcal 
responses, suggesting that HIV stunts natural acquisition of memory B cells against 
pneumococcal capsular polysaccharides. 
The in vitro response of B cells in PBMCs after exposure to various combinations of B-
cell stimulants was assessed in a bid to set up a system for evaluating the effect of 
recombinant HIV proteins on B cells. Similar to previous reports, synergistic effects 
were observed between BCR signalling. TLR signalling and CD40 signalling with 
regard to proliferation. differentiation into plasmablasts and expression of activation 
markers [328, 330]. Synergy was also observed between TLR signalling and CD40 
signalling with regard to secretion of immunoglobulins. However. BCR signalling 
dampened the secretion of immunoglobulins, a phenomenon that has been reported 
elsewhere [330]. Secretion ofTNF-alpha and IL6 was dependent on CD40 signalling. 
When the effect of HIV -I Nef was assessed on PBMCs stimulated with the different 
stimulant-combinations, unlike a previous report that suggested HIV -I Nef could inhibit 
class switching of B cells, there was no observed effect on proliferation, differentiation 
into plasmablasts, expression of activation markers and secretion of immunoglobulins 
in the B-cell compartment [25]. However, wild-type HIV-l Nef induced secretion of 
TNF-alpha by PBMCs, similar to other studies on monocytes [310]. Di1ferences in 
cytokine responses between PBMCs and purified naiVe B cells upon exposure to HI V-I 
Nef could explain the differences in results between the current study and the previous 
study. 
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Future work on B cells in HIV patients would entail the determination of the 
mechanisms of the observed defects. Of particular interest is the cause of polyclonal 
activation, whose causes and consequences have not been fully elucidated. Even though 
gp 120 has been shown to activate B cells polyc\onally via DC-SIGN and the B-cell 
receptor, the possible role of single stranded RNA via toll like receptor 7 has not been 
studied. Furthermore, polyc\onal B-cell activation could be an immune evasion strategy 
whereby the virus diverts the energies ofthe immune system towards responses that are 
not relevant for the invading pathogen. For instance, activated B cells of other 
specificities could compete with the HIV-specific B cells in utilization ofT-ceil help, a 
phenomenon that could have serious effect in blunting the antibody response against 
HIV. 
It would be also desirable to do the in-vitro experiments using purified B cells to check 
if the effects of recombinant Nef differ from those observed in my work. 
With the PHiD-CV vaccine already rolled out for routine childhood immunisation, it 
would be practical and desirable to study further the memory B-cell responses in 
healthy and HIV-infected children who receive it at 6 weeks, 10 weeks and 14 weeks; 
memory B-cell responses against pneumococcal antigens have not been evaluated in 
children who receive PHiD-CV at those ages. 
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Ethical approvals 
KENYA MEDICAL RESEARCH INSTITUTE 
po. Boll 54840 . 00200 NAIROBI. Ktnya 
Tel. (2541 (02O) 2T22541 . 2713349. 0722205901. 0733-400003: Froc: (2541 (020)2720030 
E-mall. di(eclor@kemr1 oro k'lfo@kemr1 org WebsJI8:WWW kemrt org 
KE~1Rl/RIlS/7/3/1 
TO: 
THROUG H: OR, NORll F.RT P ESIIU, 
TH rl DIIlrlCTOR, CGM Il-C 
KllJl'] 
1m : SSC 1'1l0 TOCOL NO. 1633 (R(i~"UIIMISS/Of\/) : l'lI ENO'rVroE AND 
FUNCTION OF 11 CELL IN em L01tJ7.N IN f'l,C f EO WlTll ll lE HUM N 
IMM UNOllEFICI l'.NCY VIRUS 
M.'lke refcrcnc~ to YOllr leHer dOled CK: toher 5.201)9. Thank ),011 for your I"CSponse \0 the i~sue~ rnis~d 
by lil t' Commi tt~. This ilt to inform YOII thai the issues raised during Iht, J681\ meeting of 
KEMRI/Nat<onal Ethics Review Committee hrld on TtI(';,lay 14" J uly 2001). have been adequately 
addreslJt'(l. 
It is llOW deAf that Iho informntion we require (I'Ont thl! healthy childl'en for the purpose of 
cumpnrison with \' hie, in childrt'l1 tn fC<.~lod with lt lV is nlrrndy avnilahl ~ as p:lTt of Dr. Nd\Utli'~ 
PhD awarded in June 2009 by the Universi ty of Dundce And oth", data thal will be gener.to<! in 
Mny 2010 aN part of the ongoing inv(:s ligations into B rcll l ~!Cronscs during and Ilflcr IU·\'t ~ 
mnhu'irl collected nucl e>r sse 113 1. 
Kcquesung tor pennis..,\lon to U~ data genrrntcd under sse Pro tocol 1131 for comp.uhon WI Lh 
data generated in chIldren infected " ith II IV in the abo" . mentioned protocol, is really beyond 
the purview of this committee. Usc of another study's data should b. snrll·d oul hetween the 
principal investigntors of lht' st udics in (}m'Mioll. 
Due consideration hAS been givl!Jllo ethic:,1 i~~ ll cs anel the study is hereby granted approval for 
implementation effective this BI}! duy of Novf,"mbcl" :lU0 9 . (or J period of l'Wf:J\'c ( 12) month .. 
PleAse note thnr authorization to conduct this st udy ""ri ll automAtically expire on 't tl Novemher 
20J O. If you plan to continue wi th data collection or analy~i s beyond th is date, pi ~~ submit an 
npplicMion for continuing appro""l to Ihe ERe S'>CTetarlat by 26
" 
September 201 0 . 
You arc required to submit any amendment.s to lhi'4 prol(}(;ol ;11'Id Of her infomlntiun pertinenll o 
humnn pnrticipiltlon in th is ~I udy to the ERe prior to initiotion. You may t'mb:wk no Ih (' "iludy. 
Yours si l1 ccr~ly, 
It. C. KfflU .11 , 
FOil> SIlCRIlTA RY, 
K&MRJLNJ\UO"",uJ..£cJ..U",""wu;.L\.lIUL ... QM.M.J:mm 
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KENYA MEDICAL RESEARCH INSTITUTE 
P.O. Box 54840-00200. NAIROOI. Kenya 
r eI (254) (020) 27225<1 . 2713349. 0722·205901 , 0733"0000J: Fax: (254) (020) 2720030 
E·moi: dlreetorCkomn.org Info@k.mn.org Wobsllt:www.kllf11l1.org 
KEMRI/RES/7/3/1 
TO, BITTA URBAN, 
(PRINCIPAL INVESTIGATOR) 
THROUGH, DR. SAlAH OMAR, 
DIRECTOR, CGMRC, 
lWm 
RE, sse PROTOCOL 11133 (CONTINUING R RIPORJ) PHENOTYPE AND FUNCTION 
0' B CELLS IN CHILDREN INFECTED WITH HUMAN IMMUNODEfICENCY VIRUS. 
111IS Is to Inform that during the 215" meetlng of the KEMRl/ERC meeting held on Mav 
21" 2013, the Committee conducted tho annul' rtl/lew and apoIPvecI the above 
referenced application for another year. 
111ls approval (s valid from today MIIY 21", 2013 through to MIIY 20'·, 2014. Please 
note that authorization to conduct this study will automatically expire on MIV 111"', 
2014. If you plan to continue with data collection or analysis beyond this date, please 
submit an application for continuing approval to the ERe secretariat by April II" 2014. 
You are required to submit any amendments to this protocol and other Information 
pertinent to human partldpatlon in this study to the sse and ERC for review prior to 
Initiation. 
Yours Sincerely, 
K..-Ar 
DR. ELIZABETH BUKUSJ, 
ACTING SECRETARY, 
KEMRJ ETHJCS RMEW COMMmEE 
In Search of Bettor Health 
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KENYA MEDICAL RESEARCH INSTITUTE 
PO 60. 50840 . 00200 NA IROSI . K,ny. 
T, I. (25' ) (020) 2122541 . 21 13349 0122·205901. 0133-40000); Fu' (25') (020) 2120030 
e.malL •• mtl.ftQCI1.lrobi.mlmcom.n.1 du. clor 0 _,m,1 Of 0: web,lIe ' ., •• kim,' org 
KEMRI/RES/7/3/1 September 9, 2009 
TO: 
THROUGH: 
RE: 
DR. LAURA HAMMITT (PRINCIPAL INVESTIGATOR) 
DR. NORBERTPESHU, <~ c;t.\U"l 
=RECTOR, CGMR-C ~~"v'V~ 
SSC PROTOCOL NO. 1635 (ETHICS REVlEW): IMMUNOGENICITV 
AND REACTOGENICrrv OF 10-VALENT PNEUMOCOCCAL 
CONJUGATE VACCINE IN CHILDREN AGED 12-59 MONTHS. 
this Is to inform you that during the 169'· meeting of KEMRI/Natlonal Ethics Review 
Committee held on Tuesday 1" September 2009, the abovementioned study was 
reviewed. 
Due consideration has been given to ethical Issues and the study Is hereby granted 
approval for implementation effectJve this 9th day or September 2009, for a period of 
twelve (12) months. 
Please note that authorization to conduct this study will automatically expire on 9th 
September 2010. If you plan to continue with data collection or analysis beyond this 
date, please submit an application for continuing approval to the ERe Secretariat by 
29t1t July 2010. 
You are required to submit any amendments to this protocol and other Information 
pertinent to human participation In this study to the ERC prior to Initiation. You may 
embark on the study. 
Yours sincerely, 
tsJ1K..'i/.,....'1" 
R. C. KITHINlI, 
FOR: SECRETARY, 
KEMRIINADONAL ETHICS REVIEW COMMmEE 
In Su,ch of B,"er Heelth 
KEMRI/ Wfl.LCOME TRUS r 
PS!,-,RCh. , I'~~~~"'.M,\jE 
! 
_ r-~,2~O~ . 
.. ~~Ft' t::-,= E I V E 0 
! "o.-Bft :l3M010I K1LlI'J 
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P.O. Box 54840-00200 NAIROBI, Kenya 
Tel: +254 (020) 2722541,2713349,0722-205901,0733-'100003, Fax +254 (020) 2720030, 
E.mall: dlreclor@kemri,org: Info@kemrt.org website: www.kemrt.org 
KEMRUREsn 13/1 
Dr. K. Marsh 
CGMR-C, 
IillJ.EL 
Thro' 
Rc: SSC Protocol No, 1131 (Revised) - Intcllrotcd studies of the development of 
ollturallmmunity to malarln In children In KlHfI district, by K Marsh el 01 
DlIring the 136'h Meeting oflhe KEMRIINational Ethical Review Committee held on the 
22nd of August 2006 the above protocol was discussed. 
Thank YOll for a weil written and informative proposal U13t aims to establish an 
epidemiological tramework in which to carry out longitudinal studies of the development 
of immune responses to malaria. 
Due consideration has been given to ethical issues Dnd therefore the protocol is granted 
Dpproval. You are responsible for reporting to the Ethical Review Committee Bny ehonges 
to the protocol or in the Informed Consent Document. This includes changes to research 
design or procedures that could introduce new or more than minimum risk to human 
subjects. In addition il is requirement of this Committee to include the contact orthe 
KEMRIINERC which is Secretary, KEMRIINERC, +254-02-2722541. 
Kindly rcmit n copy of the revised protocol for our records. 
w~. 
R.C.M, Kithinji 
For: Secretury, 
KEMRIINotlonnl EthlCllI Review CommiUee 
In Search 01 Belle, Hosllh 
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Informed consent form for recruiting children at CCRC 
KEMRI - Wellcome Programme Information Sheet and Consent Form 
Stutly title: Pheno(l'pe amlfunction of B cells in children infected with the human 
immunodeficiency virus-l (HIV-l) 
Lay title: Type antlfunction of B cells (immune system celM in children infected with 
the human immunodeficiency virus-l (HIV-l) 
Institution Individuals 
KEMRICGMRC Britta Urban (Principal Investigator), Evelyn Gitau, 
Eunice Nduati, Pete Bull, Francis Ndungu, Jay 
Berkley, Hellen Nabwera, Maureen Mutinda 
Your child's illness/symptoms 
Your child is attending the Comprehensive Care and Research Clinic (CCRC) where 
care is given for people infected with HIV. The normal standard of care for people 
infected with HIV is monthly clinical check-ups and checks for the body's cells, which 
protect against infection - CD4 counts. In addition to these tests a drug called 
Cotrimoxazole, which prevents infection by other diseases is given to patients, as well . 
as Anti-retroviral treatment (ART), which reduces the amount of HIV in the body. 
These drugs are given according to mitional recommendations. 
What is KEM RI and what is this study about? 
KEMRI is a government organization that carries out medical research to find better 
ways of preventing and treating illness in the future for everybody's benefit. One illness 
KEMRI is currently trying to learn more about is infection with HIV. There is currently 
very little information in Kenya about how children infected with HIV fight 265 
common childhood infections such as malaria or how they respond to vaccines. To help 
us learn more we are asking a total of300 children infected with HIV to participate in a 
study on how HIV affects the defense system of the body. We would like to include 
100 children before they start cotrimoxazole, 100 children who already receive co-
trimoxazole and 100 children who already receive ART. We will compare the function 
of the body's defense system in children infected with HIV to the function of the body's 
defense system to children not infected with HIV. 
What will it involve for me/my child if I agree? 
We will use a small amount of the blood that will be taken as part of your child's 
normal treatment at the CCRC for this research. The extra amount taken for research 
will be less than 1 tsp (3ml). We will take this sample only once when your child has a 
small amount of blood drawn for routine clinical care. 
The rest of your child's treatment will be according to the Ministry of Health 
guidelines. J f there are any other research activities that KEMRI staff would like your 
child to participate in, staff shall explain and ask your permission first. 
Are there any risks or advantages to me or my child of participating? 
Our priority for every patient is his/her care. 
Taking blood fi'om the arm causes a small amount of pain, but the amount taken is too 
small to affect your child's health. 
There is no direct benefit to your child, The information gained from this research may 
help us to improve the care of children who have HIV in the future. Where results could 
be helpful for your child's treatment, for instance how much virus is in your child's 
body, these will be given to the doctor or clinical officer providing your child's care. 
What happens if I refuse to participate? 
All participation in research is voluntary. You are free to decide if you want your child 
to take part. Your child will have the same level of care whether they take part or 
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not. If you do agree you can change your mind at any time and withdraw your child 
from the research. This will not affect your child's care now or in the future. 
What happens to the samples? 
Individual names are removed from all samples and replaced by codes, to ensure that 
samples can only be linked to the participants by people closely concerned with the 
research. 
Most of the research tests that will be done on the blood will be done here in Kiliti. We 
will test in the laboratory how infection with HIV alters your child's ability to fight 
infection and respond to vaccines. Some tests will provide information on how well you 
child is coping with the HIV virus i.e. how much virus is in the blood. We will give the 
results of these tests to the Clinician looking after your child as soon as they become 
available. Some test that cannot be done in Kenya, part of the samples will be sent to 
our collaborators in Sweden. 
After the research, a small portion of the blood will be stored. In the future, new 
research about HIV or malaria may be done on these samples. Future research must first 
be approved by a national independent expert committee in Nairobi to ensure 
participants' safety and rights are respected. 
Who will have access to information about me/my child in this research? 
All our research records are stored securely in locked cabinets and password protected 
computers. Only a few people who are closely concerned with the research will be able 
to view information from participants. 
Who has allowed this research to take place? 
An independent national committee and a committee in Kilifi have looked carefully at 
this work and agreed that the research is important, that it will be conducted properly 
and participants' safety and rights have been respected. 
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What if I have any questions? 
You may ask any of our staff questions at any time. You can also contact those who are 
responsible for the care of your child and this research: 
PI's name(s) and contacts 
Dr. Britta Urban 
KEMRI· Wellcome Trust, 
P.O. Box. 230, Kenya. Telephone: 0728024743 or 041 7522063 
If you want to ask someone independent anything about this research please 
contact 
Community Liaison Manager, KEMRI - Well come Trust 
P.O.Box 230. Kiliti. Telephone: 0723342780 or 041 7522063 
Or 
The Secretary - KEMRilNational Ethics Review Committee 
P. O. BOX 54840-00200, Nairobi, Tel number: 020 272 2541 Mobile: 0722205901 or 
0733400003 
KEMRI-Well come Research Programme Consent form for sample only studies 
Study title: Phenotype andfunction of B cells ill children infected with Ihe humlln 
immunodeficiellCY virus-J (HIV-J) 
I, being a parent/guardian of (name of 
child), have had the research explained to me. I have understood all that has been read 
and had my questions answered satisfactorily. I understand that I can change my mind 
at any stage and it will not affect me/my child in any way. 
Please tick the boxes below where relevant: 
o I agree to allow my child to take part hi this research 
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o I agree to samples being stored 
o I agree to samples being exported 
Subject/Parent/guardian's signature: ___________ Date __ _ 
Subject/Parent/guardian's name: Time __ _ 
(Please print name) 
I certify that I have followed all the study specific procedures in the SOP for obtaining 
informed consent. 
Designee/investigator's signature: ____________ Date ___ _ 
Designee/investigator's name: Time 
(Please print name) 
Only necessary if the parent/guardian cannot read: 
I *attest that the information concerning this research was accurately explained to and 
apparently understood by the parent/guardian and that informed consent was ti'eely 
given by the parent/guardian, 
Witness'signature: ________________ Date ___ _ 
Witness' name: ____________________ Time ____ _ 
(Please print name) 
'" A witness is a person who is independent from the trial or a member of staff who 
was not involved in gaining the consent. 
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Thumbprint of the parent as named above if they cannot write: 
TilE SUBJECT/PARENT/GUARDIAN SIIOULD NOW BE GIVEN A SIGNED 
COpy TO KEEP. 
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Case report form for recruiting children at CCRC 
Phenotype and Function of B Cells in Children Infected With HIV 
Arm ....... B cell Stl/(Iy (D................ eene No ................... ...... ... Today's Date ..................... .. 
1. 008 ............................................................... Gender ........... Muac ................. . 
2. Date of Enrollment Into CCRC ......................................................... ......................................... . 
3. Date of Diagnosis Md Test Used 
o PCR D.te................. 0 Antibody Test Date ........................ . 
4. Feeding practice 
II o.6months 
3) EKCluslv Oreastlng Feeding 
b) MI~ed Fe ding 
c) No Breastfeedlng 
[) 6 and above 
a) EXClusive Breast reeding 
b) MI~ed Feeding 
c) No Breastfeedlng 
S. Therapy History 
o No previous Therapy 
OARVAlone 
6. Dote started therapy 
OCTXalone 
o 80th CTX & ARV 
OCTX ...................................................................................... .. 
D ARV ............... ......................................................... ................ . 
7. Name of MV Therapy 
[J 1" Line ......................................................................................................... .. 
11 2""Line ..... " ........ ................................................ ............... ...... ............ ....... .. 
8. Adherence 
U Satisfactory 
n Unsatisfactory 
II Stoppod 
(J Not Applicable 
9. OPT Vaccination gIven 
10. Pneumococcal vaccination slven 
11. Mea'los .............................................. . 
12. Consent Given 
DVes 
(] No 
Form Filled by .................................... . 
OVes 
o 
o 
o 
o 
, Phenotype & Function of cell in Children inr('Ct~d with IIIV Vcr 4 jUlllll11 
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List of reagents 
Reagent 
A f1inipure F(ab')2 fragment goat antihul1lan 
IgA+lgG+lgM 
Anti-hul1lan C02 1 PE 
Anti-human IgO PE 
Anti -mouse Ig, k/Ilt:gati ve control (FBS) compensation 
parti cles set 
AP conjugated amnipure goat anti-human IgG, Fey 
!Tagment speci fie 
AP conjugated amnipure goat anti-hulllan IgM 
AP mouse anti-human D21 
AP -117 mouse anti-human 0 20 
Arc amine reacti ve compensation bead kit 
I3eta- ll1ercapto ethanol 
Brilliant Violet 42 1 anti-human CDI9 
DIO FIT 
DI9-ECO 
D27-P 5 
D3 E D 
0 3 FITC 
CD40L, soluble (human)(recombinunt)sel 
D8 AP -1-17 
D86-PE 
elltrace CFSE cell proliferation kit 
pG-ODN 2006 
Diphtheria toxoid 
Goat antihuman Ig's(Polyva lent) 
Guanidine hydrochloride 
IIEPES bufTer 
IIIV-I Net' protein (G2A)l-li , non-myristoylated 
I-IIV- I Nefprotcin (wild type) lli s, myristoylated 
Iluman and mouse CpG-B DNA 
IgG human serum 
IgM human serum 
IL6 Quanti kine EllS kit 
Live/dead fi xable aqua dead cell tain kit 
Lymphoprep 
SUllplicr 
Jackson Il1lmunoresearch 
eBioseience 
Beckman coulter 
BD 
Jackson I 111m unoresearch 
Jackson Imm unoresearch 
I3D 
BO 
In vitrogen 
Gibeo 
l3iolegend 
SO 
Beckman coulter 
Beckman coulter 
Beckman coulter 
Beckman coulter 
BD 
BD 
Enzo Litc sciences 
BD 
Biolegend 
In vitrogen 
Ilyeult Biotech 
Statens Serum Institute 
Invitrogen 
Sigma 
igma 
Jena bioscience 
Jena bio eiencc 
Hycult biotech 
Sigma 
Sigma 
R&D 
Life technologies 
Axis-Shie ld 
Catlliogue 
nllmber 
109-006-064 
12-0219 
736000 
552843 
109-055-098 
109-055-043 
559867 
560734 
A I0346 
31350010 
30223 
332775 
A07770 
IM0473U 
6607107 
A07748 
345763 
348809 
ALX-850-064 
64 1400 
305406 
34554 
H 4039 
) 11 7000 
03272 
H0887 
PR-J83 
PR-J82 
H 4039 
125 11 
18260 
06050 
L34957 
111 4544 
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Measles (Rubcola)virus ,ultigcn 
methulated human serum albumin 
Ncwbornc bov ine serum 
OPD peroxidase substrate 
Opti lyee C lysis solut ion 
OPti lyce Lysis solution 
PE anti-human CD I 0 
PE rat anti-human D267 (TACI) 
PEl y7 anti-human D38 
Penicillin streptom ycin solution 
Peroxidase conjugated antihuman IgM 
Peroxidase-conjugated il lTInipurc F(ab')2 Fragment 
donkey antihuman IgO 
pneumococcal capsular polysaccharides 
R848 
Recombinant human IL2 1 
RPMI -1640 medium 
Staphylococcus aureu owan strain 
Tetanus toxoid 
TNF-a lpha Quantikinc ELI SA Kit 
Meridian Lile Science 
NIBSC 
Sigma 
Sigma 
Beckman coulter 
beckman coulter 
Biolegend 
BD 
Biolegend 
Sigma 
Jackson lmmunoreseurch 
Jackson lmmunorcsearch 
ATCC 
Invivogcn 
Peprotech 
Sigma 
Sigma 
Statens Serum Institute 
R&D 
7604 
991592 
N4637 
P9 187 
AI1 895 
AI1 895 
312203 
5584 14 
3035 15 
P7539 
709-036-073 
709-036-098 
tlrl-r848 
AF-200-21 
R0883 
P 7155 
DTAOOC 
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